<SEC-DOCUMENT>0001193125-19-106686.txt : 20190415
<SEC-HEADER>0001193125-19-106686.hdr.sgml : 20190415
<ACCEPTANCE-DATETIME>20190415170652
ACCESSION NUMBER:		0001193125-19-106686
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20190520
FILED AS OF DATE:		20190415
DATE AS OF CHANGE:		20190415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		19749189

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>d662434dpre14a.htm
<DESCRIPTION>PRE 14A
<TEXT>
<HTML><HEAD>
<TITLE>PRE 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT PURSUANT TO SECTION 14(a) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&nbsp;&nbsp;&#9746;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential, for Use of the Commission Only (as permitted by
<FONT STYLE="white-space:nowrap">Rule&nbsp;14a-6(e)(2))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Pursuant to sec. <FONT STYLE="white-space:nowrap">240.14a-11(c)</FONT> or sec. <FONT
STYLE="white-space:nowrap">240.14a-12</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>AMARIN CORPORATION PLC </B></P>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In
Its Charter) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table below per Exchange Act <FONT STYLE="white-space:nowrap">Rules&nbsp;14a-6(i)(1)</FONT> and
<FONT STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Title of each class of securities to which transaction applies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Aggregate number of securities to which transaction applies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Per unit price or other underlying value of transaction computed pursuant to Exchange Act <FONT
STYLE="white-space:nowrap">Rule&nbsp;0-11</FONT> (set forth the amount on which the filing fee is calculated and state how it was determined): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proposed maximum aggregate value of transaction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Total fee paid. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Check box if any part of the fee is offset as provided by Exchange Act
<FONT STYLE="white-space:nowrap">Rule&nbsp;0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount Previously Paid. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Form, Schedule or Registration State No.: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filing Party: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Date Filed: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g662434g76b14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2 Pembroke House </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upper Pembroke Street <FONT STYLE="white-space:nowrap">28-32,</FONT> Dublin 2, Ireland </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Registered in England&nbsp;&amp; Wales under Company No.&nbsp;2353920) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOTICE IS HEREBY GIVEN</B> that the Annual General Meeting of Shareholders of Amarin Corporation plc, a public limited company registered
in England and Wales (the &#147;<B><I>Company</I></B>&#148;), will be held at The Merrion Hotel, Upper Merrion Street, Dublin 2, Ireland, on May&nbsp;20, 2019 at 2:00 p.m. local time for the purpose of considering and, if thought fit, passing the
following resolutions, of which Resolutions <FONT STYLE="white-space:nowrap">1-5</FONT> will be proposed as ordinary resolutions and Resolution 6 will be proposed as a special resolution: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To <FONT STYLE="white-space:nowrap">re-elect</FONT> Mr.&nbsp;Jan van Heek as a director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To <FONT STYLE="white-space:nowrap">re-elect</FONT> Ms.&nbsp;Kristine Peterson as a director;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To hold an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> vote to approve the compensation of
the Company&#146;s &#147;named executive officers&#148; as described in full in the &#147;Executive Compensation Discussion and Analysis&#148; section, the tabular disclosure regarding such compensation, and the accompanying narrative disclosure on
pages 25 to 55 of the accompanying Proxy Statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To appoint Ernst&nbsp;&amp; Young LLP as auditors of the Company to hold office until the conclusion of the
next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors&#146; remuneration as described in full on pages 9 to 10 of the accompanying Proxy
Statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To generally and unconditionally reauthorize the Board of Directors of the Company to exercise all powers of
the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares of the Company up to an aggregate nominal amount of &pound;148,000,000 (being the aggregate nominal amount of &pound;125,000,000 in
respect of ordinary shares and &pound;23,000,000 in respect of preference shares) as described in full on pages 11 to 12 of the accompanying Proxy Statement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To, subject to the passing of Resolution No.&nbsp;5, disapply statutory
<FONT STYLE="white-space:nowrap">pre-emption</FONT> rights otherwise applicable to shares in the Company allotted by the Board of Directors, up to an aggregate nominal amount of &pound;148,000,000 (being the aggregate nominal amount of
&pound;125,000,000 in respect of ordinary shares and &pound;23,000,000 in respect of preference shares) as described in full on pages 13 to 14 of the accompanying Proxy Statement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public limited
company organized under the laws of England and Wales, it is a statutory requirement that the Board of Directors of the Company lay before the Annual General Meeting the Company&#146;s statutory accounts, which are those accounts included in the
Company&#146;s Annual Report for the year ended December&nbsp;31, 2018 as prepared in conformity with U.S. Generally Accepted Accounting Principles (the &#147;<B><I>Annual Report</I></B>&#148;) and the accounts for the financial year ended
December&nbsp;31, 2018 prepared in accordance with International Financial Reporting Standards. The Company does not expect that other items of business will be considered at the Annual General Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only shareholders who held shares at the close of business on the record date, April&nbsp;11, 2019, may vote at the Annual General Meeting,
including any adjournment or postponement thereof. The accompanying Proxy Statement more fully describes the details of the business to be conducted at the Annual General Meeting. After careful consideration, our Board of Directors has unanimously
approved the proposals and recommends that you vote FOR each director nominee and FOR each other proposal described in the Proxy Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s principal executive offices are located at 2 Pembroke House, Upper Pembroke Street
<FONT STYLE="white-space:nowrap">28-32,</FONT> Dublin 2, Ireland. The registered office of Amarin Corporation plc is One New Change, London EC4M 9AF, England. A copy of the Company&#146;s Annual Report accompanies this Notice and the enclosed Proxy
Statement. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Important Notice of Internet Availability</I></B>. The accompanying Proxy Statement
and Annual Report will also be available to the public at <B><I>http://investor.amarincorp.com</I></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We look forward to seeing you at
the Annual General Meeting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John F. Thero</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John F. Thero</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>President and Chief Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April &nbsp;&nbsp;&nbsp;&nbsp;, 2019 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:1%; margin-right:1%; font-size:10pt; font-family:Times New Roman"><B>WHETHER OR NOT YOU EXPECT TO ATTEND THE ANNUAL GENERAL MEETING, PLEASE COMPLETE, DATE, SIGN AND RETURN THE
ENCLOSED PROXY CARD USING THE ENCLOSED RETURN ENVELOPE AS PROMPTLY AS POSSIBLE IN ORDER TO ENSURE YOUR REPRESENTATION AT THE MEETING. EVEN IF YOU HAVE VOTED BY PROXY, YOU MAY STILL VOTE IN PERSON IF YOU ATTEND THE MEETING. PLEASE NOTE, HOWEVER, THAT
IF YOUR SHARES ARE REPRESENTED BY AMERICAN DEPOSITARY SHARES AND HELD ON DEPOSIT BY CITIBANK, N.A., AS DEPOSITARY, OR IF YOUR SHARES ARE HELD OF RECORD BY A BROKER, BANK OR OTHER NOMINEE AND YOU WISH TO HAVE YOUR VOTES CAST AT THE MEETING, YOU MUST
OBTAIN, COMPLETE AND TIMELY RETURN A PROXY CARD ISSUED IN YOUR NAME FROM THAT INTERMEDIARY IN ACCORDANCE WITH ANY INSTRUCTIONS PROVIDED THEREWITH. </B></P></div> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMARIN CORPORATION PLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019
ANNUAL GENERAL MEETING OF SHAREHOLDERS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_1">GENERAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_2">PROPOSALS NOS. 1 AND 2 ELECTION OF DIRECTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_3">Nomination of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_4">Nominees and Incumbent Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_5">Directors Nominated for Election</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_6">Directors Continuing in Office</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_7">PROPOSAL NO. 3 ADVISORY VOTE ON EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_8">Background</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_9">PROPOSAL NO. 4 APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_10">Fees for Independent Registered Public Accounting
Firm&#151;E&amp;Y</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_11">PROPOSAL NO. 5 RENEWAL OF THE POWER OF THE DIRECTORS TO ALLOT
SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_12">PROPOSAL NO. 6 APPROVAL OF SUBSEQUENT PRIVATE PLACEMENT PURSUANT TO <FONT
STYLE="white-space:nowrap">PRE-EMPTIVE</FONT> RIGHT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_13">ADDITIONAL BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_14">CORPORATE GOVERNANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_15">Director Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_16">Code of Business Conduct and Ethics</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_17">Shareholder Communications</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_18">BOARD OF DIRECTORS AND COMMITTEES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_19">Board Leadership Structure and Risk Oversight</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_20">Board Committees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_21">Compensation Committee Interlocks and Insider Participation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_22">EXECUTIVE OFFICERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_23">CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_24">Transactions with Related Parties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_25">Related-Party Transaction Review and Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_26">SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_27">INSIDER TRADING POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_28">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_29">EXECUTIVE COMPENSATION DISCUSSION AND ANALYSIS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_30">2018 Operating Highlights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_31">Compensation Philosophy and Objectives</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_32">REMUNERATION COMMITTEE REPORT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_33">Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_34">Grants of Plan-Based Awards</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_35">Option Exercises and Stock Vested</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_36">Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End
</FONT></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_37">Pension Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_38">Nonqualified Deferred Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_39">Employment, Change of Control and Severance Arrangements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_40">Potential Payments upon Change of Control Termination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_41">Chief Executive Officer Pay Ratio</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_42">DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_43"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_44">REPORT OF THE AUDIT COMMITTEE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_45">SHAREHOLDER PROPOSALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_46">DELIVERY OF PROXY MATERIALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc662434_47">PROXY FORM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019 ANNUAL GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON MAY&nbsp;20, 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_1"></A>GENERAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors (the
&#147;<B><I>Board</I></B>&#148;) of Amarin Corporation plc, a public limited company registered in England&nbsp;&amp; Wales (&#147;<B><I>Amarin</I></B>&#148;, the &#147;<B><I>Company</I></B>&#148;, &#147;<B><I>we</I></B>&#148; or
&#147;<B><I>us</I></B>&#148;) for use at the Company&#146;s 2019 Annual General Meeting of Shareholders (the &#147;<B><I>Annual General Meeting</I></B>&#148;) to be held at The Merrion Hotel, Upper Merrion Street, Dublin 2, Ireland on May&nbsp;20,
2019 at 2:00 p.m. local time for the purpose of considering and, if thought fit, passing the resolutions specified in the Notice of Annual General Meeting. This Proxy Statement is being mailed to shareholders on or about April
&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a proxy to be effective, it must be properly executed and dated and lodged (together with a duly
signed and dated power of attorney or other authority (if any) under which it is executed (or a notarially certified copy of such power of attorney or other authority)) at the offices of the Company&#146;s registrars, Equiniti Limited of Aspect
House, Spencer Road, Lancing, West Sussex, BN99 6DA, England (the &#147;<B><I>Registrars</I></B>&#148;) so as to be received by 14:00 p.m. local time on 16&nbsp;May 2019. Each proxy properly tendered will, unless otherwise directed by the
shareholder, be voted FOR the nominees described in this Proxy Statement and FOR each other proposal described in the Proxy Statement, and at the discretion of the proxy holder(s) with regard to all other matters that may properly come before the
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will pay all of the costs of soliciting proxies. We will provide copies of our proxy materials to Citibank, N.A. as
the depositary for our American Depositary Shares (the &#147;<B><I>Depositary</I></B>&#148;), brokerage firms, fiduciaries and custodians for forwarding to beneficial owners and will reimburse these persons for their costs of forwarding these
materials. We have engaged Okapi Partners to assist us in the distribution and solicitation of proxies for a fee of $15,000 plus expenses. Our directors, officers and employees may also solicit proxies; however, we will not pay them additional
compensation for any of these services. Proxies may be solicited by telephone, facsimile, or personal solicitation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares Outstanding and Voting
Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amarin is registered in England&nbsp;&amp; Wales and therefore subject to the United Kingdom Companies Act 2006 (the
&#147;<B><I>Companies Act</I></B>&#148;), which, together with the Articles of Association of the Company (the &#147;<B><I>Articles</I></B>&#148;), governs the processes for shareholder voting at Annual General Meetings. There are a number of
differences between English and U.S. law in relation to voting. At the Annual General Meeting, a resolution put to the vote of the meeting shall be decided on a show of hands unless a poll is demanded (either before a show of hands on that
resolution or immediately after the result of a show of hands on that resolution is declared) by (a)&nbsp;the chairman, (b)&nbsp;at least two shareholders entitled to vote at the meeting, (c)&nbsp;a shareholder or shareholders representing not less
than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the total voting rights of all shareholders having the right to vote at the meeting (excluding any voting rights attached to shares that are held as treasury shares) or (d)&nbsp;a shareholder
or shareholders holding shares conferring a right to vote at the meeting being shares on which an aggregate sum has been paid up equal to not less than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the total sum paid up on all shares
conferring that right (excluding any shares in the Company conferring a right to vote at the meeting that are held as treasury shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only holders of record of our ordinary shares with a par value of &pound;0.50 each (&#147;<B><I>Ordinary Shares</I></B>&#148;) at the close of
business on April&nbsp;11, 2019 (the &#147;<B><I>Record Date</I></B>&#148;), are entitled to notice of, and to attend and to vote at, the Annual General Meeting. On the Record Date, approximately 334,427,855 Ordinary Shares were issued and
330,640,297 were outstanding, of which approximately 330,433,208 were held in the name of the Depositary, which issues Company-sponsored American Depositary Receipts (&#147;<B><I>ADRs</I></B>&#148;) evidencing American Depositary Shares
(&#147;<B><I>ADSs</I></B>&#148;) which, in turn, each represent one Ordinary Share. With respect to all matters to be voted on at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Annual General Meeting, each shareholder present has only one vote unless demand is made for a vote on a poll (in which case each shareholder gets one vote per Ordinary Share held). The
presence, in person or by proxy, of at least two shareholders who hold shares as of the Record Date will constitute a quorum for the transaction of business at the Annual General Meeting. At any adjournment of the Annual General Meeting, if a quorum
is not present within 15 minutes from the time appointed for such meeting, one person entitled to be counted in a quorum present at the adjournment shall be a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who hold Ordinary Shares directly on the Record Date (&#147;<B><I>record holders</I></B>&#148;) must return a proxy card or attend the
Annual General Meeting in person in order to vote on the proposals. Persons who own Ordinary Shares indirectly on the Record Date through a brokerage firm, bank or other financial institution, including persons who own Ordinary Shares in the form of
ADSs through the Depositary (&#147;<B><I>beneficial owners</I></B>&#148;) must return a voting instruction form to have their shares or the shares underlying their ADSs, as the case may be, voted on their behalf. Brokerage firms, banks or other
financial institutions that do not receive voting instructions from beneficial owners may either return a proxy leaving these shares <FONT STYLE="white-space:nowrap">un-voted</FONT> (a &#147;<B><I>broker
<FONT STYLE="white-space:nowrap">non-vote</FONT></I></B>&#148;) or vote these shares on behalf of the beneficial owners. Your brokerage firm, bank or other financial institution may vote your shares on routine matters and cannot vote your shares on
any <FONT STYLE="white-space:nowrap">non-routine</FONT> matter. The appointment of our independent registered public accounting firm (Proposal 4) is a routine matter. We encourage you to provide voting instructions to your brokerage firm, bank or
other financial institution by giving your proxy to them. This ensures that your shares will be voted at the Annual Meeting according to your instructions. You should receive directions from your brokerage firm, bank or other financial institution
about how to submit your proxy to them at the time you receive this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADR holders are not entitled to vote directly at the
Annual General Meeting, but an Amended and Restated Deposit Agreement dated as of November&nbsp;4, 2011 (the &#147;<B><I>Deposit Agreement</I></B>&#148;), exists between the Depositary and the holders of ADRs pursuant to which registered holders of
ADRs as of the Record Date are entitled to instruct the Depositary as to the exercise of voting rights pertaining to the Ordinary Shares so represented. The Depositary has agreed that it will endeavor, insofar as practicable, to vote (in person or
by delivery to the Company of a proxy) the Ordinary Shares registered in the name of the Depositary, in accordance with the instructions of the ADR holders. In the event that the instruction card is executed but does not specify the manner in which
the Ordinary Shares represented are to be voted (i.e., by marking a vote &#147;FOR&#148;, &#147;AGAINST&#148; or any other option), the Depositary will vote in respect of each proposal as recommended by the Board which is described in the Notice of
Annual General Meeting. Instructions from the ADR holders must be sent to the Depositary so that the instructions are received by no later than 10:00 a.m. New York time on May&nbsp;13, 2019 (the &#147;<B><I>Instruction Date</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has retained the Registrars to hold and maintain its register of members. The Registrars will be engaged by the Company to send
proxy forms to all registered members appearing on that register and to take delivery of completed proxy forms posted to it in accordance with the details above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted for the purpose of determining the presence or
absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal. The required vote for each of the proposals expected to be acted upon at the Annual General Meeting is described below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Resolutions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proposals No.</I><I></I><I>&nbsp;1 and No. 2&#151;Election of directors</I>. Each director nominated for election is elected if (i)&nbsp;on
a show of hands, a majority of shareholders present in person or by proxy and voting on the proposal vote in favor of such director or (ii)&nbsp;on a poll, a majority of the shares present at the meeting in person or by proxy and voting on the
proposal are voted in favor of such director. As a result, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proposal No. 3&#151;Advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> vote
to approve the compensation of the Company&#146;s named executive officers</I>. This advisory proposal will be approved if (i)&nbsp;on a show of hands, a majority of shareholders present in person or by proxy and voting on the proposal vote in favor
of the resolution or (ii)&nbsp;on a poll, a majority of the shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of the resolution. As a result, abstentions and broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proposal No. 4</I>&#151;<I>Approval of
independent registered public accounting firm</I>. This proposal will be approved if (i)&nbsp;on a show of hands, a majority of shareholders present in person or by proxy and voting on the proposal vote in favor of the resolution or (ii)&nbsp;on a
poll, a majority of the shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of the resolution. As a result, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on
the vote outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proposal No.</I><I></I><I>&nbsp;5</I>&#151;<I> Renewal of the power of the directors to allot shares</I>. This
proposal will be approved if (i)&nbsp;on a show of hands,&nbsp;a majority of shareholders present in person&nbsp;or by proxy&nbsp;and voting&nbsp;on the proposal vote&nbsp;in favor of&nbsp;the resolution or (ii)&nbsp;on a poll, a majority of the
shares present at the meeting&nbsp;in person or by proxy and&nbsp;voting on the proposal are voted in favor of the resolution. As a result, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote
outcome. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Special Resolution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proposal No.</I><I></I><I>&nbsp;6</I>&#151;<I>Approval of the disapplication of <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights
to holders of ordinary shares</I>. Approval of this proposal requires (i)&nbsp;on a show of hands, the affirmative vote of at least 75% of the holders of shares present at the meeting in person or by proxy and voting on the proposal or (ii)&nbsp;on
a poll, the affirmative vote of at least 75% of the shares present at the meeting in person or by proxy and voting on the proposal. As a result, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote
outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We encourage you to vote by proxy by mailing an executed proxy card. By voting in advance of the meeting, this ensures that your
shares will be voted and reduces the likelihood that the Company will be forced to incur additional expenses soliciting proxies for the Annual General Meeting. Any record holder of our Ordinary Shares may attend the Annual General Meeting in person
and may revoke the enclosed form of proxy at any time by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">executing and delivering to the corporate secretary a later-dated proxy; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting in person at the Annual General Meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial owners of our Ordinary Shares and ADSs representing our Ordinary Shares who wish to change or revoke their voting instructions
should contact their brokerage firm, bank or other financial institution or the Depositary, as applicable, for information on how to do so. Generally, however, beneficial owners of our Ordinary Shares and ADSs representing our Ordinary Shares who
wish to change or revoke their voting instructions may do so up until 10:00 a.m. New York time on the Instruction Date. Beneficial owners who wish to attend the Annual General Meeting and vote in person should contact their brokerage firm, bank or
other financial institution holding Ordinary Shares of Amarin on their behalf in order to obtain a &#147;legal proxy&#148; which will allow them to both attend the meeting and vote in person. Without a legal proxy, beneficial owners cannot vote at
the Annual General Meeting because their brokerage firm, bank or other financial institution may have already voted or returned a broker <FONT STYLE="white-space:nowrap">non-vote</FONT> on their behalf. Record holders of ADRs who wish to attend the
Annual General Meeting and vote in person should contact the Depositary (and beneficial owners wishing to do the same should contact their brokerage firm, bank or other financial institution holding their ADSs) to cause their ADSs to be cancelled
and the underlying shares to be withdrawn in accordance with the terms and conditions of the Deposit Agreement so as to be recognized by us as a record holder of our Ordinary Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_2"></A>PROPOSALS NOS. 1 AND 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Articles provide that, at every annual general meeting, at least <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors at the time shall retire from office (or, if the number of directors at the time is not a multiple of three, then the
number nearest to but not exceeding <FONT STYLE="white-space:nowrap">one-third</FONT> shall retire from office). The directors elected at the Annual General Meeting will hold office until their successors are elected and qualified, unless they
resign or their seats become vacant due to death, removal, or other cause in accordance with the Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described below, the Board
has nominated Mr.&nbsp;van Heek and Ms.&nbsp;Peterson for <FONT STYLE="white-space:nowrap">re-election</FONT> at the Annual General Meeting. Each of the nominees has indicated his or her willingness to serve if
<FONT STYLE="white-space:nowrap">re-elected.</FONT> Should any of the nominees become unavailable for election at the Annual General Meeting, the persons named on the enclosed proxy as proxy holders may vote all proxies given in response to this
solicitation for the election of a substitute nominee chosen by the Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_3"></A>Nomination of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee, which acts as the Company&#146;s nominating committee, reviews and recommends to the Board
potential nominees for election to the Board. In reviewing potential nominees, the Nominating and Corporate Governance Committee considers the qualifications of each potential nominee in light of the Board&#146;s existing and desired mix of
experience and expertise. Specifically, as set forth in our Nominating and Corporate Governance Committee Charter, it considers whether the nominee satisfies the following minimum criteria: has experience at a strategic or policymaking level in a
business, government, <FONT STYLE="white-space:nowrap">non-profit</FONT> or academic organization of high standing; is highly accomplished in his or her field, with superior credentials and recognition; is well regarded in the community and has a
long-term reputation for the highest ethical and moral standards; has sufficient time and availability to devote to the affairs of the Company, particularly in light of the number of boards on which the nominee may serve; has a demonstrated history
of actively contributing at board meetings (to the extent that the nominee serves or has previously served on other boards). In addition to these minimum qualifications, the Nominating and Corporate Governance Committee recommends that the Board
select persons for nomination to help ensure that: a majority of the Board shall be independent in accordance with in the listing standards of the NASDAQ Global Select Market (&#147;<B><I>NASDAQ</I></B>&#148;); each of the Company&#146;s Audit,
Remuneration and Nominating and Corporate Governance Committees shall be comprised entirely of independent directors; and at least one member of the Audit Committee shall qualify as an audit committee financial expert as defined by Securities and
Exchange Commission (&#147;<B><I>SEC</I></B>&#148;) rules. In addition, the Nominating and Corporate Governance Committee may consider whether the nominee has direct experience in the pharmaceutical, biotechnology or healthcare industries or in the
markets in which the Company operates and whether the nominee, if elected, would assist in achieving a mix of Board members that represents a diversity of background and experience. Although the Nominating and Corporate Governance Committee may
consider whether nominees assist in achieving a mix of Board members that represents a diversity of background and experience, which is not only limited to race, gender or national origin, we have no formal policy regarding board diversity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After reviewing the qualifications of potential Board candidates, the Nominating and Corporate Governance Committee presents its
recommendations to the Board, which selects the final director nominees. Upon the recommendation of the Nominating and Corporate Governance Committee, the Board nominated Mr.&nbsp;van Heek and Ms.&nbsp;Peterson for
<FONT STYLE="white-space:nowrap">re-election</FONT> as directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee considers shareholder
nominees using the same criteria set forth above. Shareholders who wish to present a potential nominee to the Nominating and Corporate Governance Committee for consideration for election at a future annual general meeting of shareholders must
provide the Nominating and Corporate Governance Committee with notice of the nomination and certain information regarding the candidate within the time periods set forth below under the caption &#147;Shareholder Proposals.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_4"></A>Nominees and Incumbent Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee has recommended, and the Board has nominated, Mr.&nbsp;van Heek and Ms.&nbsp;Peterson to be <FONT
STYLE="white-space:nowrap">re-elected</FONT> as directors at the Annual General Meeting. The table below sets forth the following information for these nominees and the Company&#146;s continuing directors: the year each was first elected as a
director of the Company, their respective ages and the positions currently held with the Company: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Nominee / Director Name and Year First Became a
<BR>Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position(s) with the Company</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Nominees for Director:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jan van Heek (2010)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson (2010)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors Continuing in Office:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lars G. Ekman, M.D., Ph.D. (2008)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Stack (2012)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph S. Zakrzewski (2010)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. O&#146;Sullivan (2011)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero (2014)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer, Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_5"></A>Directors Nominated for Election </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following persons have been nominated by the Board to be elected as directors at the Annual General Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Jan van Heek</I> joined Amarin as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director in February 2010. He is currently a
Principal and Partner at BioPoint Group, where he advises biotechnology and other healthcare companies in commercial strategy development, financing and business development. Prior to establishing BioPoint, Mr.&nbsp;van Heek spent more than 18 years
at Genzyme Corporation, most recently as an Executive Vice President and Senior Advisor to the Chief Executive Officer and senior management team. Mr.&nbsp;van Heek is currently a board member of Minerva Neurosciences, Inc. and was a board member
and Chairman of the Audit Committee of ViaCell Corporation, a U.S. public company, from 2002 until it was sold to Perkin Elmer Corporation in 2007. He received an M.B.A. from St. Gallen University in Switzerland and an executive degree from Stanford
Business School. Based on Mr.&nbsp;van Heek&#146;s experience within the biotechnology industry and his executive experience, specifically his experience in executive officer positions at other companies in the biotechnology industry, as well as his
service on other boards of directors, the Board believes Mr.&nbsp;van Heek has the appropriate set of skills to serve as a member of our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Kristine Peterson</I> joined Amarin as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director in November 2010. Ms.&nbsp;Peterson
has more than 30 years of pharmaceutical industry experience, including 20 years at Bristol-Myers Squibb Company, where she was responsible for sales, marketing and general management in a variety of therapeutic areas, including leading the
cardiovascular and metabolic disease business unit. From June 2009 to February 2016, she served as Chief Executive Officer at Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug
delivery solutions, with its lead product for the treatment of diabetes. Prior to joining Valeritas, Ms.&nbsp;Peterson was Company Group Chair for the biotech business at Johnson&nbsp;&amp; Johnson from May 2006 through June 2009, was an Executive
Vice President at Johnson&nbsp;&amp; Johnson from August 2004 through May 2006 and was Senior Vice President of commercial operations at Biovail Corporation from May 2003 to August 2004. Ms.&nbsp;Peterson is currently a director of Paratek
Pharmaceuticals, Inc., ImmunoGen, Inc., EyePoint Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc. and the Greater Philadelphia Life Sciences Congress. Ms.&nbsp;Peterson has an M.B.A. in Marketing from the University of Illinois. Based on
Ms.&nbsp;Peterson&#146;s leadership experience in the pharmaceutical industry and her executive experience, specifically her experience as an executive officer at other commercial stage companies in the biotechnology industry, as well as her service
on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other boards of directors in the biotechnology industry and a leading biotech industry trade organization, the Board believes Ms.&nbsp;Peterson has the appropriate set of skills to serve as a
member of our Board. Ms.&nbsp;Peterson&#146;s contribution to the Company in the areas of commercialization and regulatory and political matters has been particularly helpful as the Company continues its current stage of development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_6"></A>Directors Continuing in Office </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Lars G. Ekman, M.D., Ph.D</I>. joined Amarin as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director in November 2008, and was
named Amarin&#146;s lead independent director in October 2011 and Amarin&#146;s Chairman of the Board effective January 2014. With more than 30 years of experience in the pharmaceutical industry, Dr.&nbsp;Ekman is currently an executive partner at
Sofinnova Ventures and serves as Chairman of Sophiris Bio Inc. (formerly Protox Therapeutics) as well as Chairman of Prothena Biosciences. From October 2008 to 2011 he served as <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive
Officer of Cebix Inc. He was Executive Vice President and President of Global Research and Development at Elan Corporation plc, from January 2001 to December 2007. Prior to joining Elan, he was Executive Vice President, Research and Development at
Schwarz Pharma AG from February 1997 to December 2000, and prior to that was employed in a variety of senior scientific and clinical functions at Pharmacia, now Pfizer. Dr.&nbsp;Ekman also sits on the board of directors of Ultragenyx Pharmaceutical
Inc. and Spark Therapeutics. Dr.&nbsp;Ekman is a board-certified surgeon with a Ph.D. in experimental biology and has held several clinical and academic positions in both the United States and Europe. He obtained his Ph.D. and M.D. from the
University of Gothenburg, Sweden. Based on Dr.&nbsp;Ekman&#146;s experience within the pharmaceutical industry and his executive experience, specifically his experience as Chief Executive Officer and other executive positions in the biotechnology
industry, as well as his service on boards of directors in the biotechnology industry, the Board believes Dr.&nbsp;Ekman has the appropriate set of skills to serve as a member of our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>David Stack</I> joined Amarin as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director in December 2012. Mr.&nbsp;Stack is
currently the President and Chief Executive Officer of Pacira Pharmaceuticals, Inc. Mr.&nbsp;Stack was a managing director of MPM Capital from 2005 until 2017 and a managing partner of Stack Pharmaceuticals, Inc. since 1998. From 2001 to 2004, he
was President and Chief Executive Officer of The Medicines Company. Previously, Mr.&nbsp;Stack was President and General Manager at Innovex, Inc. He was Vice President, Business Development/Marketing at Immunomedics from 1993 until 1995. Prior to
that, he was with Roche Laboratories from 1981 until 1993, in various positions including therapeutic world leader in infectious disease and director, business development and planning, infectious disease, oncology, and virology. He currently serves
as a member of the board of directors of Pacira Pharmaceuticals, Inc., Chiasma, Inc. and Prognos AI. He was a member of the boards of directors of Molecular Insight Pharmaceuticals, Inc. from 2006 to 2010 and BioClinica, Inc. from 1999 to 2010.
Mr.&nbsp;Stack holds a B.S. in Pharmacy from Albany College of Pharmacy and a B.S. in Biology from Siena College. The Board believes that Mr.&nbsp;Stack&#146;s qualifications to sit on our Board include his extensive experience with pharmaceutical
companies as an executive and director, his financial expertise and his years of experience providing strategic and financial advisory services to pharmaceutical and biotechnology organizations in all stages of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Joseph S. Zakrzewski</I> joined Amarin as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director in January 2010. From November
2010 to December 2013, Mr.&nbsp;Zakrzewski served as Amarin&#146;s Chief Executive Officer and Chairman of the Board of Directors. From May 2007 to May 2010, Mr.&nbsp;Zakrzewski served as President and Chief Executive Officer of Xcellerex, a
privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics, and from January 2005 to May 2007, Mr.&nbsp;Zakrzewski served as the Chief Operating Officer of Reliant Pharmaceuticals.
From 1988 to 2004, Mr.&nbsp;Zakrzewski served in a variety of positions at Eli Lilly and Company including as Vice President, Corporate Business Development from 2003 through 2004. In addition, Mr.&nbsp;Zakrzewski served as a Venture Partner with
Orbimed in 2010 and 2011. Mr.&nbsp;Zakrzewski is currently the Chairman of Onxeo and serves on the board of directors of Onxeo, Acceleron Pharma, and Sangamo Therapeutics as well as a number of privately held companies. Mr.&nbsp;Zakrzewski earned a
B.S. in Chemical Engineering and an M.S. in Biochemical Engineering from Drexel University as well as an M.B.A. in Finance from Indiana University. The Board believes that Mr.&nbsp;Zakrzewski should serve on our Board
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
based on his knowledge of our Company gained from his former position as Chief Executive Officer and his substantial experience serving as an executive officer of other pharmaceutical companies,
as well as Mr.&nbsp;Zakrzewski&#146;s service as a member of boards of directors of other pharmaceutical companies. Mr.&nbsp;Zakrzewski&#146;s contribution to the Company in the areas of operations and business development matters has been
particularly helpful as the Company continues its current stage of development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Patrick J. O&#146;Sullivan </I>joined Amarin as a <FONT
STYLE="white-space:nowrap">non-executive</FONT> director in December 2011. Mr.&nbsp;O&#146;Sullivan has more than 40 years of pharmaceutical industry experience, including more than 30 years as Chief Executive Officer and board member of the LEO
Pharma companies in Ireland and more than 10 years as a board member of the parent company of the LEO Pharma Group in Denmark. He was also a member of the board of directors of Allergan plc from 2013 to 2018. Since 2007, Mr.&nbsp;O&#146;Sullivan has
been a business consultant to the pharmaceutical industry. Mr.&nbsp;O&#146;Sullivan trained as a pharmacist. He earned a Bachelor of Commerce and an M.B.A. from University College in Dublin. The Board believes that Mr.&nbsp;O&#146;Sullivan&#146;s
experience from serving as an officer director of various companies within the pharmaceutical industry, as well as his educational training in business administration, make him a valuable member of our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>John F. Thero</I> joined Amarin in November 2009. He was promoted to President and Chief Executive Officer, and appointed to the Board,
effective January 2014. Prior to his promotion, he was Amarin&#146;s President since November 2010 before which he was Amarin&#146;s Chief Financial Officer. Mr.&nbsp;Thero has more than 25 years of senior financial and operational management
experience, including supporting the growth of life science companies for over 15 years. Prior to Amarin, Mr.&nbsp;Thero also served in a variety of roles and has helped manage both the successful commercial growth and the successful sale of
companies between 1994 and 2007. Mr.&nbsp;Thero began his professional career at Arthur Andersen LLP, during which time he became a Certified Public Accountant. He currently serves as a member of the board of directors of Chiasma, Inc. He received a
B.A. in Economics from the College of the Holy Cross. The Board believes that Mr.&nbsp;Thero&#146;s experience in management positions at life sciences companies, as well as his experience as Amarin&#146;s President and Chief Executive Officer and,
before that, as Amarin&#146;s President and Chief Financial Officer, provide him with the appropriate qualifications and skills to serve as a member of the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each nominee will be
elected to the Board if (i)&nbsp;on a show of hands, a majority of shareholders present in person or by proxy and voting on the proposal vote in favor of such director or (ii)&nbsp;on a poll, a majority of the shares present at the meeting in person
or by proxy and voting on the proposal are voted in favor of such director. As a result, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of proxies solicited by this Proxy Statement will vote the proxies received by them as directed on the proxy card or, if no direction
is made, then FOR the election of all the nominees named in this Proxy Statement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE
&#147;FOR&#148; </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EACH OF THE NOMINEES IDENTIFIED ABOVE. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_7"></A>PROPOSAL NO. 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADVISORY VOTE ON EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_8"></A>Background </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
recommended by our shareholders at our 2017 annual general meeting and subsequently approved by our Board, we give our shareholders the opportunity to cast an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> vote to approve the
compensation of the Company&#146;s &#147;named executive officers,&#148; each year (a <FONT STYLE="white-space:nowrap">so-called</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> vote). At
the 2018 annual general meeting, the Company&#146;s shareholders supported the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote with 96.2% of the votes cast in favor of the proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote is a
<FONT STYLE="white-space:nowrap">non-binding</FONT> vote to approve the compensation of the Company&#146;s &#147;named executive officers,&#148; as described in this Proxy Statement under the &#147;Executive Compensation Discussion and
Analysis&#148; section, the tabular disclosure regarding such compensation, and the accompanying narrative disclosure on pages 25 to 55 of this Proxy Statement. Our philosophy in setting compensation policies for executive officers has two
fundamental objectives: (1)&nbsp;to attract and retain a highly skilled team of executives and (2)&nbsp;to align our executives&#146; interests with those of our shareholders by rewarding short-term and long-term performance and tying compensation
to increases in shareholder value. The Remuneration Committee believes that executive compensation should be directly linked both to continuous improvements in corporate performance <FONT STYLE="white-space:nowrap">(so-called</FONT> &#147;pay for
performance&#148;) and accomplishments that are expected to increase shareholder value. The &#147;Executive Compensation Discussion and Analysis&#148; section herein provides a more detailed discussion of the executive compensation program and
compensation philosophy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vote under this Proposal No.&nbsp;3 is advisory, and therefore not binding on the Company, the Board or our
Remuneration Committee. However, our Board, including our Remuneration Committee, values the opinions of our shareholders and, considers changes to our executive compensation program as appropriate in response to input from shareholders and evolving
factors such as the business environment and competition for talent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders will be asked at the Annual General Meeting to approve
the following resolution pursuant to this Proposal No.&nbsp;3: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>RESOLVED</B>, that the shareholders of the Company approve, on a <FONT
STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation of the Company&#146;s &#145;named executive officers,&#146; as disclosed in this Proxy Statement under the &#147;Executive Compensation Discussion and Analysis&#148;
section, the compensation tables and the narrative disclosures that accompany the compensation tables.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This advisory proposal will be approved if (i)&nbsp;on a show of hands, a majority of shareholders present in person or by proxy and voting on
the proposal vote in favor of the resolution or (ii)&nbsp;on a poll, a majority of the shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of the resolution. As a result, abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE
&#147;FOR&#148; PROPOSAL NO. 3. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_9"></A>PROPOSAL NO. 4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Audit Committee has selected Ernst&nbsp;&amp; Young LLP (&#147;<B><I>E&amp;Y</I></B>&#148;) as our independent registered public
accounting firm for the fiscal year ending December&nbsp;31, 2019, and has further directed that we submit the selection of E&amp;Y for approval by our shareholders at the Annual General Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee reviews and <FONT STYLE="white-space:nowrap">pre-approves</FONT> all audit and
<FONT STYLE="white-space:nowrap">non-audit</FONT> services performed by its independent registered public accounting firm, as well as the fees charged for such services. All fees incurred in fiscal 2018 for services rendered by E&amp;Y were approved
in accordance with these policies. In its review of <FONT STYLE="white-space:nowrap">non-audit</FONT> service fees, the Audit Committee considers, among other things, the possible impact of the performance of such services on the auditor&#146;s
independence. The Audit Committee has determined that the <FONT STYLE="white-space:nowrap">non-audit</FONT> services performed by E&amp;Y in the fiscal year ended December&nbsp;31, 2018 were compatible with maintaining the auditor&#146;s
independence. Additional information concerning the Audit Committee and its activities can be found in the following sections of this Proxy Statement: &#147;Board Committees&#148; and &#147;Report of the Audit Committee.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E&amp;Y commenced auditing our annual financial statements with the fiscal year ended December&nbsp;31, 2014. Representatives of E&amp;Y are
expected to be available telephonically at the Annual General Meeting, will have the opportunity to make a statement if they desire to do so and will be available to respond to appropriate shareholder questions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_10"></A>Fees for Independent Registered Public Accounting Firm&#151;E&amp;Y </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the fees billed to the Company by E&amp;Y for professional services rendered for the fiscal years ended
December&nbsp;31, 2018 and 2017. Audit fees are for services relating to the years ended December&nbsp;31, 2018 and 2017 as described in (1)&nbsp;below and all <FONT STYLE="white-space:nowrap">non-audit</FONT> fees are for services invoiced in 2018
and 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Audit
Fees<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,663,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,287,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Audit-Related Fees:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Tax
Fees<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>All Other Fees:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Total All Fees:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,678,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,293,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit fees for 2018 include fees incurred in connection with the audit of our financial statements as of
December&nbsp;31, 2018, as prepared in accordance with U.S. Generally Accepted Accounting Principles (&#147;<B><I>GAAP</I></B>&#148;), costs incurred in connection with the audit of statutory financial statements as of December&nbsp;31, 2017, as
prepared in accordance with International Financial Reporting Standards (&#147;<B><I>IFRS</I></B>&#148;), and costs incurred in connection with registration statement filings. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax fees consist primarily of tax advisory fees and costs incurred for the preparation of tax returns and other
related statutory filings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders will be asked at the Annual General Meeting to approve the following resolution
pursuant to this Proposal No.&nbsp;4: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>RESOLVED</B>, to appoint Ernst&nbsp;&amp; Young LLP as the Company&#146;s auditors to hold
office from the conclusion of this meeting until the conclusion of the next meeting at which the annual accounts are laid before the Company and to authorize the directors to agree upon the remuneration of the auditors.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that shareholders do not approve the foregoing resolution, we will need to
engage a third-party auditor who will act as our independent registered public accounting firm under U.S. law and as our statutory auditor under UK law for the fiscal year ending December&nbsp;31, 2019. We may proceed to engage such firm as our
Board and Audit Committee deem advisable, which firm may include E&amp;Y. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proposal will be approved if (i)&nbsp;on a show of hands, a majority of shareholders present in person or by proxy and voting on the
proposal vote in favor of the resolution or (ii)&nbsp;on a poll, a majority of the shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of the resolution. As a result, abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE
&#147;FOR&#148; PROPOSAL NO. 4 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_11"></A>PROPOSAL&nbsp;NO.&nbsp;5 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RENEWAL OF THE POWER OF THE DIRECTORS TO ALLOT SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Companies Act, the directors of a public company may exercise the power of the company to allot shares in the company or to grant
rights to subscribe for or to convert any security into shares in the company if they are authorized to do so by the company&#146;s articles of association or by resolution of the company. Any such authorization is only valid for a maximum period of
five years. The grant of a general power of allotment by the Company&#146;s shareholders is an additional step not generally required when companies domiciled in the United Sates are issuing securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Proposal&nbsp;No. 5 seeks shareholder approval of a grant of authority to the Board to allot shares in the Company or grant rights to
subscribe for or to convert any security into shares (the &#147;<B><I>Rights</I></B>&#148;) up to an aggregate nominal amount of &pound;148,000,000 (being the aggregate nominal amount of &pound;125,000,000 in respect of ordinary shares and
&pound;23,000,000 in respect of preference shares), provided that such authority shall, unless renewed, varied or revoked by the Company, expire on the fifth anniversary of the passing of the applicable resolution, except that the Company may,
before such expiration, make an offer or agreement which would, or might, require shares to be allotted or Rights to be granted after the expiration of such period and the Board may allot relevant securities in pursuance of any such offer or
agreement notwithstanding that the authority conferred by this resolution has expired. This proposal is consistent with the authorization approved by our shareholders at a general meeting of the Company held on July 6, 2015 and includes the same
level of limitation as the proposal that was previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The previously approved authorization, pursuant to which the Company
currently may allot shares, will expire on July&nbsp;6, 2020. The Board believes that it is important for the Company to retain the flexibility to allot equity securities on an accelerated basis should the Board determine it is necessary or
advisable and in the best interests of shareholders, without incurring the costs or delays associated with calling a special meeting and preparing and circulating proxy materials to approve specific allotments of shares. The Board also believes that
a large majority of public companies based in the United States do not require shareholder approval of each issuance and allotment of common equity. Without the approval of this Proposal No.&nbsp;5, the Company may not be able to raise additional
capital, in a timely manner or at all, if and as needed to fund its ongoing business and operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has no present plans or
proposals to effect share issues in a single transaction, or to a small number of persons resulting in one or more of such persons becoming a principal shareholder of the Company with the attendant ability to exercise significant influence over the
Company&#146;s affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders will be asked at the Annual General Meeting to approve the following resolution pursuant to this
Proposal No.&nbsp;5: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>RESOLVED</B>, to generally and unconditionally reauthorize the Board of Directors of the Company, in
accordance with Section&nbsp;551 of the Companies Act 2006, to exercise all powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares of the Company
(&#147;<B><I>Rights</I></B>&#148;) up to an aggregate nominal amount of &pound;148,000,000 (being the aggregate nominal amount of &pound;125,000,000 in respect of ordinary shares and &pound;23,000,000 in respect of preference shares), provided that
this authority shall, unless renewed, varied, or revoked by the Company, expire on the date five years from the date on which this resolution is passed, except that the Company may, before such expiration, make an offer or agreement which would, or
might, require shares to be allotted or Rights to be granted after the expiration of such period and the Board may allot shares or grant Rights in pursuance of any such offer or agreement notwithstanding that the authority conferred by this
resolution has expired.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proposal will be approved if (i)&nbsp;on a show of hands,&nbsp;a majority of shareholders present in person&nbsp;or by proxy&nbsp;and
voting&nbsp;on the proposal vote&nbsp;in favor of&nbsp;the resolution or (ii)&nbsp;on a poll, a majority of the shares present </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at the meeting&nbsp;in person or by proxy and&nbsp;voting on the proposal are voted in favor of the resolution. As a result, abstentions and broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE
&#147;FOR&#148; PROPOSAL NO. 5 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_12"></A>PROPOSAL&nbsp;NO.&nbsp;6 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISAPPLICATION OF <FONT STYLE="white-space:nowrap">PRE-EMPTIVE</FONT> RIGHTS TO HOLDERS OF ORDINARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-emptive</FONT> rights can be disapplied with respect to a specific allotment of securities by a special
resolution of shareholders. Obtaining disapplication of <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights at the time of each individual proposed stock issuance is time-consuming and costly. To reduce such costs, minimize the delays
associated with convening special meetings of shareholders, and provide the Company with sufficient flexibility in the issuance of equity securities on such terms and conditions as the Board considers to be in the best interests of the Company and
its shareholders, the Board is asking the Company&#146;s shareholders to resolve, subject to Proposal No.&nbsp;5 being passed and in accordance with Section&nbsp;570 of the Companies Act, that the directors be generally empowered to allot equity
securities (as defined in Section&nbsp;560 of the Companies Act) pursuant to the authority conferred by Proposal No.&nbsp;5, as if Section&nbsp;561(1) of the Companies Act did not apply to any such allotment, provided that this power shall
(1)&nbsp;be limited to the allotment of equity securities up to an aggregate nominal amount of &pound;148,000,000 (being the aggregate nominal amount of &pound;125,000,000 in respect of ordinary shares and &pound;23,000,000 in respect of preference
shares) and (2)&nbsp;expire on the date being the fifth anniversary of the date of passing of this resolution (unless renewed, varied or revoked by the Company prior to or on that date), except that the Company may, before such expiration, make an
offer or agreement which would, or might, require equity securities to be allotted after such expiration and the directors may allot equity securities in pursuance of any such offer or agreement notwithstanding that the authority conferred hereby
has expired. The securities in respect of which the Board is seeking disapplication of shareholders&#146; <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights are equity securities as defined in Section&nbsp;560 of the Companies Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has no present plans or proposals to effect share issues in a single transaction, or to a small number of persons resulting in one
or more of such persons becoming a principal shareholder of the Company with the attendant ability to exercise significant influence over the Company&#146;s affairs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company currently may allot shares without such allotment being subject to statutory <FONT STYLE="white-space:nowrap">pre-emptive</FONT>
rights of its ordinary shareholders pursuant to an authorization approved by our shareholders at a general meeting of the Company held on 6&nbsp;July 2015. This authorization expires on July&nbsp;6, 2020. The Board believes that a large majority of
public companies based in the United States do not have mandatory <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights provisions with respect to their common equity. Without the approval of this Proposal No.&nbsp;6, the Company may not be
able to raise additional capital, in a timely manner or at all, if and as needed to fund its ongoing business and operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders will be asked at the Annual General Meeting to approve the following resolution pursuant to this Proposal No.&nbsp;6: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>RESOLVED,</B> to generally empower the Board, subject to the passing of Resolution No.&nbsp;5 above and in accordance with
Section&nbsp;570 of the Companies Act 2006, to allot equity securities (as defined in Section&nbsp;560 of the Companies Act) pursuant to the authority conferred upon them by Resolution No.&nbsp;5, as if Section&nbsp;561(1) of the Companies Act did
not apply to any such allotment, provided that the power hereby conferred shall (a)&nbsp;be limited to the allotment of equity securities up to an aggregate nominal amount of &pound;148,000,000 (being the aggregate nominal amount of
&pound;125,000,000 in respect of ordinary shares and &pound;23,000,000 in respect of preference shares); and (b)&nbsp;expire on the date five years from the date on which this resolution is passed (unless renewed, varied or revoked by the Company
prior to or on that date), except that the Company may, before such expiration, make an offer or agreement which would, or might, require equity securities to be allotted after the expiration of such period and the directors may allot equity
securities in pursuance of any such offer or agreement notwithstanding that the authority conferred by this resolution has expired.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of this proposal requires (i)&nbsp;on a show of hands,&nbsp;the affirmative vote of at least 75% of the holders of shares present at
the meeting in person or by proxy and&nbsp;voting on the proposal or (ii)&nbsp;on a poll, the affirmative vote of at least 75% of the&nbsp;shares present at the meeting in person or by proxy and&nbsp;voting on the proposal. As a result, abstentions
and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS
A VOTE &#147;FOR&#148; PROPOSAL NO. 6 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_13"></A>ADDITIONAL BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public limited company organized under the laws of England and Wales, it is a statutory requirement that the Board lay before the Annual
General Meeting the Company&#146;s statutory accounts, which are the Company&#146;s Annual Report for the year ended December&nbsp;31, 2018, as prepared in conformity with GAAP (the &#147;<B><I>Annual Report</I></B>&#148;) and the accounts for the
financial year ended December&nbsp;31, 2018, prepared in accordance with International Financial Reporting Standards (the &#147;<B><I>Statutory Accounts</I></B>&#148;). As required by the Companies Act and the Articles, the Statutory Accounts will
be made available for download in &#147;PDF&#148; format on the Company&#146;s website (<I>http://investor.amarincorp.com</I>) as soon as they are complete, but no later than April&nbsp;28, 2019, which is at least
<FONT STYLE="white-space:nowrap">twenty-one</FONT> clear days in advance of the Annual General Meeting. In addition, hard copies of the Statutory Accounts may be obtained, once they are complete, by contacting the Company&#146;s investor relations
department at Amarin Corporation plc, c/o Amarin Pharma, Inc., 1430 Route 206, Bedminster, NJ 07921 or by telephone at (908) <FONT STYLE="white-space:nowrap">719-1315.</FONT> Shareholders of the Company will not be asked to take any action in
respect of the Statutory Accounts at the Annual General Meeting but shareholders in attendance will have opportunity to ask questions relating to the Statutory Accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We know of no other matters to be submitted to a vote of shareholders at the Annual General Meeting. If any other matter is properly brought
before the Annual General Meeting or any adjournment thereof, it is the intention of the persons named in the enclosed proxy to vote the shares they represent in accordance with their judgment. In order for any shareholder to nominate a candidate at
a given annual general meeting, he or she must provide timely written notice to our corporate secretary pursuant to the terms of our Articles, as described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_14"></A>CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_15"></A>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the Company benefits from having a strong and independent Board. For a director to be considered independent, the Board must
determine that the director does not have any direct or indirect material relationship with the Company that would affect his or her exercise of independent judgment. On an annual basis, the Board reviews the independence of all directors under
guidelines established by NASDAQ and in light of each director&#146;s affiliations with the Company and members of management, as well as significant holdings of Company securities. This review considers all known relevant facts and circumstances in
making an independence determination. Based on this review, the Board has made an affirmative determination that all directors, other than Mr.&nbsp;Thero, are independent. It was determined that Mr.&nbsp;Thero lacks independence because of his
status as the Company&#146;s President and Chief Executive Officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_16"></A>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our Board and its committees, led by a group of strong and independent directors, provide the necessary leadership, wisdom and
experience that the Company needs in making sound business decisions. Our Code of Business Conduct and Ethics helps clarify the operating standards and ethics that we expect of all of our officers, directors and employees in making and implementing
those decisions. Waivers of our Code of Business Conduct and Ethics for the benefit of a director or an executive officer may only be granted by the Board or, if permitted, a committee of the Board, and will be publicly announced promptly in our SEC
filings. Waivers of our Code of Business Conduct and Ethics for the benefit of other employees may be made by our Compliance Officer, the Board or, if permitted, a committee of the Board. In furthering our commitment to these principles, we invite
you to review our Code of Business Conduct and Ethics and other corporate governance materials located on our website at <I>www.amarincorp.com</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_17">
</A>Shareholder Communications </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, shareholders who have questions or concerns regarding the Company should contact our
Investor Relations department at (908) <FONT STYLE="white-space:nowrap">719-1315.</FONT> However, any shareholders who wish to address questions regarding the business or affairs of the Company directly with the Board, or any individual director,
should direct his or her questions in writing to the Lead Independent Director of the Board, Amarin Corporation plc, 2 Pembroke House, Upper Pembroke Street <FONT STYLE="white-space:nowrap">28-32,</FONT> Dublin 2 Ireland or c/o Amarin Pharma, Inc.,
1430 Route 206, Bedminster, NJ 07921. Upon receipt of any such communications, the correspondence will be directed to the appropriate person, including individual directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_18"></A>BOARD OF DIRECTORS AND COMMITTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During our 2018 fiscal year, our Board met in person four times and met by teleconference one time. Each director attended at least 75% of the
aggregate of the meetings of the Board and meetings of the committees of which he or she was a member in our last fiscal year. During fiscal year 2018, our Board had an Audit Committee, a Remuneration Committee and a Nominating and Corporate
Governance Committee. All members of the Audit, Remuneration and Nominating and Corporate Governance Committees are <FONT STYLE="white-space:nowrap">non-employee</FONT> directors who are deemed independent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All members of our Board who were directors at the time attended the 2018 Annual General Meeting of Shareholders, either in person or via
telephone. Although the Company has no formal policies regarding director attendance at annual general meetings, it encourages directors to attend annual general meetings and expects that all members of the Board will attend the 2019 Annual General
Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_19"></A>Board Leadership Structure and Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Lars Ekman is our Chairman of the Board. Dr.&nbsp;Ekman is independent and all key committees of the Board are comprised solely of,
and chaired by, independent directors. The Board believes that this structure, combined with the Company&#146;s established corporate governance guidelines, provides an effective leadership structure for the Company. In addition, to ensure effective
independent oversight of the Company, the Board holds meetings of the independent directors of the Board at every meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has
overall responsibility for the oversight of the Company&#146;s risk management process, which is designed to support the achievement of organizational objectives, including strategic objectives, to improve long-term organizational performance and
enhance shareholder value. Risk management includes not only understanding company-specific risks and the steps management implements to manage those risks, but also what level of risk is acceptable and appropriate for the Company. Management is
responsible for establishing our business strategy, identifying and assessing the related risks and implementing appropriate risk management practices. The Board periodically reviews our business strategy and management&#146;s assessment of the
related risk, and discusses with management the appropriate level of risk for the Company. The Board also delegates oversight to Board committees to oversee selected elements of risk as set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Board&#146;s risk oversight role, our Remuneration Committee reviews and evaluates the risks associated with our compensation
programs. Our Remuneration Committee has reviewed our compensation policies as generally applicable to our employees and believes that our policies do not encourage excessive and unnecessary risk-taking, and that the level of risk that they do
encourage is not reasonably likely to have a material adverse effect on Amarin. In making this determination, our Remuneration Committee considered the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s use of different types of compensation vehicles to provide a balance of long and short-term
incentives with fixed and variable components; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the granting of equity based awards with time-based vesting and performance-based vesting, both of which
encourage participants to look to long-term appreciation in equity values; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s annual bonus determinations for each employee being tied to achievement of company goals,
which goals promote long-term value; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s system of internal control over financial reporting and code of conduct and ethics, which
among other things, reduce the likelihood of manipulation of the Company&#146;s financial performance to enhance payments under any of its incentive plans. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_20"></A>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Audit Committee. </I>The Audit Committee is currently comprised of Mr.&nbsp;van Heek (Chairman), Mr.&nbsp;O&#146;Sullivan and
Ms.&nbsp;Peterson. The Audit Committee oversees the accounting and financial reporting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
processes of the Company and the audits of the Company&#146;s financial statements. The Audit Committee also assists the Board in overseeing the integrity of the Company&#146;s financial
statements, the Company&#146;s compliance with legal and regulatory requirements, the external auditors&#146; qualifications and independence, the performance of the Company&#146;s internal audit function and external auditors and performs other
duties, as set forth in the Audit Committee charter. The Audit Committee charter is available on our website at <I>www.amarincorp.com</I>. The Audit Committee met by teleconference seven times during our 2018 fiscal year. All members of the Audit
Committee satisfy the current independence standards promulgated by NASDAQ and the SEC and the Board has determined that Mr.&nbsp;van Heek is an &#147;audit committee financial expert,&#148; as the SEC has defined that term in Item 407 of Regulation
<FONT STYLE="white-space:nowrap">S-K.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Nominating and Corporate Governance Committee</I>. Currently, the Nominating and Corporate
Governance Committee is comprised of Mr.&nbsp;O&#146;Sullivan (Chairman), Mr.&nbsp;Zakrzewski and Dr.&nbsp;Ekman. The Nominating and Corporate Governance Committee is responsible for identifying individuals qualified to become members of the Board,
consistent with criteria approved by the Board. The Nominating and Corporate Governance Committee also develops and implements policies and processes regarding corporate governance matters, assesses Board membership needs and acts as the
Company&#146;s nominating committee by reviewing potential director nominees and recommending nominees to the Board. The Nominating and Corporate Governance Committee charter is available on our website at <I>www.amarincorp.com</I>. The Nominating
and Corporate Governance Committee met in person two times during our 2018 fiscal year. All members of the Nominating and Corporate Governance Committee satisfy the current NASDAQ independence standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Remuneration Committee. </I>The Remuneration Committee is currently comprised of Mr.&nbsp;Stack (Chairman), Ms.&nbsp;Peterson and
Mr.&nbsp;van Heek. The Remuneration Committee, together with the Board, determines the framework for the compensation of the Company&#146;s Chief Executive Officer and such other members of executive management as it is designated to consider. The
Remuneration Committee also determines the corporate and individual performance goals under the Company&#146;s management incentive plan and achievement of these goals, as well as reviews and reassess the Company&#146;s processes and procedures for
the consideration and determination of executive remuneration. Further, the Remuneration Committee oversees any major changes in employee benefit structures throughout the Company, reviews and authorizes the reimbursement of any claims for expenses
of the Chief Executive Officer and chairman in excess of &#128;10,000 and performs other duties as set forth in the Remuneration Committee charter. Additionally, the Remuneration Committee reviews and evaluates the risks associated with our
compensation programs. The Remuneration Committee may delegate its authority to a subcommittee composed of one or more of its members. The Remuneration Committee charter is available on our website at <I>www.amarincorp.com</I>. The Remuneration
Committee met in person two times, met by teleconference one time, and acted by unanimous written consent two times during our 2018 fiscal year. All members of the Remuneration Committee satisfy the current NASDAQ and SEC independence standards and
qualify as &#147;outside directors&#148; under Section&nbsp;162(m) of the United States Internal Revenue Code of 1986, as amended (the &#147;<I></I><B><I>Code</I></B><I></I>&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_21"></A>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the 2018 fiscal year, Mr.&nbsp;Stack (Chairman), Ms.&nbsp;Peterson and Mr.&nbsp;van Heek served as members of the Remuneration
Committee. During the last completed fiscal year, no member of the Remuneration Committee was an officer or employee of Amarin and no member of the Remuneration committee has ever served as an officer of Amarin. None of our executive officers served
as a member of the compensation committee (or board of directors serving the compensation function) of another entity where such entity&#146;s executive officers served on our Remuneration Committee. Moreover, none of our executive officers served
as a member of the board of directors or compensation committee (or other committee of the board of directors serving the compensation function) of another entity where such entity&#146;s executive officers served on our Board or Remuneration
Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_22"></A>EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current executive officers and their respective positions are set forth in the following table. Biographical information regarding each
executive officer is set forth following the table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="67%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer (principal executive officer)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, General Counsel and Strategic Initiatives, Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President of Research and Development, Senior Vice President and Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Chief Financial Officer, Assistant Secretary (principal financial officer and principal accounting officer)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aaron Berg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Chief Commercial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>John F. Thero</I>. Please refer to Proposals No.&nbsp;1 and No.&nbsp;2 &#147;Election of Directors&#148;
for Mr.&nbsp;Thero&#146;s biography. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Joseph T. Kennedy </I>joined Amarin in December 2011 as Senior Vice President, General Counsel
and was named Amarin&#146;s Secretary and Chief Compliance Officer in February 2012. He was promoted to Executive Vice President, General Counsel and Strategic Initiatives in July 2015 and no longer serves as the company&#146;s compliance officer
for pharmaceutical industry matters as of August 2017. From March 2009 to December 2011, he was Vice President, General Counsel and Secretary of Transcept Pharmaceuticals, Inc., where he played a lead role negotiating the company&#146;s strategic
collaboration with Purdue Pharma, helped obtain U.S. Food and Drug Administration (&#147;<B><I>FDA</I></B>&#148;) approval for the company&#146;s lead product and had responsibility for all legal and compliance matters affecting the company.
Mr.&nbsp;Kennedy represented large pharmaceutical companies, developing life science companies and venture capital firms in private law practice from January 2006 to March 2009. Prior to that, Mr.&nbsp;Kennedy served as Chief Corporate Counsel, then
Vice President, Acting Chief Legal Officer with Eyetech Pharmaceuticals, Inc. His work at Eyetech included transitioning the company from private to public, legal matters related to the company&#146;s development and commercialization collaboration
with Pfizer Inc., public company and pharmaceutical industry compliance, and the sale of the company to OSI Pharmaceuticals Inc. Previously, Mr.&nbsp;Kennedy served as Vice President and U.S. Counsel, Corporate Business Development, with &Eacute;lan
Corporation, plc where he helped acquire technologies, managed legal issues related to multiple collaborations and participated in the company&#146;s sale of assets that raised over $2.0&nbsp;billion in a restructuring. Mr.&nbsp;Kennedy was honored
by the President of Ireland as one of the inaugural &#147;Irish Life Science 50&#148; which recognized Irish-Americans for contributions to the life science industry, by <I>Financial Times</I> in its recognition of Amarin in 2016 as a standout legal
innovator in its North American Most Innovative Lawyers awards and was named as one of the top general counsel in the industry in connection with his selection on the <I>Legal500 GC Powerlist: United States 2019</I>. He also serves as a member of
the Business Advisory Board of Fountain Healthcare Partners, a life science venture capital fund. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Steven B. Ketchum, Ph.D</I>., joined
Amarin in February 2012 as Senior Vice President and President of Research and Development. He was named Chief Scientific Officer in January 2016. Dr.&nbsp;Ketchum has 20 years of experience in late-stage product development and clinical regulatory
strategy. From 2008 to 2012, Dr.&nbsp;Ketchum served as Senior Vice President of Research and Development for Sunesis Pharmaceuticals, Inc. where he provided strategic direction for all facets of research and development, including clinical strategy
and operations, regulatory affairs, and pharmaceutical development and has served on its board of directors since his departure. From 2005 to 2008, Dr.&nbsp;Ketchum served as Senior Vice President of Research and Development and Medical Affairs for
Reliant Pharmaceuticals where he led development and support activities for Lovaza and other commercialized cardiovascular products. Prior to 2005, Dr.&nbsp;Ketchum was Senior Vice President of Operations and Regulatory Affairs at IntraBiotics
Pharmaceuticals, Inc., and also held positions of increasing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responsibility in regulatory affairs during his nearly eight-year tenure at ALZA Corporation, where he supported the development and commercialization of a number of products, including Concerta.
Dr.&nbsp;Ketchum earned a Ph.D. in pharmacology from University College London and a B.S. in biological sciences from Stanford University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Michael W. Kalb</I> joined Amarin in June 2016 as Senior Vice President and Chief Financial Officer. Mr.&nbsp;Kalb served as Group Vice
President, Chief Financial Officer and Chief Accounting Officer of Taro Pharmaceutical Industries Ltd. from August 2014 to June 2016. Prior to that, Mr.&nbsp;Kalb was GVP, Interim CFO and CAO from November 2010 to August 2014 and GVP, Chief
Financial Officer&#151;U.S. and CAO from May 2010 to November 2010. Mr.&nbsp;Kalb joined Taro in June 2009 as VP, Chief Financial Officer&#151;U.S. He has over 20 years of financial and accounting advisory experience. From June 2004 to June 2009,
Mr.&nbsp;Kalb served as a Director in the Accounting and Financial Consulting Group of Huron Consulting Group Inc. His experience also includes over ten years at Ernst&nbsp;&amp; Young, LLP within the Transaction Advisory Services Group and Audit
and Assurance Services Group. Mr.&nbsp;Kalb received a B.S. in Accounting from the University at Albany, State University of New York. Mr.&nbsp;Kalb is a Certified Public Accountant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Aaron Berg</I> joined Amarin in November 2012 as Vice President, Marketing and Managed Care and has since served in roles of increasing
responsibility, including as Senior Vice President, Marketing and Sales from February 2014 until April 2018. Since April 2018, Mr.&nbsp;Berg has served as our Senior Vice President and Chief Commercial Officer. <I></I>Before joining Amarin, he
served as President and Chief Executive Officer for Essentialis, Inc., a development stage pharmaceutical company, where he led the company&#146;s work on triglyceride management. Prior to joining Essentialis, Mr.&nbsp;Berg served as Vice President
of Marketing and Sales at Kos Pharmaceuticals, where he was instrumental in driving annual revenues approaching $1&nbsp;billion until the acquisition of the company by Abbott Laboratories in December 2006. Mr.&nbsp;Berg began his pharmaceutical
industry career as a sales representative with Bristol-Myers Squibb, followed by various commercial positions with Schering-Plough and GlaxoSmithKline. He obtained his B.S. in Business Management, Marketing from the University of Maryland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_23"></A>CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_24"></A>Transactions with Related Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the compensation arrangements described below under the captions &#147;Executive Compensation&#148; and &#147;Director
Compensation,&#148; we are not a party to any transactions between us and certain &#147;related parties,&#148; which are generally considered to be our directors and executive officers, nominees for director, holders of 5% or more of our outstanding
Ordinary Shares and members of their immediate families. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_25"></A>Related-Party Transaction Review and Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has adopted policies and procedures for the review and approval of related-party transactions and has delegated to our Compliance
Officer the authority to review and approve the material terms of any proposed related-party transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our Code of
Business Conduct and Ethics, any transaction or relationship that reasonably could be expected to give rise to a conflict of interest should be promptly reported to the Compliance Officer. Our Compliance Officer may notify the Board or a committee
thereof as deemed appropriate. Conflicts of interest may arise in the following situations: if an individual is simultaneously employed or engaged by Amarin and another business (particularly a client or business partner of Amarin); if an individual
participates in any activity that enhances or supports a competitor&#146;s position; if an individual or member of such person&#146;s immediate family accepts a gift with the intent to improperly influence the normal business relationship between
Amarin and its clients or business partners or gives to or accepts gifts from a competitor; if an individual or a member of such person&#146;s immediate family holds a financial interest in another business (particularly a client or business partner
of Amarin); and if an individual conducts business on behalf of Amarin with a business in which a family member of such individual is associated in any significant role. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_26"></A>SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Securities Exchange Act of 1934 (the &#147;<B><I>Exchange Act</I></B>&#148;) requires our executive
officers and directors, and persons who own more than 10% of a registered class of our equity securities, to file reports of beneficial ownership and changes in beneficial ownership with the SEC. Executive officers, directors and <FONT
STYLE="white-space:nowrap">greater-than-10%</FONT> shareholders are required by SEC regulations to furnish us with copies of all reports filed under Section&nbsp;16(a). To the Company&#146;s knowledge, based solely on the review of copies of the
reports filed with the SEC, all reports required to be filed by our executive officers, directors and <FONT STYLE="white-space:nowrap">greater-than-10%</FONT> shareholders during the fiscal year ended December&nbsp;31, 2018 were timely filed, except
for one inadvertently late filing on Form 4 for each of Joseph S. Zakrzewski, Jan G. van Heek, David M. Stack, Kristine Peterson, Patrick J. O&#146;Sullivan and Lars Ekman. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_27"></A>INSIDER TRADING POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amarin has an insider trading policy that applies to all officers, directors and employees and certain affiliated persons. Amarin&#146;s
insider trading policy prohibits sale of any Amarin securities that are not owned by such persons at the time of the sale, so called short sales. Those persons subject to Amarin&#146;s insider trading policy may not pledge Amarin&#146;s securities
as collateral for a loan (or modify an existing pledge) unless the pledge has been approved by the Audit Committee of the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_28"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on information available to us and filings with the SEC, the following table sets forth certain information regarding the
beneficial ownership (as defined by Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act) of our outstanding Shares for (i)&nbsp;each of our directors, (ii)&nbsp;each of our &#147;named executive officers,&#148; as defined in
Executive Compensation below, (iii)&nbsp;all of our directors and executive officers as a group, and (iv)&nbsp;persons known to us to beneficially hold more than 5% of our outstanding Ordinary Shares. Unless otherwise noted, the following
information is presented as of March&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership and percentage ownership are determined in accordance with the
rules of the SEC and include voting or investment power with respect to our Ordinary Shares. This information does not necessarily indicate beneficial ownership for any other purpose. Under these rules, Ordinary Shares issuable under stock options,
warrants, or other convertible securities that are exercisable within 60 days of March&nbsp;31, 2019 are deemed outstanding for the purpose of computing the percentage ownership of the person holding the options or warrant(s), but are not deemed
outstanding for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated and subject to
applicable community property laws, to our knowledge, each shareholder named in the following table possesses sole voting and investment power over their Ordinary Shares, except for those jointly owned with that person&#146;s spouse. Unless
otherwise indicated below, the address of each person listed on the table is c/o Amarin Pharma, Inc., 1430 Route 206, Bedminster, NJ 07921. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent&nbsp;of<BR>Class<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Greater than 5% Holders:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors LP.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,592,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Current directors and named executive officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,294,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lars G. Ekman, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jan van Heek<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. O&#146;Sullivan<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Stack<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph S. Zakrzewski<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,089,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current directors and executive officers as a group (11 persons)<SUP
STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,275,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents Ordinary Shares, or Shares, held as of March&nbsp;31, 2019, plus Shares that may be acquired upon
exercise of options exercisable within 60 days of March&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on 330,578,168 Ordinary Shares outstanding as of March&nbsp;31, 2019. The percentage ownership and voting
power for each person (or all directors and executive officers as a group) is calculated by assuming the exercise or conversion of all options exercisable within 60 days of March&nbsp;31, 2019 held by such person and the <FONT
STYLE="white-space:nowrap">non-exercise</FONT> and <FONT STYLE="white-space:nowrap">non-conversion</FONT> of all outstanding options held by all other persons. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information provided in a Schedule 13G filed by Baker Bros. Advisors LP, Baker Bros. Advisors (GP)
LLC, Felix J. Baker and Julian C. Baker on February&nbsp;13, 2019. Consists of (i) 5,474,310 Shares held by 667, L.P. and (ii) 37,118,514 Shares held by Baker Brothers Life Sciences, L.P. (collectively with 667,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
L.P., &#147;Baker Funds&#148;). The number of Shares reported herein excludes the Shares issuable upon conversion of Series A Preference Shares of the Company held by the Baker Funds. The Series
A Preference Shares are only convertible to the extent that the holders thereof together with their affiliates would beneficially own, for purposes of Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended, no more than 4.99% of the
outstanding Ordinary Shares or ADS of the Company after conversion (&#147;Series A Beneficial Ownership Limitation&#148;). By written notice to the Company, Baker Funds may from time to time increase or decrease the Series A Beneficial Ownership
Limitation applicable to each fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Company. Baker Bros. Advisors LP is the investment advisor to Baker
Funds and has sole voting and investment power with respect to the shares held by Baker Funds. Baker Bros. Advisors (GP) LLC is the sole general partner of Baker Bros. Advisors LP. The managing members of Baker Bros. Advisors (GP) LLC are Julian C.
Baker and Felix J. Baker. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of all shares except to the extent of their pecuniary interest. The address for each of these entities is 860 Washington Street, 3<SUP
STYLE="font-size:85%; vertical-align:top">rd</SUP> Floor, New York, NY 10014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 2,110,171 Shares directly owned and 4,184,430 Shares issuable upon the exercise of options exercisable
within 60 days of March&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 136,016 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31,
2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 165,968 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31,
2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 14,168 Shares directly owned and 122,121 Shares issuable upon the exercise of options exercisable
within 60 days of March&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 254,468 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31,
2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 51,991 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 84,547 Shares directly owned and 1,004,510 Shares issuable upon the exercise of options exercisable
within 60 days of March&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 31,260 Shares directly owned and 3,344 Shares issuable upon the exercise of options exercisable within
60 days of March&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 354,492 Shares directly owned and 310,228 Shares issuable upon the exercise of options exercisable
within 60 days of March&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 20,551 Shares directly owned and 70,452 Shares issuable upon the exercise of options exercisable
within 60 days of March&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 209,086 Shares issuable upon the exercise of options exercisable as of the date of the termination of
Mr.&nbsp;Salyer&#146;s employment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See notes 4 through 13 above; also includes Aaron Berg, who is a current executive officer but not a named
executive officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_29"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISCUSSION AND ANALYSIS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following compensation discussion and analysis (&#147;<B><I>CD&amp;A</I></B>&#148;) describes the philosophy, objectives and structure of
our fiscal year 2018 executive compensation program. This section is intended to be read in conjunction with the tables that immediately follow, which provide further historical compensation information for our named executive officers
(&#147;<B><I>NEOs</I></B>&#148;), who for the fiscal year ended December&nbsp;31, 2018, were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, General Counsel and Strategic Initiatives, Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President of Research and Development, Senior Vice President and Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Chief Financial Officer, Assistant Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer*</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Former Senior Vice President and Chief Commercial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">*&#8201;&#8201;Mr.&nbsp;Salyer&#146;s employment with the Company commenced on September&nbsp;11, 2017 and terminated
on April&nbsp;18, 2018.</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_30"></A>2018 Operating Highlights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We made tremendous progress this year on multiple fronts, including the achievement of various commercial, regulatory, clinical development and
other milestones, highlighted by our announcement of positive results of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> outcomes study in the second half of 2018 and our strong stock price performance. As discussed more fully below,
achievement of these objectives were considered by our Remuneration Committee in determining executive compensation for 2018. Key operating highlights from the past year include the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Results:</B> In the second half of 2018, the Company
presented and published results, which were positive, of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT><SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> cardiovascular outcomes study of Vascepa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules. This study demonstrated, compared to placebo, a 25% reduction in major adverse cardiovascular events, with a number needed to treat of 21, including a 20% reduction in
cardiovascular death. These results are the largest shown as an <FONT STYLE="white-space:nowrap">add-on</FONT> to statin therapy, by any therapy in any studied patient population. This important result, recognized by the <I>New England Journal of
Medicine Journal Watch Cardiology 2018</I> as a top story, and included by the American College of Cardiology as one of its top clinical trials for 2018, positions Vascepa to potentially help millions of patients. During 2018, the Company supported
40 scientific publications and presentations. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Revenue Growth and Gross Margin Improvement:</B> The Company recognized a record level of total revenue of
$229.2&nbsp;million in 2018 mostly comprised of $228.4&nbsp;million in net product revenue from sales of Vascepa in the United States. The net product revenue for 2018 represented an increase of $48.5&nbsp;million over 2017. Gross margin on product
revenues was 76% in 2018, versus 75% in 2017. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g662434g14q60.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Prescription Growth:</B> The Company increased normalized prescriptions for Vascepa by 25% and 27% in 2018
compared to 2017 based on data from Symphony Health and IQVIA, respectively, further increasing its market share of prescription <FONT STYLE="white-space:nowrap">omega-3</FONT> products in the United States. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Commercial Expansion: </B>The Company began its transition from a U.S. sales presence with a relatively small
specialty sales team reliant on a <FONT STYLE="white-space:nowrap">co-promotion</FONT> partner promoting Vascepa based on biomarker data to a broader direct sales model with more sales representatives, more physician targets and promotion which
includes reference to cardiovascular outcomes study results. Prior to learning results of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study, the Company had approximately 150 sales representatives in the United States. After recruitment,
hiring and training, the Company increased to having approximately 400 sales representatives in the United States in January 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Strengthened Balance Sheet: </B>As of December&nbsp;31, 2018, the Company had $249.2&nbsp;million of cash and
cash equivalents with no outstanding term debt or convertible debt. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Superior Stock Price Performance. </B>As depicted in the graph below, over the three-year time period through
December&nbsp;31, 2018, cumulative total return for Amarin&#146;s ADSs exceeded both the NASDAQ Composite Index and NASDAQ Biotechnology Index. In particular, the total return for Amarin&#146;s ADSs well exceeded the cumulative returns for the
NASDAQ Composite Index and NASDAQ Biotechnology Index in each of the past three calendar years. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g662434g35m74.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_31"></A>Compensation Philosophy
and Objectives </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pay for Performance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our philosophy in setting compensation policies for executive officers has two fundamental objectives: (1)&nbsp;to attract and retain a highly
skilled team of executives and (2)&nbsp;to align our executives&#146; interests with those of our shareholders by rewarding short-term and long-term performance and tying compensation to increases in shareholder value. The Remuneration Committee
believes that executive compensation should be directly linked both to continuous improvements in corporate performance (&#147;<B><I>pay for performance</I></B>&#148;) and accomplishments that are expected to increase shareholder value. In
furtherance of this goal, the Remuneration Committee has adhered to the following guidelines as a foundation for decisions that affect the levels of compensation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide a competitive total compensation package that enables the Company to attract and retain highly qualified
executives with the skills and experience required for the achievement of business goals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">align compensation elements with the Company&#146;s annual goals and long-term business strategies and
objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">promote the achievement of key strategic and financial performance measures by linking short-term and long-term
cash and equity incentives to the achievement of measurable corporate and individual performance goals; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">align executives&#146; incentives with the creation of shareholder value. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee has historically compensated executive officers with three primary compensation components: base salary, annual and
short-term incentive bonuses, and long-term equity-based compensation. The Remuneration Committee believes that cash compensation in the form of base salary and incentive bonuses provides our executives with short-term rewards for success in
operations, and that long-term compensation through the grant of equity awards aligns the objectives of management with those of our shareholders with respect to long-term performance and success. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Chief Executive Officer Performance and Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Remuneration Committee believes that it is especially important to set compensation for our Chief Executive Officer in a manner that
address the two fundamental objectives described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">John F. Thero has served as our President and Chief Executive Officer since
January 2014. Before that, he served as our President and Chief Financial Officer since November 2010 and before that as our Chief Financial Officer since November 2009. Mr.&nbsp;Thero has over 25 years of executive level experience and, in the view
of the Remuneration Committee, a strong record of accomplishment before and during his tenure at the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Thero became Chief
Executive Officer in 2014 to stabilize and grow the Company following significant corporate setbacks emanating from a change in position by the FDA regarding requirements for approval of the ANCHOR indication as became evident in an FDA advisory
committee meeting in late 2013, which meeting concluded with a vote against a significant proposed label expansion for Vascepa followed by the FDA rescinding the related ANCHOR study special protocol assessment agreement. Since becoming President
and Chief Executive Officer, Mr.&nbsp;Thero has played a critical role in selecting, retaining and motivating experienced personnel throughout the Company, repositioning the Company&#146;s commercial strategy and tactics resulting in significant
product revenue growth, expanding managed care coverage for Vascepa, entering into multiple strategic transactions, ensuring that the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study was successfully completed,
pursuing and achieving multiple remedies through favorable court decisions and achieving the 2018 operating highlights described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout his tenure as Chief Executive Officer, Mr.&nbsp;Thero&#146;s cash compensation has been at or below the 50th percentile of the
Company&#146;s peer group set by the Remuneration Committee with greater emphasis on Mr.&nbsp;Thero&#146;s compensation in the form of equity incentive awards. Effective February 2018, Mr.&nbsp;Thero&#146;s base compensation was adjusted to $664,800
per year, which was at the 50th percentile of other Chief Executive Officers in our peer group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Thero&#146;s bonus potential is
tied to achievement of <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate goals for the applicable year, with no consideration given to individual performance goals. For 2018, Mr.&nbsp;Thero&#146;s target bonus potential, which was 75% of
his base compensation and slightly below the 50th percentile for other Chief Executive Officers in our peer group, was tied to achievement of meaningful and challenging corporate goals established at the start of the year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee believes that Mr.&nbsp;Thero&#146;s cash compensation is strongly aligned with corporate performance and the
interests of our shareholders. Our Remuneration Committee has an established practice of paying no or partial incentive cash bonuses when the <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate goals are not achieved or achieved only in
part. For example, for 2013, Mr.&nbsp;Thero was awarded no cash bonus following the failure of the FDA to approve the ANCHOR indication, a key corporate goal for that year, and in 2015 and 2014, Mr.&nbsp;Thero was awarded 98% and 75% of his bonus
target, respectively, based on only partial achievement of the <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate goals for those years. Conversely, when <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate goals are achieved in
whole, or when <FONT STYLE="white-space:nowrap">pre-defined</FONT> &#147;stretch&#148; goals are achieved, incentive cash bonuses are paid commensurate with the level of achievement in that year. For example, in 2017 and 2016, both years in which
corporate achievement was especially strong, including the achievement of <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate goals and <FONT STYLE="white-space:nowrap">pre-defined</FONT> stretch goals, Mr.&nbsp;Thero was awarded 117% and
122% of his bonus target, respectively. In 2018, Mr.&nbsp;Thero was awarded 95% of his bonus target based on substantial achievement of the <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate goals and an additional 50% of his bonus target
based on the achievement of one <FONT STYLE="white-space:nowrap">pre-defined</FONT> stretch goal pertaining to the results of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study exceeding expectations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, a substantial portion of Mr.&nbsp;Thero&#146;s compensation is in the form of equity incentive awards, which the Remuneration
Committee believes further aligns Mr.&nbsp;Thero&#146;s interests with those of our shareholders. The equity incentive awards are made in the form of stock options and restricted stock units, all subject to vesting requirements, that target the 50th
of the Company&#146;s peer group. These equity incentive awards are subject to both time-based and performance-based vesting criteria. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Time-based stock options generally vest over a four-year period. Performance-based stock
options generally vest only if certain <FONT STYLE="white-space:nowrap">pre-defined</FONT> performance criteria are achieved (<I>e.g.</I>, commercial, clinical or regulatory milestones), plus an additional time-based vesting schedule if and only if
those performance milestones are achieved. The stock options realize value only if our stock price increases after the date of grant. Time-based restricted stock units generally vest over a three- or four-year period. Performance-based restricted
stock units generally vest only if certain <FONT STYLE="white-space:nowrap">pre-defined</FONT> performance criteria are achieved (<I>e.g.</I>, commercial, clinical or regulatory milestones). Certain of the performance-based restricted stock units
also include an additional time-based vesting schedule if and only if those performance milestones are achieved. The restricted stock units realize more value the better our stock price performs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted in the graph below, approximately 82% of Mr.&nbsp;Thero&#146;s 2018 total compensation as reported in the Summary Compensation Table
below, including the value of the performance-based restricted stock units referred to in footnote 2 of such table, relates to stock options and restricted stock units and 91% of his total target compensation is performance-based and at risk, in
either the form of equity awards or incentive bonus: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g662434g28t07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of the Company&#146;s performance since Mr.&nbsp;Thero became Chief Executive Officer in January
2014, the Company&#146;s stock price performance during his tenure as Chief Executive Officer, including each of the past one, two and three year periods and his compensation during that same time periods, the Remuneration Committee believes that
the amount and nature of Mr.&nbsp;Thero&#146;s compensation in 2018 are strongly aligned with corporate performance and the interests of our shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roles in Determining Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Remuneration
Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee, together with the Board, determines the framework for the compensation of the Company&#146;s
executive officers. The Remuneration Committee also determines the corporate and individual performance goals under the Company&#146;s management incentive plan and achievement of these goals, and determines the policy for and scope of service
agreements for the executive officers and contractual severance payments. While the Remuneration Committee draws on a number of resources, including input from the Chief Executive Officer and independent compensation consultants, to make decisions
regarding the Company&#146;s executive compensation program, ultimate decision-making authority rests with the Remuneration Committee, subject in key cases to ratification by the independent members of the Board. The Remuneration Committee relies
upon the judgment of its members in making compensation decisions, after reviewing the performance of the Company and evaluating an executive&#146;s performance during the year against established goals, operational performance, and business
responsibilities. In addition, the Remuneration Committee incorporates judgment in the assessment process to respond to and adjust for the evolving business environment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risks Related to Compensation Policies and Practices </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Board&#146;s risk oversight role, our Remuneration Committee reviews and evaluates the risks associated with our compensation
programs. Our Remuneration Committee has reviewed our compensation policies as generally applicable to our employees and believes that our policies do not encourage excessive and unnecessary risk-taking, and that the level of risk that they do
encourage is not reasonably likely to have a material adverse effect on Amarin. In making this determination, our Remuneration Committee considered the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s use of different types of compensation vehicles to provide a balance of long- and short-term
incentives with fixed and variable components; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the granting of equity-based awards with time-based vesting and performance-based vesting, both of which
encourage participants to work towards long-term appreciation in equity values; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s annual bonus determinations for each employee and vesting of performance-based equity awards
being tied to achievement of Company goals, which goals promote long-term value; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s system of internal control over financial reporting and code of conduct and ethics, which
among other things, reduce the likelihood of manipulation of the Company&#146;s financial performance to enhance payments under any of its incentive plans. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Consultant </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration
Committee retains the services of Radford, an Aon company, as independent external compensation consultants. The mandate of the consultants includes assisting the Remuneration Committee in its review of executive and director compensation practices,
including the competitiveness of pay levels, executive compensation design, and benchmarking with the Company&#146;s peers in the industry. The Remuneration Committee regularly evaluates the performance of its compensation consultants, considers
alternative compensation consultants, and has the final authority to engage and terminate such services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee has
assessed the independence of Radford pursuant to SEC rules and concluded that no conflict of interest exists that would prevent Radford from serving as an independent consultant to the Remuneration Committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Chief
Executive Officer attends Remuneration Committee meetings and works with the Remuneration Committee Chairman and its compensation consultants to develop compensation recommendations for executive officers (excluding the Chief Executive Officer) and
other key executives, based upon individual experience and breadth of knowledge, internal considerations, individual performance during the fiscal year, and other factors deemed relevant by the Remuneration Committee. The recommendations are then
submitted to the Remuneration Committee for review and consideration. The Remuneration Committee works directly with its compensation consultants to determine compensation actions for the Chief Executive Officer. In accordance with NASDAQ listing
rules, our Chief Executive Officer is not present during voting or deliberations concerning his own compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Say-on-Pay</FONT></FONT></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annually, at our general meeting of shareholders, we hold a <FONT
STYLE="white-space:nowrap">non-binding</FONT> advisory vote regarding the compensation of our named executive officers, which we refer to as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay.</FONT></FONT> The Remuneration
Committee has considered and will continue to consider the outcome of such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> votes, including the percentage of votes cast in favor and against the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> proposal, when making future compensation decisions for our named executive officers. The Remuneration Committee believes that the most relevant period of time to
assess </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the performance of the Company&#146;s Chief Executive Officer is the period over which he has held this position, which commenced in January 2014, during which period of time the Company&#146;s
stock price significantly outperformed both its peer group and the NASDAQ Biotechnology Index as a whole. The Remuneration Committee also relies on advice from its compensation consultants, its evaluation of Company performance against <FONT
STYLE="white-space:nowrap">pre-defined</FONT> corporate goals, its understanding of the challenges facing the Company and its observations of executive officer performance to determine executive officer compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our last annual general meeting of shareholders in May 2018, the <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote of
shareholders supported the compensation of our named executive officers as reported in our 2018 proxy statement by 96.2% of the votes cast at the meeting. These votes for and against the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">say-on-pay</FONT></FONT> proposal, together with available feedback from investors, have been and will continue to be considered by the Remuneration Committee in connection with the evaluation of executive compensation.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholder Outreach Program </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
make a point of annually engaging with our shareholders to solicit feedback on our executive compensation program. From time to time, we meet with our institutional shareholders to obtain their feedback and views on matters relating to our Company,
including our executive compensation program. Based on the feedback received from this type of engagement, we relied more heavily on performance-based equity compensation in the past couple of years and may adjust our compensation arrangement based
on future feedback. For example, in 2017 and early 2018, executive officers of the company were granted performance-based restricted stock units which are earned only if the Company&#146;s <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
cardiovascular outcomes study was deemed to be successful and only if product revenue reaches <FONT STYLE="white-space:nowrap">pre-defined</FONT> annual milestone levels ranging from $300&nbsp;million to $500&nbsp;million and then vest only if the
recipient remains with the Company for an extended period of time following completion of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study, subject to acceleration in the event of a change in control transaction. We will continue to
engage with shareholders and believe that our shareholders will continue to support our core compensation principles and our executive compensation program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competitive Market Benchmarking </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee draws on a number of resources to assist in the evaluation of the various components of the Company&#146;s executive
compensation program. While we do not establish compensation levels based solely on benchmarking, pay practices at other companies are a factor that the Remuneration Committee considers in assessing the reasonableness of compensation and ensuring
that our compensation practices are competitive in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our peer companies used in determining compensation actions with
respect to 2018 fiscal year compensation were selected by the Remuneration Committee with the support of Radford, which beginning in 2011 has been retained to conduct comprehensive reviews of the Company&#146;s executive compensation practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our peer companies for 2018 compensation evaluation were selected prior to the start of 2018 in consultation with Radford on the basis of
their similarity to us in terms of competition for talent, their status as a commercial or near-commercial stage company, revenue level and other financial attributes, phase of products in development, research and development expenditures, employee
number, and market capitalization. Radford also qualitatively evaluated each company based on business focus and corporate strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee considered the foregoing analysis in selecting the following 18
publicly-traded peer companies for use in evaluating compensation actions in the 2018 fiscal year: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accorda Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Eagle Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Repligen Corporation*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AMAG Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Halozyme Therapeutics*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SciClone Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amicus Therapeutics*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ImmunoGen*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Spectrum Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Arena Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Lexicon Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sucampo Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Corcept Therapeutics*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Pacira Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Supernus Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Depomed*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Momenta Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vanda Pharmaceuticals*</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Included in prior-year peer group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the peer group above, the Remuneration Committee also reviews competitive compensation data from the Radford Global Life
Sciences Compensation Survey. For 2018 compensation decisions, the Radford survey group included 34 publicly traded biopharmaceutical companies with fewer than 5,000 employees, revenue under five million dollars, and market value between
$200&nbsp;million and $12.0&nbsp;billion. Seventeen companies in our named peer group participated in this market survey. For benchmarking purposes, Radford then developed a competitive market composite of which 50% is based on proxy data from the
named peer group and 50% is based on a market survey composite. Radford then assessed Amarin&#146;s 2018 compensation against market pay elements such as base salary, target short-term incentives as a percentage of base salary, target total cash
compensation, long-term incentives and target total direct compensation. Additionally, Amarin&#146;s incumbent officers were matched to benchmark positions according to each officer&#146;s primary responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee reviews the Company&#146;s list of peer companies periodically to reflect changes in market capitalization,
developments at the Company relative to its peer companies, and other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of compensation for 2019, the Remuneration
Committee, with the advice of Radford, examined our 2018 peer group in light of our continued growth throughout 2018, the stage of our commercialization efforts, changes in our market capitalization, and changes in the size and status of comparative
companies. With reference to these and other key business metrics, the Remuneration Committee approved the following 20 companies as our 2019 peer group for evaluating compensation actions for 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Accorda Therapeutics*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exelixis</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Pacira Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Akcea Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Halozyme Therapeutics*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">PTC Therapeutics</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alnylam Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ImmunoGen*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Repligen Corporation*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AMAG Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Intercept Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Spectrum Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Clovis Oncology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ionis Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Supernus Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Corcept Therapeutics*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ironwood Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vanda Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Eagle Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Momenta Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Included in prior-year peer group. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Implementation of Objectives </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
fiscal 2018, our executive compensation program consisted of the following forms of compensation, each of which are described below in greater detail: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Base Salary </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Incentive Bonus </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Equity Compensation (subject to time and/or performance vesting) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Employee Benefit Programs </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, our Remuneration Committee aims to set executives&#146; total cash compensation
(base salary plus target bonus) at levels near the 50th percentile for executives with similar roles in the Company&#146;s peer group. Long-term incentive awards include stock options and restricted stock units and the value of such awards is
generally targeted at the 50th percentile of our peer group. Our Remuneration Committee believes that the 50th percentile for total compensation is the minimum total compensation level that will allow us to attract and retain highly skilled
executives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base Salary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Remuneration Committee aims to set executives&#146; base salaries, in the aggregate, at levels near the 50th percentile of salaries of
executives with similar roles at the Company&#146;s peer group. The Remuneration Committee believes it is important to provide adequate fixed compensation to our executive officers working in a highly volatile and competitive industry. The
Remuneration Committee&#146;s choice of this target percentile reflects consideration of our shareholders&#146; interests in paying what is necessary to attract and retain qualified executives and achieve our corporate goals, while conserving cash
and equity as much as practicable. We believe that, given the industry in which we operate and our compensation philosophy and objectives, base salaries at the 50th percentile are generally sufficient to retain our current executives and to hire new
executives when and as required. In determining appropriate base salary levels for a given executive officer, the Remuneration Committee also considers the following factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">individual performance of the executive, as well as overall performance of the Company, during the prior year;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level of responsibility, including breadth, scope and complexity of the position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level of experience and expertise of the executive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">internal review of the executive&#146;s compensation relative to other executives to ensure internal equity;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">level of the executive&#146;s compensation in the form of equity incentive awards; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">executive officer compensation levels at other similar companies to ensure competitiveness.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Salaries for executive officers are determined on an individual basis at the time of hire and are set to be competitive
with peer companies in our industry. Adjustments to base salary are considered annually in light of each executive officer&#146;s individual performance, the Company&#146;s performance and compensation levels at peer companies in our industry, as
well as changes in job responsibilities or promotion. The Chief Executive Officer assists the Remuneration Committee in its annual review of the base salaries of other executive officers based on the foregoing criteria. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in Base Salaries for Fiscal 2018 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2018, the Remuneration Committee approved for 2018 an average salary increase of 3.5% for all employees other than certain executive
officers, including those identified below, each of whom received individually targeted salary increases. These increases were determined to take into consideration the rate of inflation and to approximate the estimated rate of compensation increase
in the Company&#146;s peer group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of Mr.&nbsp;Thero, a salary of $664,800, effective February&nbsp;1, 2018, was approved.
This base salary was targeted at the 50th percentile for Chief Executive Officers within our peer group. In the case of Mr.&nbsp;Kennedy, a salary of $462,300, effective February&nbsp;1, 2018, was approved. This base salary was higher than the 50th
percentile for officers of similar position within our peer group; this determination was made in light of the Remuneration Committee&#146;s recognition of Mr.&nbsp;Kennedy&#146;s extensive experience and significant contributions to the Company
during his tenure with the Company, in particular in connection with our ongoing regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efforts, several litigation matters and continued advancement of the Company&#146;s intellectual property estate. In the case of Dr.&nbsp;Ketchum, a salary of $462,300, effective February&nbsp;1,
2018, was approved. This base salary was higher than the 50th percentile for officers of similar position within our peer group; this determination was made in light of the Remuneration Committee&#146;s recognition of Dr.&nbsp;Ketchum&#146;s
extensive experience and significant contributions to the Company during his tenure with the Company, in particular in connection with our ongoing regulatory efforts and continued advancement of the Company&#146;s
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes trial, the scope of which is larger than advanced by most peer sized companies. In the case of Mr.&nbsp;Kalb, a salary of $424,400, effective February&nbsp;1, 2018, was
approved. This base salary approximated the 50th percentile for CFOs within our peer group; this determination was made in light of the Remuneration Committee&#146;s recognition of Mr.&nbsp;Kalb&#146;s experience and his contributions to the Company
during his tenure with the Company, in particular in connection with strengthening our balance sheet and managing our cash flow. In the case of Mr.&nbsp;Salyer, a salary of $459,000, effective February&nbsp;1, 2018, was approved. This base salary
was higher than the 50th percentile for Chief Commercial Officers within our peer group; this determination was made in light of Mr.&nbsp;Salyer&#146;s compensation prior to joining the Company and the Remuneration Committee&#146;s recognition of
his experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Incentive Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also provides executive officers with the opportunity to earn annual performance-based cash bonuses, which are specifically
designed to reward executives for overall corporate performance as well as for executives other than the Chief Executive Officer, individual performance in a given year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has adopted a Management Incentive Compensation Plan (&#147;<B><I>MICP</I></B>&#148;), under which the Remuneration Committee each
year determines and approves corporate and individual performance goals and achievement of these goals for purposes of determining annual performance-based cash bonuses. The MICP is intended to provide structure and predictability regarding the
determination of performance-based cash bonuses. Specifically, the MICP is intended to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">increase management focus on realistic goals intended to create value for shareholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">encourage management to work as a team to achieve the Company&#146;s goals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">encourage individuals to realize goals that are meaningful to the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide incentives for management to strive for achievement above and beyond the Company goals; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">help attract and retain high quality senior management personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MICP provides that the bonus potential for our executive officers will be established on an annual basis by the Remuneration Committee.
Under the MICP, the actual amount of the bonus paid is calculated on a formulaic basis based upon achievement of <FONT STYLE="white-space:nowrap">pre-determined</FONT> performance goals. In order to be eligible to receive a bonus, the Company must
have achieved at least a specified percentage of the corporate goals for that year. The corporate goals and the relative weighting of the corporate and individual performance goals, as well as the relative weighting for each individual of individual
performance goals, are established by the Remuneration Committee on an annual basis, shortly after our Board approves our annual operating plan. The Remuneration Committee has determined it appropriate to have our Chief Executive Officer&#146;s
goals match our corporate goals and for no portion of his annual incentive bonus to be determined based on individual performance goals. For all other executive officers, individual goals are determined on an annual basis by the Remuneration
Committee based on their areas of functional responsibility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MICP, the Remuneration Committee reserves the right to make
subjective assessments of executive performance and to separately reward performance beyond established individual or corporate goals and targets, and to award a smaller or larger bonus than provided for in the MICP, or to award no bonus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For fiscal 2018, the bonus potential for our management employees as a percentage of base salary ranged from 75% for our President and Chief
Executive Officer, 45% for our Executive Vice President, 40% for our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Senior Vice Presidents, 30% for our Vice Presidents, and 15 to 25% for our Directors and Managers. All of the bonus potential for our President and Chief Executive Officer was tied to the 2018
corporate goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fiscal 2018 Annual Bonus Incentive </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following our announcement of the positive results of <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study, in December 2018, the
Remuneration Committee assessed the Company and our executive officer&#146;s overall performance and achievement of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> stretch goal established in 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is the <FONT STYLE="white-space:nowrap">pre-specified</FONT> stretch goal, which achievement that was approved by the
Remuneration Committee in assessing overall performance for the 2018 fiscal year and reviewed at the December 2018 meeting of the Remuneration Committee, as well as the relative weighting of this goal and the Remuneration Committee&#146;s
determination of achievement for this goal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Pre-Specified</FONT> &#147;Stretch&#148; Goal</U>: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">REDUCE-IT:</FONT></I> Achieve 20% or more in relative risk reduction for
primary endpoint: 50% </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, upon completion of fiscal 2018, the Remuneration Committee assessed the Company and
our executive officer&#146;s overall performance against the achievement of corporate and individual performance goals established in 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below are the corporate goals (except for the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> stretch goal discussed above) that
were approved by the Remuneration Committee in assessing overall performance for the 2018 fiscal year, as well as the relative weighting of these goals and the Remuneration Committee&#146;s determination of achievement for each goal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2018 Corporate Goals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Commercial (40%)</U>: These
goals established target performance for the Company regarding the commercialization of Vascepa. The specific goals were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Revenues:</I> Achieve net revenue target of $245.0&nbsp;million </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Compliance</I>: Favorable outside audit report regarding compliance program and no lost claim due to
untruthful or misleading statements to healthcare professionals </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Pre-REDUCE-IT</FONT></FONT> Readiness:
</I>Increase Vascepa awareness; launch media campaign regarding MARINE indication* </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">Post-REDUCE-IT</FONT> Results: </I>Hire, train and activate expanded sales
team within 90 days of corporate approval* </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> (30%)</U>: These goals established
target performance for the Company regarding the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes trial. The specific goals were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">Close-out</FONT> Plan: </I>Perform and complete all required procedures
anticipating adjudication of targeted number of primary events by target dates; submit regulatory approval applications by target deadline* </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Final Study Quality: </I>Achieve target rate for patients with compliance data, target rate of final visit
contact with patients on study, and target rate of patients with vital status information </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Timing of Publication:</I> Complete study report for consideration as late breaker for American Heart
Association in 2018, and, assuming success, publish results in <FONT STYLE="white-space:nowrap">top-tier</FONT> journal in parallel with late breaker presentation in the fourth quarter of 2018 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Media/KOL Education and Support:</I> Engage with the advisory board and national / regional key opinion leader
(&#147;<B><I>KOL</I></B>&#148;) groups; <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results reported by major national media with supportive statements from KOLs </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Quality</U><U></U><U>&nbsp;&amp; Supply (10%)</U>: These goals established target performance for the Company regarding the commercial and clinical supply.
The specific goals were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Quality</I>: Ensure uninterrupted supply of commercial and clinical material based on supply chain schedule
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Supply</I>: Purchase inventory needed for operating plan (plus safety stock) at an average price consistent
with operating plan* </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Financial and Public Relations / Investor Relations (20%)</U>: These goals established target performance for
the Company regarding the operational finance performance and with respect to public and investor relations matters. The specific goals were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Cash Outflow from Operations</I>: Ensure gross cash outflow is not greater than operating plan*
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Cash Flow Positive from Operations</I> <I>(excluding R&amp;D, interest and royalty costs)</I>: Achieve for
full year 2018 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Financing</I>: Complete financings as needed, subject to corporate approval, to ensure the Company is
adequately financed </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Pre-Specified</FONT> &#147;Stretch&#148; Goals</U>: The specific goals were as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Exceed net revenue target per 2018 Operating Plan ($245 million)</I>: Zero for &lt; 5% above net revenue
target; 10% for 5% or more above net revenue target increasing ratably to 100% maximum for achievement of 50% above net revenue target </P></TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The above-described metrics tied to the 2018 Operating Plan include highly sensitive data including cash
flows, expense targets, research goals and clinical trials. We do not disclose the specific target levels for these metrics because we believe that such disclosure would result in competitive harm to our Company. We purposely set these target levels
at aggressive levels. Revealing these metrics, including the reasoning for setting targets at specific levels, could potentially reveal insights about our commercialization plans and research and other objectives that our competitors could use
against us in the marketplace for similar pharmaceutical products. We believe each of these target levels were designed to be challenging but attainable under assumed conditions if we had what we considered to be a successful year.
</I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In reviewing the Company&#146;s performance against the <FONT STYLE="white-space:nowrap">pre-specified</FONT>
corporate goals set by the Remuneration Committee as described above, the Remuneration Committee determined the goals were achieved as follows: (i)&nbsp;that each of the commercial goals was achieved at the 100% level, except for the achievement of
revenues goal, which was achieved at the 90% level, resulting in a weighted score of 35% for this component of the corporate goals; (ii)&nbsp;that each of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> goals was achieved at the 100% level,
resulting in a combined weighted score of 30% for this component of the corporate goals; (iii)&nbsp;that each of the quality and supply goals was achieved at the 100% level, resulting in a combined weighted score of 10% for this component of the
corporate goals; and (iv)&nbsp;that each of the financial and public relations/investor relations goals was achieved at the 100% level, resulting in a combined weighted score of 20% for this component of the corporate goals. In total, the
Remuneration Committee determined that these <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate goals were achieved at the 95% level. In addition, the Remuneration Committee determined that the
<FONT STYLE="white-space:nowrap">pre-defined</FONT> net revenue stretch goal was not achieved and that the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> stretch goal was achieved, resulting in a total score of 50% for the stretch goals and 145%
cumulative achievement of the <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate and stretch goals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Individual Performance-Based Cash Bonus Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>John F. Thero, President and Chief Executive Officer (principal executive officer) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee calculated Mr.&nbsp;Thero&#146;s 2018 MICP bonus to be $473,670 in connection with, and based entirely on, the
Company&#146;s achievement of base corporate goals as described above (95% level). This amount is separate from the $249,300 cash bonus award the Remuneration Committee calculated for Mr.&nbsp;Thero based on the 50% of target bonus amount in
connection with the Company&#146;s achievement of the <FONT STYLE="white-space:nowrap">pre-defined</FONT> <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> stretch goal described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Joseph T. Kennedy, Executive Vice President, General Counsel and Strategic Initiatives, Secretary </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Mr.&nbsp;Kennedy, individual performance goals for fiscal 2018 were focused on the areas outlined below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Litigation: 25% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>ANDA litigation</I>: Manage legal resources to support progression of the ANDA litigation
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>IP litigation</I>: Aggressively assert Amarin patents, subject to corporate decisions from time to time
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Supplement Issues: 35% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Achieve or take further legal steps to help distinguish Vascepa from dietary supplements </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>SEC Compliance/Investor Relations: 10% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Statutory</I>: Ensure timely filing of SEC filings and compliance of public disclosures with applicable law
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>IR</I>: Provide timely and constructive advice on investor relations issues while helping to ensure accurate
disclosures consistent with industry practice </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>General Corporate: 10% </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Operational support</I>: Ensure timely value-adding legal advice to support all Company functions, including
business development, finance, regulatory, managed care, sales and marketing, manufacturing, human resources and general corporate matters, the effectiveness of which will be judged by the Chief Executive Officer and Board </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Minutes</I>: Timely completion of committee meeting minutes for meetings attended, conduct orderly annual
meeting </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Documentation</I>: Oversee legal systems to help manage risks affecting the company and ensure access to key
information as needed, including disaster recovery, document control and long-term staff turnover considerations </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Pharmaceutical
Industry Compliance: 10% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Industry</I>: Stay abreast of developments on First Amendment issues and advise company on pharmaceutical
industry compliance matters consistent with First Amendment settlement, including disclosures regarding knowledge derived from the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Intellectual Property: 10% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Patents</I>: Obtain and defend robust patent coverage for Company products consistent with Company plan,
including prompt review of <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results and creating appropriate documentation to protect the Company&#146;s intellectual property rights </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Company&#146;s MICP, 75% of Mr.&nbsp;Kennedy&#146;s bonus for 2018 was based on
achievement of the corporate goals (in proportion to the extent such goals were achieved) and 25% of his bonus was based on achievement of his individual goals (in proportion to the extent such goals were achieved). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee approved the achievement of 2018 corporate goals at the 95% level as described above, in addition to the 50%
achievement of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> stretch goal. In reviewing the above-described individual performance goals, the Remuneration Committee determined that Mr.&nbsp;Kennedy had fully achieved all of his individual
goals (100%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee thus calculated Mr.&nbsp;Kennedy&#146;s 2018 MICP bonus to be $200,234, or 96% of his target
bonus amount. The calculation was based on 75% weight given to the 95% achievement of 2018 corporate base goals and 25% weight given to the 100% achievement of Mr.&nbsp;Kennedy&#146;s individual goals. This amount is separate from the $104,018 cash
bonus award the Remuneration Committee calculated for Mr.&nbsp;Kennedy based on the 50% of target bonus amount in connection with the Company&#146;s achievement of the <FONT STYLE="white-space:nowrap">pre-defined</FONT> <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> stretch goal described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Steven B. Ketchum, Ph.D., President of Research and
Development, Senior Vice President and Chief Scientific Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Dr.&nbsp;Ketchum, individual performance goals for fiscal 2018
were focused on the areas outlined below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U><FONT STYLE="white-space:nowrap">REDUCE-IT:</FONT> 80% </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">Close-out</FONT> plan: </I>Perform and complete all required procedures
anticipating adjudication of targeted number of primary events by target dates; submit regulatory approval applications by target deadline* </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Final study quality</I>: Achieve target rate for patients with compliance data, target rate of final visit
contact with patients on study, and target rate of patients with vital status information </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Timing</I>: Complete topline data analyses in time to support a late breaker presentation for American Heart
Association in 2018 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Publication and congress support</I>: Work with <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> steering
committee and medical affairs team to secure publication of <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results in <FONT STYLE="white-space:nowrap">top-tier</FONT> journal in parallel with late breaker presentation in the fourth quarter of
2018 </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Additional Clinical&nbsp;&amp; <FONT STYLE="white-space:nowrap">Non-Clinical</FONT> Initiatives: 10% </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Serum to plasma</I><I></I><I>&nbsp;&amp; red blood cell (RBC) correlation research</I>: Support fatty acid
measurements and report completion and correlation analyses by target dates * </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Mechanistic <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical initiatives</I>: Support <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> differentiation through mechanistic <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical initiatives aimed at defining eicosapentaenoic acid mechanisms of action/uniqueness of activity;
support three or more publications; consider/support new mechanistic studies through detailed interactions with six or more potential investigators; continue ongoing assessment for investigator initiated trials, design, conduct, and publication of
seven or more investigator initiated trials </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>c)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Clinical/Scientific support of other Departments</I>: Provide timely support and training to various other
departments including regulatory, medical affairs, business development, corporate strategy, finance, legal and commercial teams* </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Regulatory&nbsp;&amp; Quality Control: 10% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">Ex-US</FONT> partnership:</I> Support clinical trial application approval
and initiation of registration clinical trial(s) in China; support registration activities in Middle East and North Africa territories, achieving </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
approval in at least two countries for partner to market Vascepa before the end of 2018; support <FONT STYLE="white-space:nowrap">pre-NDS</FONT> meeting and create regulatory strategy with
partner in Canada </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Existing NDA maintenance</I>: Ensure all regulatory required reporting elements are prepared and submitted
on time; support vendors&#146; timely transitions from paper drug master files to electronic submissions; and ensure they have no impact on Chemistry, Manufacturing, and Control (&#147;<B><I>CMC</I></B>&#148;) portions of new Drug application
(&#147;<B><I>NDA</I></B>&#148;) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Post-marketing safety compliance</I>: Review and assess all serious adverse events and timely submit all
required reports in compliance with strategic operating plans </P></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The above-described metrics tied to the 2018 Operating Plan include highly sensitive data including research
goals and clinical trials. We do not disclose the specific target levels for these metrics because we believe that such disclosure would result in competitive harm to our Company. We purposely set these target levels at aggressive levels. Revealing
these metrics, including the reasoning for setting targets at specific levels, could potentially reveal insights about our commercialization plans and research and other objectives that our competitors could use against us in the marketplace for
similar pharmaceutical products. We believe each of these target levels were designed to be challenging but attainable under assumed conditions if we had what we considered to be a successful year. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Company&#146;s MICP, 75% of Dr.&nbsp;Ketchum&#146;s bonus for 2018 was based on achievement of the corporate goals (in proportion to
the extent such goals were achieved) and 25% of his bonus was based on achievement of his individual goals (in proportion to the extent such goals were achieved). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee approved the achievement of 2018 corporate goals based at the 95% level as described above, in addition to the 50%
achievement of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> stretch goal. In reviewing the above-described individual performance goals, the Remuneration Committee concluded that Dr.&nbsp;Ketchum had fully achieved all of his individual
goals (100%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee calculated Dr.&nbsp;Ketchum&#146;s 2018 MICP bonus to be $177,986, or 96% of his target bonus
amount. The calculation was based on 75% weight given to the 95% achievement of 2018 corporate base goals and 25% weight given to the 100% achievement of Dr.&nbsp;Ketchum&#146;s individual goals. This amount is separate from the $92,460 cash bonus
award the Remuneration Committee calculated for Dr.&nbsp;Ketchum based on the 50% of target bonus amount in connection with the Company&#146;s achievement of the <FONT STYLE="white-space:nowrap">pre-defined</FONT>
<FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> stretch goal described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Michael W. Kalb, Senior Vice President and Chief
Financial Officer, Assistant Secretary (principal financial officer and principal accounting officer) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Mr.&nbsp;Kalb,
individual performance goals for fiscal 2018 were focused on the areas outlined below as: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Financial Reporting&nbsp;&amp; Budgeting: 40%
</U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Manage cash balance and net operating cash flow such that it is equal to or greater than the operating plan*
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Timely completion and filing of all required SEC and foreign statutory filings </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Timely file all domestic and international tax returns </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maintain tax compliance and professional fees for routine items </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shorten quarterly close process </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assume lead role in preparation of Board of Directors meeting presentations </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Internal Controls: 15% </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ensure no material control weaknesses from 2018 compliance testing or from 2017 compliance testing completed in
2018 </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Strategic&nbsp;&amp; Tax Matters, including Preparation for <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> <FONT
STYLE="white-space:nowrap">Read-out:</FONT> 15% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Working Capital Line</I>: Engage with financial institutions to obtain asset-based lending, subject to
receiving waiver from debt holder and subject to corporate approval </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Compliance:</I> Work with tax advisors to comply with all Internal Revenue Service
(&#147;<B><I>IRS</I></B><I>&#148;</I>), and other taxing authorities, requests for information </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Tax:</I> Complete assessment of global tax position for the Company and subsidiaries considering potential
changes in U.S. corporate tax law and evaluate discontinuing inactive subsidiaries </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Commercial&nbsp;&amp; Business Development
Support: 10% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Support</I>: Support commercial operations, including pricing and contracts review and negotiation and
decision-making regarding managed care and marketing to achieve gross margin levels as per operating plan*; support business development, including diligence, and other strategic initiatives as needed </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Strategic Model:</I> Work with investment bank to create robust multi-scenario long-term model to support
strategic analysis </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Fund Raising:</I> Coordinate successful fund raising efforts as needed, subject to Board approval
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Investor Relations: 20% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Financial and Corporate Communications:</I> Oversee and direct all financial and corporate communications by
developing, managing and controlling the message platform and information flow; benchmark current communications metrics and obtain Chief Executive Officer and CFO approval for 2018 improvement metric </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Investor Outreach:</I> Complete peer ownership analysis, identify at least 10 high quality investors, and
establish meetings with these firms; create plan for expanded use of social media and, subject to necessary approval, implement such plan </P></TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The above-described metrics tied to the 2018 Operating Plan include highly sensitive data including research
goals and clinical trials. We do not disclose the specific target levels for these metrics because we believe that such disclosure would result in competitive harm to our Company. We purposely set these target levels at aggressive levels. Revealing
these metrics, including the reasoning for setting targets at specific levels, could potentially reveal insights about our commercialization plans and research and other objectives that our competitors could use against us in the marketplace for
similar pharmaceutical products. We believe each of these target levels were designed to be challenging but attainable under assumed conditions if we had what we considered to be a successful year. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Company&#146;s MICP, 75% of Mr.&nbsp;Kalb&#146;s bonus for 2018 was based on achievement of the corporate goals (in proportion to
the extent such goals were achieved) and 25% of his bonus was based on achievement of his individual goals (in proportion to the extent such goals were achieved). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee approved the achievement of 2018 corporate goals based at the 95% level as described above, in addition to the 50%
achievement of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> stretch goal. In reviewing the above-described individual performance goals, the Remuneration Committee concluded that Mr.&nbsp;Kalb had achieved 95% of his individual goals
(reflecting partial achievement of the goal pertaining to assuming lead role in preparation of Board of Directors meeting presentations and creation and implementation of investor outreach initiatives). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee calculated Mr.&nbsp;Kalb&#146;s 2018 MICP bonus to be $161,272,
or 95% of his target bonus amount. The calculation was based on 75% weight given to the 95% achievement of 2018 corporate base goals and 25% weight given to the 95% achievement of Mr.&nbsp;Kalb&#146;s individual goals. This amount is separate from
the $84,880 cash bonus award the Remuneration Committee calculated for Mr.&nbsp;Kalb based on the 50% of target bonus amount in connection with the Company&#146;s achievement of the <FONT STYLE="white-space:nowrap">pre-defined</FONT> <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> stretch goal described above.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Mark W. Salyer, Former Senior Vice President and
Chief Commercial Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Salyer was not eligible to receive a bonus under the MICP for 2018 as a result of the
termination of his employment with the Company in April 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special Incentive Bonus Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Remuneration Committee establishes special bonus programs to incentivize individual performance toward goals that are
judged by the Remuneration Committee as important for corporate progress, very difficult to achieve, and of significant shareholder value if achieved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options and Restricted Stock Units.</I> As an additional component of our compensation program, executive officers are eligible to
receive equity compensation, which has historically been in the form of stock options and restricted stock units. The Remuneration Committee grants stock options and restricted stock units to executive officers to aid in their retention, to motivate
them to assist with the achievement of both near-term and long-term corporate objectives and to align their interests with those of our shareholders by creating a return tied to the performance of our stock price. In determining the form, date of
issuance and value of a grant, the Remuneration Committee considers the contributions and responsibilities of each executive officer, appropriate incentives for the achievement of our long-term growth, the size and value of grants made to other
executives at peer companies holding comparable positions, individual achievement of designated performance goals, and the Company&#146;s overall performance relative to corporate objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that equity awards, through stock options and restricted stock units, align the objectives of management with those of our
shareholders with respect to long-term performance and success. We believe that equity awards serve as useful performance-recognition mechanisms with respect to key employees, as most awards are subject to time-based vesting provisions. Stock
options are typically awarded to executive officers upon their hiring. We believe that such equity awards encourage executive officers to remain with the Company and also focus on our long-term performance as well as the achievement of specific
performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Award Grant Policy.</I> We have an equity award grant policy that formalizes our process for granting
equity-based awards to officers and employees. Under our equity award grant policy, all grants to executive officers must be approved by our Board or Remuneration Committee and all grants to other employees must be granted within guidelines approved
by our Board or Remuneration Committee. All stock options have an exercise price equal to the fair market value of our Ordinary Shares, calculated based on our closing market price on the applicable grant date. Under our equity award grant policy,
equity awards will generally be granted as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grants made in conjunction with the hiring of a new employee or the promotion of an existing employee will
generally be made at meetings of the Remuneration Committee, and effective on the first trading day of the month following the later of (1)&nbsp;the hire date or the promotion date or (2)&nbsp;the date on which such grant is approved; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grants made to existing employees other than in connection with a promotion will be made, if at all, on an annual
basis and generally shall be made effective on the first trading day of the month following the date on which such grant is approved. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Grants Awarded in Fiscal 2018 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
considering annual equity awards for our executive officers in 2018, our Remuneration Committee aimed to grant equity at a level generally targeted between the 50th and 75th percentile of the Company&#146;s peer group. Equity awards in 2018 were
comprised of a mix of time-based stock options (vesting over a four-year period), time-based restricted stock unit awards (vesting over a three-year period) and performance-based restricted stock unit awards (vesting tied to the achievement of <FONT
STYLE="white-space:nowrap">pre-defined</FONT> performance milestones (specifically the achievement of both (i)&nbsp;a successful outcome of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study and
<FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-defined</FONT> commercial sales milestones), and subsequent to such achievement, time-based vesting and acceleration in the event of a change in control). Equity awards in 2018 were granted with a view
towards both retaining and incentivizing our executives in future periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The grant date fair values of the equity awards granted to
executive officers for the 2018 fiscal year are reflected in the Summary Compensation Table below and the number of shares subject to equity awards granted in 2018 is reflected in the Grants of Plan-Based Awards table below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Black-Scholes option-pricing model required under Financial Accounting Standards Board (&#147;<B><I>FASB</I></B>&#148;)
Accounting Standards Codification (&#147;<B><I>ASC</I></B>&#148;) Topic 718 and discussed further below, historical variable assumptions and other variables can cause model prices to be more or less than the actual value of an option when exercised
or in an ultimate exit. Actual option value is instead based on stock performance which can vary significantly from these historical variable assumption based valuation estimates. Because the actual value is based on stock performance, the
Remuneration Committee believes that the equity awards granted create added and important alignment of management with our other shareholders regarding our long-term growth. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Benefit Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive officers are eligible to participate in all of our employee benefit plans, including medical, dental, group life, disability and
accidental death and dismemberment insurance, in each case on the same basis as other employees, subject to applicable law. We also provide vacation and other paid holidays to all employees, including executive officers, all of which we believe to
be comparable to those provided at peer companies. These benefit programs are designed to enable us to attract and retain our workforce in a competitive marketplace. Health, welfare and vacation benefits ensure that we have a productive and focused
workforce through reliable and competitive health and other benefits. Our executive officers participate in the same employee benefit plans as other employees in the Company on the same terms as such employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our retirement savings plan (&#147;<B><I>401(k) Plan</I></B>&#148;) is a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement
savings plan, pursuant to which all employees, including the named executive officers, are able to contribute certain amounts of their annual compensation, subject to limits prescribed by the IRS, which contributed amounts are eligible for a
discretionary percentage match, in cash, as defined in the 401(k) Plan and determined by the Board of Directors. We recognized $0.7&nbsp;million of related compensation expense for the 401(k) Plan for the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax and Accounting Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Deductibility of Executive Compensation.</I> In making compensation decisions affecting our executive officers, the Remuneration Committee
considers our ability to deduct under applicable federal corporate income tax law compensation payments made to executives. Specifically, the Remuneration Committee considers the requirements and impact of Section&nbsp;162(m) of the Code. With
respect to taxable years before January&nbsp;1, 2018, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
remuneration in excess of $1&nbsp;million was exempt from this deduction limit if it qualified as &#147;performance-based compensation&#148; within the meaning of Section&nbsp;162(m) and was
payable pursuant to a binding written agreement in effect on November&nbsp;2, 2017 that was not subsequently materially modified. Under the Tax Cuts and Jobs Act of 2017, effective for taxable years beginning after December&nbsp;31, 2017, (1) the
scope of Section&nbsp;162(m) was expanded such that all named executive officers are &#147;covered employees&#148; and anyone who was a named executive officer in any year after 2016 will remain a covered employees for as long as he or she (or his
or her beneficiaries) receive compensation from the Company and (2)&nbsp;the exception to the deduction limit for commission-based compensation and performance-based compensation was eliminated except with respect to certain grandfathered
arrangements in effect as of November&nbsp;2, 2017 that are not subsequently materially modified. Accordingly, compensation paid to our named executive officers in excess of $1&nbsp;million will not be deductible unless it qualifies for the
transition relief applicable to certain arrangements in place as of November&nbsp;2, 2017, as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee
believes that stockholder interests are best served if the Committee retains maximum flexibility to design executive compensation programs that meet stated business objectives. The Remuneration Committee considers the Section&nbsp;162(m) rules as a
factor in determining compensation, but does not necessarily limit compensation to amounts deductible under Section&nbsp;162(m). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Ownership
Guidelines </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board believes it is important to align the interests of our executive officers with those of its shareholders. To
this end, in March 2013, the Board established Stock Ownership Guidelines for its executive officers. The guidelines require that each executive officer maintain an equity interest in the Company with a value at least equal to a multiple of the
executive officer&#146;s base salary, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Target</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3x annual base salary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Executive Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1x annual base salary</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity interests that count toward the satisfaction of the ownership guidelines include the value of Ordinary
Shares beneficially owned (other than unvested restricted stock) or issuable upon the settlement of vested restricted stock units. The calculation of an individual&#146;s equity interest, however, does not include the value of stock options (whether
or not vested), unvested restricted stock, and unvested restricted stock units, except unvested deferred stock units. Executive officers have five years from the date of the policy adoption in March 2013 or later commencement of their appointment as
an executive officer to attain these ownership levels. If an executive officer does not meet the applicable guideline by the end of the five-year period, the officer is required to hold a minimum of 50% to 100% of the shares resulting from any
future equity awards until the applicable guideline is met, net of shares sold or withheld to exercise stock options and pay withholding taxes. The Remuneration Committee, however, may make exceptions for any officer on whom this requirement could
impose a financial hardship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this Proxy Statement, all of the Company&#146;s named executive officers have satisfied
these ownership guidelines, or have time to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we have instituted Stock Ownership Guidelines for our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. For information regarding these guidelines, see the section entitled &#147;<I>Director <FONT STYLE="white-space:nowrap">Compensation&#151;Non-Employee</FONT> Director Compensation.</I>&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clawback </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of
this Proxy Statement, we do not have a formal compensation recovery policy, often referred to as a &#147;clawback&#148; policy, which would typically provide that the officers or directors subject to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
policy must reimburse the Company for any bonus or other incentive-based or equity-based compensation improperly received. The Remuneration Committee intends to adopt a formal clawback policy
once the final rules relating to such policies are issued pursuant to the Dodd-Frank Act. The Company has not had an accounting restatement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_32"></A>REMUNERATION COMMITTEE REPORT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The information contained in this report shall not be deemed to be (1) &#147;soliciting material,&#148; (2) &#147;filed&#148; with the SEC,
(3)&nbsp;subject to Regulations 14A or 14C of the Exchange Act, or (4)&nbsp;subject to the liabilities of Section&nbsp;18 of the Exchange Act. This report shall not be deemed incorporated by reference into any of our other filings under the Exchange
Act or the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates it by reference into such filing. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee of the Board of Directors has reviewed and discussed the Executive Compensation Discussion and Analysis contained
in this Proxy Statement with management. Based on such review and discussion, we have recommended to the Board of Directors that the Executive Compensation Discussion and Analysis be included in this Proxy Statement for the fiscal year ended
December&nbsp;31, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Submitted by the Remuneration Committee of the Board of Directors </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">David Stack (Chairman) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Jan van Heek </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Kristine Peterson </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_33"></A>2018 Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the compensation of the named executive officers for the fiscal years ended
December&nbsp;31, 2018, 2017 and 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive
Plan<BR>Compensation&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">660,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,409,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,405,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">722,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,205,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">President and<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Chief Executive<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,414,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">575,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">530,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,178,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,363,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman">Executive Vice<BR>President,<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">General Counsel and<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Strategic Initiatives,<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">918,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,329,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="6"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman">President of<BR>Research and<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman">Development, Senior<BR>Vice President and<BR>Chief Scientific<BR>Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,205,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">877,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Michael W. Kalb<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,267,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman">Senior Vice<BR>President and Chief<BR>Financial Officer,<BR>Assistant Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,151,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">978,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,272,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Mark W. Salyer<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">984,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman">Former Senior Vice<BR>President and Chief<BR>Commercial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,627,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,959,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in the &#147;Bonus&#148; column for 2017 and 2016 consist of discretionary cash bonuses
awarded under the MICP for exceptional performance in 2017 or 2016, respectively. In addition, the amount reported for 2017 for Mr.&nbsp;Salyer includes a <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus of $60,000 and an annual cash bonus of
$65,000, each paid pursuant to the terms of his employment agreement with the Company. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">This column reflects the aggregate grant date fair value of time- and performance-based vesting restricted stock
unit awards granted in each year calculated in accordance with FASB ASC 718, excluding the effect of estimated forfeitures, related to service-based vesting. For performance-based restricted stock units, the value reported reflects the value of the
award at the grant date based upon the probable outcome of the performance conditions. For the performance-based restricted stock units granted to Mr.&nbsp;Thero in 2018, as achievement of the performance criteria was deemed not probable on the
grant date, the grant date fair value of such award included in the table is $0. The value of Mr.&nbsp;Thero&#146;s 2018 performance-based restricted stock units, assuming that the highest level of performance conditions will be achieved, is
$3,559,900. For the performance-based restricted stock units granted in 2017, as achievement of the performance criteria was deemed not probable on the grant date, the grant date fair value of each such award included in the table for each was $0.
The value of the 2017 performance-based restricted stock units, assuming that the highest level of performance conditions will be achieved, is $795,600 for Mr.&nbsp;Kennedy and $673,200 for each of Dr.&nbsp;Ketchum and Mr.&nbsp;Kalb. Assumptions
used in the calculations for these amounts are set forth in Note 11 to our consolidated financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">This column reflects the aggregate grant date fair value of time-based stock option awards granted in each year
and calculated in accordance with FASB ASC 718, excluding the effect of estimated forfeitures. Assumptions used in the calculations for these amounts are set forth in Note 11 to our consolidated financial statements included in our Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">This column reflects payments made under the MICP and special incentive bonus programs in respect of the year
earned. See the discussion regarding annual and special incentive compensation in &#147;Executive Compensation Discussion and Analysis&#148; for further information regarding the performance measures. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Kalb joined the Company on June&nbsp;30, 2016. His annualized base salary for 2016 was $400,000.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Salyer joined the Company on September&nbsp;11, 2017. His employment with the Company terminated on
April&nbsp;18, 2018. His annualized base salary for 2017 was $455,000. His annualized base salary for 2018 was $459,000. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">The amounts included in this column represent company-paid match of 401(k) contributions and life insurance
premiums unless otherwise noted. The amount reported in 2018 for Mr.&nbsp;Salyer includes the following severance payments, which were paid to him in connection with the termination of his employment pursuant to the terms of his employment agreement
with the Company: (i) $229,500 for six months of base salary continuation, (ii) $10,592 for accrued paid time off, and (iii) $8,397 for the Company portion of the COBRA premiums for six months following termination. In addition, the vesting of
Mr.&nbsp;Salyer&#146;s equity awards subject to time-based vesting was accelerated by six months upon the termination of his employment pursuant to the terms of his employment agreement. The amount reported for 2017 for Mr.&nbsp;Salyer includes
$61,538 of relocation costs paid pursuant to the terms of his employment agreement with the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Narrative to the Summary
Compensation Table </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts reported in the Summary Compensation Table, including base salary, stock awards, option awards, and
payments made under the MICP, are described more fully under &#147;Executive Compensation Discussion and Analysis.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_34"></A>Grants of Plan-Based Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding grants of plan-based option awards to the named executive officers during fiscal
year 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other&nbsp;Option<BR>Awards:<BR>Number&nbsp;of&nbsp;Securities<BR>Underlying&nbsp;Options&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price of<BR>Option<BR>Awards<BR>($/Sh)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date<BR>Fair Value<BR>of Option<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,405,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the aggregate grant date fair value of option awards granted in 2018, and is calculated in
accordance with FASB ASC 718, using the Black-Scholes option-pricing model, excluding the effect of estimated forfeitures. Assumptions used in the calculations for these amounts are set forth in Note 11 to our financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These options vest monthly over 48 months beginning on February&nbsp;28, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Salyer&#146;s employment with the Company terminated in April 2018. As of the termination date,
options to purchase 19,502 shares with a total grant date fair value of $49,136 had vested and all remaining unvested options were immediately forfeited. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding grants of plan-based restricted stock unit awards subject to time-based vesting
to the named executive officers during fiscal year 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other&nbsp;Stock<BR>Awards:<BR>Number&nbsp;of&nbsp;Shares<BR>of Stock or<BR>Units (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date<BR>Fair Value<BR>of Stock<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,409,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the aggregate grant date fair value of time-based restricted stock unit awards granted in
2018, calculated in accordance with FASB ASC 718, excluding the effect of estimated forfeitures. Assumptions used in the calculations for these amounts are set forth in Note 11 to our financial statements included in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These restricted stock unit awards vest in three equal annual installments on each of January&nbsp;31, 2019,
January&nbsp;31, 2020 and January&nbsp;31, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Salyer&#146;s employment with the Company terminated in April 2018, at which time the entire
restricted stock unit award was immediately forfeited. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding
grants of plan-based restricted stock unit awards subject to performance-based vesting to the named executive officers during fiscal year 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Future&nbsp;Payouts<BR>Under Equity<BR>Incentive Plan Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target (#)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date<BR>Fair Value<BR>of Stock<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/12/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">970,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,559,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There is no threshold for these awards and the target equates to the maximum. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the aggregate grant date fair value, calculated in accordance with FASB ASC 718 assuming
the probable outcome of the performance conditions on the grant date, which was assumed to be maximum achievement of such conditions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount represents restricted stock unit awards that vest and are earned only if both of the following
performance goals are achieved by December&nbsp;31, 2027: (i) a successful outcome of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study and <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-defined</FONT> commercial sales milestones. To date,
only the successful outcome of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study has been achieved, so none of the restricted stock units have vested. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding grants of <FONT STYLE="white-space:nowrap">non-equity</FONT> incentive plan-based
awards to the named executive officers during fiscal year 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Future&nbsp;Payouts&nbsp;Under<BR><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan<BR>Awards ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">498,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,246,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in the &#147;Target&#148; and &#147;Maximum&#148; columns reflect the potential payouts under the
2018 MICP. Actual bonuses awarded to the individuals were based on achievement of objectives, as discussed in the &#147;Executive Compensation Discussion and Analysis&#148; section above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Salyer&#146;s employment with the Company terminated in April 2018 and therefore he was not eligible
to receive a cash incentive bonus for 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_35"></A>Option Exercises and Stock Vested </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the number of shares acquired by the named executive officers upon the exercise of stock options and vesting of
restricted stock units in fiscal year 2018 as well as the value realized upon exercise or vesting. The value realized represents the aggregate difference between the fair market value of shares on the dates of exercise or vesting and the exercise
prices, if any, multiplied by the number of shares acquired upon exercise or vesting, prior to payment of any applicable withholding taxes. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired&nbsp;on&nbsp;Exercise<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized on<BR>Exercise<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired&nbsp;on&nbsp;Vesting<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized on<BR>Vesting<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,223,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,914,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,992,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,149,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,130,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">536,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,962,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,518,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,093,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,033,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,234,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,689,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_36"></A>Outstanding Equity Awards at Fiscal
<FONT STYLE="white-space:nowrap">Year-End</FONT></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows information regarding outstanding stock option awards at
December&nbsp;31, 2018 for our named executive officers: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of Securities<BR>Underlying&nbsp;Unexercised&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($/Sh)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unexercisable<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/10/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/2/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">607,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/8/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">391,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,333</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/2/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,007</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,998</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,998</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">401,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,956</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286,458</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">430,125</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/16/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/2/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,953 </TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/2/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,511</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,854</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,937</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,187</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,953</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/2/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,998</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,001</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,854</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,270</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,187</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,374</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/1/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,270</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,187</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/18/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying these stock options vest monthly over 48 months beginning February&nbsp;28, 2015.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying these stock options vest monthly over 48 months beginning July&nbsp;31, 2015.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying these stock options vest monthly over 48 months beginning on July&nbsp;31, 2015, and
relate to grants with certain financial and clinical performance milestones that were achieved during fiscal year 2016 and 2017. Upon achievement of the milestones, the options that had vested monthly without regard to the requirement for
achievement of the milestones and had been previously deferred until achievement became exercisable. Such grants will continue to vest monthly until fully vested. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying these stock options vest monthly over 48 months beginning February&nbsp;28, 2016.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying these stock options vest monthly over 48 months beginning February&nbsp;28, 2017.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying these stock options vest monthly over 48 months beginning February&nbsp;28, 2018.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares underlying this stock option vest monthly over 48 months beginning on July&nbsp;31, 2015, but were
deferred until the achievement of certain clinical performance milestones, which occurred in September </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
2018 upon positive <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results. Upon the achievement of the milestone, the shares underlying the options vested to the extent they would have vested
on a monthly basis without regard to the requirement for achievement of the performance criteria and will continue to vest monthly thereafter. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Twenty-five percent (25%) of the shares underlying this stock option vested on June&nbsp;30, 2017, and the
remaining 75% of the options vest ratably over the next 36 months. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Salyer&#146;s employment with the Company terminated in April 2018, at which time the vesting of all
unvested stock options subject to time-based vesting was accelerated by six months pursuant to the terms of his employment agreement with the Company and any remaining unvested stock options were immediately forfeited. Any remaining vested but
unexercised options expire upon the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of his termination date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows information regarding outstanding restricted stock unit awards at December&nbsp;31, 2018, for our named executive
officers: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;or&nbsp;Units<BR>of Stock That<BR>Have&nbsp;Not&nbsp;Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value&nbsp;of<BR>Shares&nbsp;or&nbsp;Units&nbsp;of<BR>Stock That Have<BR>Not
Vested<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;Incentive<BR>Plan Awards:<BR>Number of<BR>Unearned&nbsp;Shares,<BR>Units or Other<BR>Rights That Have<BR>Not Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;Incentive<BR>Plan Awards:<BR>Market&nbsp;or&nbsp;Payout<BR>Value&nbsp;of&nbsp;Unearned<BR>Shares, Units or<BR>Other Rights That<BR>Have Not
Vested<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,333</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,257,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,049,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265,250</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,220,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">970,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,201,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,374</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,284,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,666</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">979,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,061,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,715,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,538,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,666</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">789,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,061,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,715,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,994,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">789,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,061,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,994,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The market value of the restricted stock unit awards represents the product of the closing price of Amarin
stock as of December&nbsp;31, 2018, the last trading day of the year, which was $13.61, and the number of shares underlying each such award and, with respect to performance-based awards, assumes satisfaction of the applicable performance criteria.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These restricted stock unit awards vest in 16 equal quarterly installments, commencing September&nbsp;30, 2015.
Amount unvested at December&nbsp;31, 2018 represents the remaining two vesting tranches. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These restricted stock unit awards vest in equal annual installments over three years, commencing
January&nbsp;31, 2017. Amount unvested at December&nbsp;31, 2018 represents the third and final vesting tranche. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These restricted stock unit awards vest in equal annual installments over three years, commencing
January&nbsp;31, 2018. Amount unvested at December&nbsp;31, 2018 represents the remaining two vesting tranches. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These restricted stock unit awards vest in equal annual installments over three years, commencing
January&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These restricted stock unit awards vest upon achievement of a certain financial performance goal. To date, the
specified criteria have not been achieved. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These restricted stock unit awards vest ratably in 36 equal monthly installments, commencing September&nbsp;30,
2018, but are deferred unless and until, and are subject to the achievement of, certain financial and clinical performance milestones, such that upon the achievement of the clinical milestone together with each individual financial milestone, the
shares underlying the restricted stock units awards for the related grant shall be vested to the extent they would have vested on a monthly basis without regard to the requirement for achievement of the performance criteria and will continue to vest
monthly thereafter. To date, only the clinical performance goal has been achieved, such that no awards have vested. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This restricted stock unit award vests in 16 equal quarterly installments on the last day of each quarter,
commencing upon achievement of certain legal performance criteria in October 2015. Amount unvested at December&nbsp;31, 2017 represents the remaining two vesting tranches. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Salyer&#146;s employment with the Company terminated in April 2018, at which time all unvested
restricted stock unit awards were immediately forfeited. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_37"></A>Pension Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have a defined benefit plan. Our named executive officers did not participate in, or otherwise receive any special benefits under,
any pension or defined benefit retirement plan sponsored by us during fiscal year 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_38"></A>Nonqualified Deferred Compensation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During fiscal year 2018, our named executive officers did not contribute to, or earn any amount with respect to, any defined
contribution or other plan sponsored by us that provides for the deferral of compensation on a basis that is not <FONT STYLE="white-space:nowrap">tax-qualified.</FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_39"></A>Employment, Change of Control and Severance Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements or arrangements with each of our named executive officers. These agreements set forth the
individual&#146;s base salary, bonus compensation, equity compensation and other employee benefits, which are described above in the &#147;Executive Compensation Discussion and Analysis&#148;. In addition, these agreements provide for severance
payments and benefits upon a termination of employment under certain circumstances, as described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>John F. Thero </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Mr.&nbsp;Thero&#146;s employment is terminated by the Company without cause or he resigns for good reason, he will be
entitled to severance as follows: continuation of base salary for twelve (12)&nbsp;months; continuation of group health plan benefits for up to twelve (12)&nbsp;months to the extent authorized by and consistent with 29 U.S.C. &#167; 1161 et seq.
(commonly known as &#147;COBRA&#148;) with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and Mr.&nbsp;Thero as in effect on the date of termination; and twelve (12)&nbsp;months of accelerated
vesting of all outstanding equity incentive awards to the extent subject to time-based vesting. In lieu of the foregoing, if Mr.&nbsp;Thero&#146;s employment is terminated by the Company without cause or he resigns for good reason, in either case,
within twenty-four (24)&nbsp;months following a change of control, he will be entitled to severance as follows: continuation of base salary for eighteen (18)&nbsp;months; continuation of group health plan benefits for up to eighteen (18)&nbsp;months
to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and Mr.&nbsp;Thero as in effect on the date of termination; a lump sum cash payment
equal to the full target annual performance bonus for the year during which the termination occurred; and 100% acceleration of vesting of all outstanding equity incentive awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Joseph T. Kennedy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Mr.&nbsp;Kennedy&#146;s employment is terminated by the Company without cause, he will be entitled to severance as follows:
continuation of base salary for six (6)&nbsp;months; continuation of group health plan benefits for up to six (6)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the
same relative proportion by the Company and Mr.&nbsp;Kennedy as in effect on the date of termination; and six (6)&nbsp;months of accelerated vesting of all outstanding equity incentive awards to the extent subject to time-based vesting. In lieu of
the foregoing, if Mr.&nbsp;Kennedy&#146;s employment is terminated by the Company without cause or he resigns for good reason, in either case, within twenty-four (24)&nbsp;months following a change of control, then he will be entitled to severance
as follows: continuation of base salary for twelve (12)&nbsp;months; continuation of group health plan benefits for up to twelve (12)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such
benefits shared in the same relative proportion by the Company and Mr.&nbsp;Kennedy as in effect on the date of termination; a lump sum cash payment equal to the full target annual performance bonus for the year during which the termination
occurred; and 100% acceleration of vesting of all outstanding equity incentive awards.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Steven B. Ketchum, Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Dr.&nbsp;Ketchum&#146;s employment is terminated by the Company without cause, he will be entitled to severance as follows:
continuation of base salary for six (6)&nbsp;months; continuation of group health plan benefits for up to six (6)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the
same relative proportion by the Company and Dr.&nbsp;Ketchum as in effect on the date of termination; and six (6)&nbsp;months of accelerated vesting of all outstanding equity incentive awards to the extent subject to time-based vesting. In lieu of
the foregoing, if Dr.&nbsp;Ketchum&#146;s employment is terminated by the Company without cause or he resigns for good reason, in either case, within twenty-four (24)&nbsp;months following a change of control, then he will be entitled to severance
as follows: continuation of base salary for twelve (12)&nbsp;months; continuation of group health plan benefits for up to twelve (12)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such
benefits shared in the same relative proportion by the Company and Dr.&nbsp;Ketchum as in effect on the date of termination; a lump sum cash payment equal to the full target annual performance bonus for the year during which the termination
occurred; and 100% acceleration of vesting of all outstanding equity incentive awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Michael W. Kalb </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Mr.&nbsp;Kalb&#146;s employment is terminated by the Company without cause, he will be entitled to severance as follows:
continuation of base salary for six (6)&nbsp;months; continuation of group health plan benefits for up to six (6)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the
same relative proportion by the Company and Mr.&nbsp;Kalb as in effect on the date of termination; and six (6)&nbsp;months of accelerated vesting on all outstanding equity incentive awards to the extent subject to time-based vesting. In lieu of the
foregoing, in the event that Mr.&nbsp;Kalb is terminated without cause or he resigns for good reason, in either case, within twenty-four (24)&nbsp;months following a change of control, he will be entitled to severance as follows: continuation of
base salary for twelve (12)&nbsp;months; continuation of group health plan benefits for up to twelve (12)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the same
relative proportion by the Company and Mr.&nbsp;Kalb as in effect on the date of termination; a lump sum cash payment equal to the full target annual performance bonus for the year during which the termination occurred; and 100% acceleration of
vesting on all outstanding equity incentive awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Mark W. Salyer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;18, 2018, Mr.&nbsp;Salyer&#146;s employment relationship with the Company terminated. In connection with the termination of his
employment, Mr.&nbsp;Salyer received the following severance payments and benefits pursuant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the terms of his employment agreement: continuation of base salary for six (6)&nbsp;months; continuation of group health plan benefits for six (6)&nbsp;months, with the cost of the regular
premium for such benefits shared in the same relative proportion by the Company and Mr.&nbsp;Salyer as in effect on the date of termination; and six (6)&nbsp;months of accelerated vesting of all outstanding equity incentive awards to the extent
subject to time-based vesting. Severance amounts actually paid to Mr.&nbsp;Salyer in connection with the termination of his employment are set forth in the 2018 Summary Compensation Table above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_40"></A>Potential Payments upon Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the benefits potentially payable to each of our named executive officers assuming the named executive officer&#146;s
employment was terminated without cause or for good reason within twenty-four (24)&nbsp;months following a change of control and such termination occurred on December&nbsp;31, 2018, the last business day of fiscal year 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base&nbsp;Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>Payment<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Vesting of<BR>Options<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Vesting of<BR>RSUs<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Continuation&nbsp;of<BR>Health Benefits<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">997,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">498,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,141,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,382,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,046,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,488,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,112,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,298,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">462,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,172,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,923,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,769,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,299,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,845,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,766,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The value of the accelerated vesting of options equals the difference (if positive) between the option exercise
price and the closing price per share of our ADSs on December&nbsp;31, 2018 ($13.61), multiplied by the number of shares that would have been accelerated upon a termination occurring on December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The value of the accelerated vesting of restricted stock units equals the closing price per share of our ADSs
on December&nbsp;31, 2018 ($13.61) multiplied by the number of restricted stock units that would have been accelerated upon a termination occurring on December&nbsp;31, 2018. Included in these amounts are amounts related to performance-based
restricted stock units that would vest upon a change in control of $30,421,753 for Mr.&nbsp;Thero, $6,253,795 for Mr.&nbsp;Kennedy, $5,709,395 for Mr.&nbsp;Ketchum, and $2,994,200 for Mr.&nbsp;Kalb. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Salyer&#146;s employment with the Company terminated in April 2018 and was therefore ineligible to
receive severance payments as of December&nbsp;31, 2018. The amounts actually paid to Mr.&nbsp;Salyer in connection with the termination of his employment are set forth in the 2018 Summary Compensation Table above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the benefits potentially payable to each of our named executive officers assuming the named executive officer&#146;s
employment was terminated by the Company without cause (and, in the case of Mr.&nbsp;Thero, he resigned for good reason) other than within twenty-four (24)&nbsp;months following change of control and assuming such termination occurred on
December&nbsp;31, 2018, the last business day of fiscal year 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base&nbsp;Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>Payment<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Vesting of<BR>Options<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Vesting
of<BR><FONT STYLE="white-space:nowrap">Time-Based</FONT><BR>RSUs<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Continuation&nbsp;of<BR>Health Benefits<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,562,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,965,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,211,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,828,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,661,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,734,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,647,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,111,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,003,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,212,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">748,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,187,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The value of the accelerated vesting of time-based options equals the difference (if positive) between the
option exercise price and the closing price per share of our ADSs on December&nbsp;31, 2018 ($13.61), multiplied by the number of shares that would have been accelerated upon termination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The value of the accelerated vesting of time-based restricted stock units equals the closing price per share of
our ADSs on December&nbsp;31, 2018 ($13.61) multiplied by the number of time-based restricted stock units that would have been accelerated upon termination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Salyer&#146;s employment with the Company terminated in April 2018 and was therefore ineligible to
receive severance payments as of December&nbsp;31, 2018. The amounts actually paid to Mr.&nbsp;Salyer in connection with the termination of his employment are set forth in the 2018 Summary Compensation Table above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_41"></A>Chief Executive Officer Pay Ratio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a mandate of the Dodd-Frank Act, the SEC adopted a rule requiring annual disclosure of the ratio of the median employee&#146;s
total annual compensation to the total annual compensation of the principal executive officer (&#147;<B><I>PEO</I></B>&#148;). The PEO of our Company is John F. Thero. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our compensation philosophy must be consistent and internally equitable to motivate our employees to create shareholder value.
The purpose of the new required disclosure is to provide a measure of pay equity within the organization. We are committed to internal pay equity, and our Remuneration Committee monitors the relationship between the pay our PEO receives and the pay
our <FONT STYLE="white-space:nowrap">non-executive</FONT> employees receive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As illustrated in the table below, our 2018 PEO to median
employee pay ratio was approximately 41:1. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PEO 2018 Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,205,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Employee 2018 Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">101,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ratio of PEO to Median Employee Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>41:1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We identified the median employee using annualized base salary for 2018, bonus(es) earned in 2018, and
aggregate grant date fair values for equity awards granted in 2018 for all individuals who were employed by us on December&nbsp;31, 2018, the last day of our fiscal year (whether employed on a full-time, part-time or seasonal basis). Employees on
leave of absence were excluded from the list and reportable wages were annualized for those employees who were not employed for the full calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules, based on our internal records and the
methodology described above. The SEC rules for identifying the median compensated employee allow companies to adopt a variety of methodologies, to apply certain exclusions and to make reasonable estimates and assumptions that reflect their employee
populations and compensation practices. Accordingly, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and may use
different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_42"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc662434_43"></A><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon recommendation of the Remuneration Committee, the Board approved an amended <FONT STYLE="white-space:nowrap">non-employee</FONT> director
compensation program effective December&nbsp;10, 2012, as amended on May&nbsp;20, 2013, and March&nbsp;11, 2014. The amended <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program was intended to approximate the 50th
percentile of <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation within the Company&#146;s peer group. A summary of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation arrangements for fiscal year
2018 is set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retainer&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual Board Retainer Fee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chairman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All <FONT STYLE="white-space:nowrap">non-employee</FONT> directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual Chairman Retainer Fees:*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chairman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remuneration Committee Chairman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee Chairman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual Committee Member Retainer Fees:*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remuneration Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These fees are in addition to the Annual Board Retainer Fee, as applicable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual retainers are paid in equal installments in arrears within 30 days of the end of each calendar quarter, or upon the earlier
resignation or removal of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director. For <FONT STYLE="white-space:nowrap">non-employee</FONT> directors who join the Board during the calendar year, annual retainers are prorated based on the
number of calendar days served by such director in the calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are
given an annual election option, which option is to be exercised within ten calendar days of the end of each quarter, of receiving their annual retainers in the form of either (i)&nbsp;cash or (ii)&nbsp;unregistered
<FONT STYLE="white-space:nowrap">non-ADR</FONT> ordinary shares, with any such issuances to be priced at the greater of (i)&nbsp;the closing price of the Company&#146;s ADSs on NASDAQ on the date which is ten calendar days after the end of each
quarter or (ii) &pound;0.50 per share (i.e., par value per ordinary share). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, upon their initial appointment to the Board, <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors receive equity awards with a grant date fair value of $300,000, split equally in value between option awards and restricted stock units. The option awards vest in full upon the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of grant. The restricted stock units are subject to deferred settlement upon the director&#146;s separation of service with the Company (&#147;<B><I>DSUs</I></B>&#148;) and vest in
equal installments over three years on each anniversary of the date of grant. The grant date for such awards is date of initial appointment, and the exercise price of any option award is equal to the closing market price on NASDAQ of the ADSs
representing the Company&#146;s Ordinary Shares on such date. In addition, for so long as the <FONT STYLE="white-space:nowrap">non-employee</FONT> director remains on the Board, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director
receives annual equity awards with a grant date fair value of $200,000, split equally in value between option awards and DSUs. Such option awards vest in full upon the earlier of the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of
the date of grant or the annual general meeting of shareholders in such anniversary year. Such DSUs vest in equal annual installments over three years, in each case upon the earlier of the anniversary of the date of grant or the annual general
meeting of shareholders in such anniversary year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chairman of the
Board that continues on the Board following the Company&#146;s annual general meeting of shareholders (and who was not first elected to the Board at such meeting) is eligible to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receive an annual equity award with a grant date fair value of $20,000, split equally in value between option awards and DSUs. Such awards have a grant date and exercise price identical to other
annual equity awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All equity awards are made pursuant to the terms of the Company&#146;s Equity Incentive Plan, as amended and in
effect from time to time. In the event of a change of control (as defined in the Equity Incentive Plan), all option awards and DSUs shall immediately become fully vested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are also reimbursed for their reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with attending Board and committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
May&nbsp;14, 2018, the Company awarded options representing the right to purchase 46,973 ordinary shares and 31,153 restricted stock units to each of Mr.&nbsp;O&#146;Sullivan, Ms.&nbsp;Peterson, Mr.&nbsp;Stack, Mr.&nbsp;van Heek and
Mr.&nbsp;Zakrzewski in connection with their service on the Board. The options vest in full upon the earlier of the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the grant date or the Company&#146;s 2019 Annual General Meeting,
while the restricted stock units vest in equal annual installments over three years, in each case upon the earlier of the anniversary of the grant date or the annual general meeting of shareholders in such anniversary year, commencing in 2019. The
total grant-date fair value of each of these awards is $100,001 and $100,001, respectively, based on a closing price of $3.21 on NASDAQ of the ADSs representing the Company&#146;s Ordinary Shares on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on May&nbsp;14, 2018, the Company awarded an option to purchase 51,671 ordinary shares and 34,269 restricted stock units to
Dr.&nbsp;Ekman in connection with his service on the Board and as <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chairman of the Board. The option vests in full upon the earlier of the <FONT STYLE="white-space:nowrap">one-year</FONT>
anniversary of the grant date or the Company&#146;s 2019 Annual General Meeting, while the restricted stock units vest in equal annual installments over three years, in each case upon the earlier of the anniversary of the date of grant or the annual
general meeting of shareholders in such anniversary year, commencing in 2019. The total grant-date fair value of each of these awards is $110,003 and $110,003, respectively, based on a closing price of $3.21 on NASDAQ of the ADSs representing the
Company&#146;s Ordinary Shares on the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the compensation paid in fiscal year 2018 to the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned&nbsp;or<BR>Paid in<BR>Cash<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lars G. Ekman, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. O&#146;Sullivan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Stack</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jan van Heek</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph S. Zakrzewski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The value of the stock awards reflects the aggregate grant date fair value, calculated in accordance with FASB
ASC 718, excluding the effect of estimated forfeitures. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The value of the option awards reflects the aggregate grant date fair value, calculated in accordance with FASB
ASC 718 using the Black-Scholes option-pricing model, excluding the effect of estimated forfeitures. Assumptions used in the calculations for these amounts are set forth in Note 11 to our financial statements included in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2019. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2013, our Board established Stock Ownership Guidelines for its <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. The guidelines require that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director maintain an equity interest in the Company at least equal to three times the amount of such
director&#146;s annual cash retainer. Equity interests that count toward the satisfaction of the ownership guidelines include the value of Ordinary Shares beneficially owned (other than unvested restricted stock) or issuable upon the settlement of
vested restricted stock units. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors have five years from the date of the commencement of their appointment as a director to attain these ownership levels. If a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director does not meet the applicable guideline by the end of the five-year period, the director is required to hold a minimum of 50% to 100% of the shares received upon the exercise or vesting of
any future equity awards until the applicable guideline is met, net of shares sold or withheld to exercise stock options and pay withholding taxes. The Remuneration Committee, however, may make exceptions for any director on whom this requirement
could impose a financial hardship. As of the date of this Proxy Statement, all of the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors have satisfied these ownership guidelines, or have time to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the amount of unexercised stock options, unvested stock unit awards and vested stock unit awards subject to deferred
delivery as of December&nbsp;31, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unexercised&nbsp;Unvested<BR>Stock Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unexercised&nbsp;Vested<BR>Stock Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unvested&nbsp;Stock&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vested&nbsp;but&nbsp;Deferred<BR>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lars G. Ekman, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,671</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. O&#146;Sullivan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,973</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,973</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Stack</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,973</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jan van Heek</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,973</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph S. Zakrzewski</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,973</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,723,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_44"></A>REPORT OF THE AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee oversees the accounting and financial reporting processes of the Company and the audits of the Company&#146;s financial
statements, evaluates auditor performance, manages relations with the Company&#146;s independent registered public accounting firm and evaluates policies and procedures relating to internal control systems. The Audit Committee operates under a
written Audit Committee charter that has been adopted by the Board. All members of the Audit Committee currently meet the independence and qualification standards for Audit Committee membership set forth in the listing standards provided by NASDAQ
and the SEC, and the Board has determined that Audit Committee Member Jan van Heek is an &#147;audit committee financial expert,&#148; as the SEC has defined that term in Item 407 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee members are not professional accountants or auditors. The members&#146; functions are not intended to duplicate or to
certify the activities of management and the independent registered public accounting firm. The Audit Committee serves a board-level oversight role in which it provides advice, counsel and direction to management and the auditors on the basis of the
information it receives, discussions with management and the auditors, and the experience of the Audit Committee&#146;s members in business, financial and accounting matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee oversees the Company&#146;s financial reporting process on behalf of the Board. The Company&#146;s management has the
primary responsibility for the financial statements and reporting process, including the Company&#146;s system of internal controls. In fulfilling its oversight responsibilities, the Audit Committee reviewed with management the audited financial
statements included in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2018. This review included a discussion of the quality and the acceptability of the Company&#146;s financial
reporting, including the nature and extent of disclosures in the financial statements and the accompanying notes. The Audit Committee also reviewed the progress and results of the testing of the design and effectiveness of its internal controls over
financial reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee also reviewed with the
Company&#146;s independent registered public accounting firm, which is responsible for expressing an opinion on the conformity of the audited financial statements with accounting principles generally accepted in the United States of America, their
judgments as to the quality and the acceptability of the Company&#146;s financial reporting and such other matters as are required to be discussed with the Committee by Public Company Accounting Oversight Board (&#147;<B><I>PCAOB</I></B>&#148;)
AU380, <I>Communications with Audit Committees</I>, and SEC Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> Rule 207, <I>Communication with Audit Committees</I>. The Audit Committee has received the written disclosures and the letter from the
independent registered public accounting firm required by the Public Company Accounting Oversight Board. The Audit Committee discussed with the independent registered public accounting firm their independence from management and the Company,
including the matters required by the applicable rules of the Public Company Accounting Oversight Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the matters
specified above, the Audit Committee discussed with the Company&#146;s independent registered public accounting firm the overall scope, plans and estimated costs of their audit. The Committee met with the independent registered public accounting
firm periodically, with and without management present, to discuss the results of the independent registered public accounting firm&#146;s examinations, the overall quality of the Company&#146;s financial reporting and the independent registered
public accounting firm&#146;s reviews of the quarterly financial statements, and drafts of the quarterly and annual reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In reliance
on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors that the Company&#146;s audited financial statements should be included in the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:32%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Submitted by the Audit
Committee of the Board of Directors </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:43%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Jan van Heek (Chairman) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:43%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Kristine Peterson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:43%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Patrick J. O&#146;Sullivan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_45"></A>SHAREHOLDER PROPOSALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act of 1934, as amended, shareholder proposals intended to
be included in the 2020 Annual General Meeting proxy materials must be received by the Secretary of the Company no later than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, or otherwise as
permitted by applicable law; <I>provided, however</I>, that if the 2020 Annual General Meeting date is advanced or delayed by more than 30 days from the anniversary date of the 2019 Annual General Meeting, then shareholders must submit proposals
within a reasonable time before the Company begins to print and send its proxy materials. Proposals received after this timeframe will not be included in the Company&#146;s proxy materials for the 2020 Annual General Meeting. The form and substance
of these proposals must satisfy the requirements established by the Company&#146;s Articles, the Nominating and Corporate Governance Committee charter and the SEC, and the timing for the submission of any such proposals may be subject to change as a
result of changes in SEC rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Companies Act, in order for a shareholder proposal to be presented at an Annual
General Meeting, such proposal must have been requisitioned either by shareholders representing 5% of the voting rights of all members having a right to vote on such proposal at the Annual General Meeting or by at least 100 shareholders who have a
right to vote on such proposal at the relevant Annual General Meeting and who hold shares in the Company on which there has been paid up an average sum, per member, of at least &pound;100. Such proposal must have been signed or otherwise
authenticated by all requisitionists and submitted to the Company not later than (1)&nbsp;six weeks before the Annual General Meeting to which the requests relate, or (2)&nbsp;if later, the time at which notice of that meeting is given by the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, shareholders who intend to nominate a director to be elected at the 2020 Annual General Meeting must provide the
Secretary of the Company with written notice of such nomination between 7 and 42 days prior to the date of such meeting, together with written notice signed by the director nominee regarding his or her willingness to be elected. Any shareholder
seeking to recommend a director candidate or any director candidate who wishes to be considered by the Nominating and Corporate Governance Committee, the committee that recommends a slate of nominees to the Board for election at each annual general
meeting, must also provide the Secretary of the Company with: the name and address of the shareholder seeking to recommend a director candidate; a representation that the shareholder is a record holder of the Company&#146;s securities (or, if the
shareholder is not a record holder, evidence of ownership in accordance with Rule <FONT STYLE="white-space:nowrap">14a-8(b)(2)</FONT> of the Exchange Act); the name, age, business and residential address, educational background, current principal
occupation or employment for the preceding five full fiscal years of the proposed director candidate; a description of the qualifications and background of the proposed director candidate, which addresses the minimum qualifications and other
criteria for Board membership approved by the Board from time to time; a description of all arrangements or understandings between the shareholder and the proposed director candidate; the consent of the proposed director candidate to be named in the
proxy statement relating to the Company&#146;s annual general meeting and to serve as a director if elected at such annual general meeting; and any other information regarding the proposed director candidate that is required to be included in a
proxy statement filed pursuant to SEC rules, if then required. The Nominating and Corporate Governance Committee will consider all director candidates who comply with these requirements and will evaluate these candidates using the criteria described
above under the caption, &#147;Nomination of Directors.&#148; Director candidates who are then approved by the Board will be included in the Company&#146;s proxy statement for that annual general meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_46"></A>DELIVERY OF PROXY MATERIALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2018, including audited
financial statements, accompanies this Proxy Statement. Copies of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2018, and the exhibits thereto are available from the Company
without charge upon written request of a shareholder. Copies of these materials are also available online through the SEC at <I>www.sec.gov</I>. The Company may satisfy SEC rules regarding delivery of proxy materials, including this Proxy Statement
and the Annual Report, by delivering a single set of proxy materials to an address shared by two or more Company shareholders. This delivery method can result in meaningful cost savings for the Company. In order to take advantage of this
opportunity, the Company may deliver only a single set of proxy materials to multiple shareholders who share an address, unless contrary instructions are received prior to the mailing date. Similarly, if you share an address with another shareholder
and have received multiple copies of our proxy materials, you may write or call us at the address and phone number below to request delivery of a single copy of the proxy materials in the future. We undertake to deliver promptly upon written or oral
request a separate copy of the proxy materials, as requested, to a shareholder at a shared address to which a single copy of the proxy materials was delivered. If you hold Ordinary Shares as a record shareholder and prefer to receive separate copies
of proxy materials either now or in the future, please contact the Company&#146;s investor relations department at Amarin Corporation plc, c/o Amarin Pharma, Inc., 1430 Route 206, Bedminster, NJ 07921 or by telephone at (908) <FONT
STYLE="white-space:nowrap">719-1315.</FONT> If you hold Ordinary Shares in the form of ADSs through the Depositary or hold Ordinary Shares through a brokerage firm or bank and you prefer to receive separate copies of proxy materials either now or in
the future, please contact the Depositary, your brokerage firm or bank, as applicable. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EACH SHAREHOLDER IS URGED TO COMPLETE, DATE,
SIGN </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND PROMPTLY RETURN THE ENCLOSED PROXY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662434_47"></A>PROXY FORM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMARIN CORPORATION PLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For use at the Annual General Meeting to be held at The Merrion Hotel, Upper Merrion Street, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dublin 2, Ireland at 2:00 p.m. on Monday, 20&nbsp;May 2019. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">I/We</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Name in full block capitals please)</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">of</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">being (a)&nbsp;member(s) of Amarin Corporation plc (the <B>&#147;Company&#148;</B>) hereby appoint the Chairman of the meeting or (<I>see</I><I></I><I>&nbsp;note 6 below</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as my/our proxy to attend, speak and vote for me/us and on my/our behalf as identified by an &#147;X&#148; in the appropriate box below at the Annual General Meeting of the Company to be held at 2:00 p.m. on Monday,
20&nbsp;May 2019 and at any adjournment of the meeting. This form of proxy relates to the resolutions referred to below.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">I/We instruct my/our proxy to vote as follows:</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Resolutions</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>For</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Against</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Abstain</B> <I></I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>(see note 2)</I></P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Discretionary</B> <I>(see note 3)</I></P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;1.&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary resolution to <FONT STYLE="white-space:nowrap">re-elect</FONT> Mr.&nbsp;Jan van Heek as a
director.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;2.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary resolution to <FONT STYLE="white-space:nowrap">re-elect</FONT> Ms.&nbsp;Kristine Peterson
as a director.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;3.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary resolution (advisory, <FONT STYLE="white-space:nowrap">non-binding</FONT> vote) to
approve the compensation of the Company&#146;s &#147;named executive officers.&#148;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;4.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary resolution to appoint Ernst&nbsp;&amp; Young LLP as auditors of the Company to hold
office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors&#146; remuneration.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;5.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary resolution to generally and unconditionally reauthorize the Board of Directors of the
Company to exercise all powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares of the Company up to an aggregate nominal amount of &pound;148,000,000.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;6.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special resolution to, subject to the passing of Resolution No.&nbsp;5, disapply statutory <FONT
STYLE="white-space:nowrap">pre-emption</FONT> rights otherwise applicable to shares in the Company allotted by the Board of Directors, up to an aggregate nominal amount of &pound;148,000,000.</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Dated this
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U> 2019 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Signature(s)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Please indicate with an &#147;X&#148; in the appropriate box how you wish the proxy to vote. In the absence of
any indication, the proxy will exercise his/her discretion as to whether and how he/she votes. The proxy may also vote or abstain from voting as he/she thinks fit on any other business which may properly come before the meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you mark the box &#147;abstain&#148;, it will mean that your proxy will abstain from voting and,
accordingly, your vote will not be counted either for or against the relevant resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you mark the box &#147;discretionary&#148;, the proxy can vote as it chooses or can decide not to vote at
all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The form of proxy should be signed and dated by the member or his attorney duly authorised in writing. If the
appointer is a corporation this proxy should be under seal or under the hand of an officer or attorney duly authorised. Any alteration made to the form of proxy should be initialed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be valid, this form of proxy, together with a duly signed and dated power of attorney or any other authority
(if any) under which it is executed (or a notarially certified copy of such power of attorney or other authority) must be signed and dated and lodged at the Company&#146;s registrars at the address below, so as to be received by 14:00 p.m. on
Thursday, 16&nbsp;May 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A proxy need not be a member of the Company. A member may appoint a proxy of his/her own choice. If you wish to
appoint someone else, please delete the words &#147;the Chairman of the meeting&#148; and insert the name of the person whom you wish to appoint in the space provided. The Chairman of the meeting will act as your proxy, whether or not such deletion
is made, if no other name is inserted. A member may appoint more than one proxy in relation to the meeting provided that each proxy is appointed to exercise rights attached to different shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the case of joint holders, signature of any one holder will be sufficient, but the names of all the joint
holders should be stated. The vote of the senior holder (according to the order in which the names stand in the register of members in respect of the holding) who tenders a vote in person or by proxy will be accepted to the exclusion of the vote(s)
of the other joint holder(s). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Completion and return of a form of proxy will not preclude a member from attending the meeting and voting in
person. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Address for lodgment of Proxies: </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equiniti </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aspect House </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spencer Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lancing </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">West Sussex </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BN99 6DA </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g662434g14q60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662434g14q60.jpg
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MC]X\:.%SC&H>R=TG[)2X,& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M-WFVSSZ,BU7T@>&B56$,#]XFP(X4&-S^/PH1WC!@P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M*:8B'$H>T:Q\,3D4N2Z4>0&ZT*XP%AJ]EI=IK-5B;E&H-8AXB2XM[2K"2$O
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# *P]H><2Z?6*3_$'RZT7A<$<?4]N$9W1GG4J?^+*^PI3,Q]+VY0P=2WX9
M8_D2Q'=MQ4Z2=UVO7!M8+(XI]HL7BQ$6]IK39SZH^$36B.IJ#F6M;"GN:[7(
M)W8Y1I'-;+8Y.*KRJA)(WA,I8.<&- S"?$?IM6L!;DK:JI$#,I5XJ!*U:S6
M\VMKQ+;:482I!!C:CO#:N63V"*!(85"5$339RE9IJ*%#^]'1)R08RU&F)6+>
M-I&,DZG(2$=(,EDW+-\Q>PZSEH\:.$C'27;.6ZB:R"R1C)JI'(<AA*8!$9BT
M?AF1K7S<K_T)%?@$,!:+PN#-X-& , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M+I>W(PYXE_=B?2.N->MRB1O1*<@03"82(UF%2*)A  $PE(R* F$"E 1Y<^0
M'Z #(S.I6%161N>#1@&OVSYJV;ZOS/LYS@QZ/P^#ZUKYN5_Z$BOP"& M%X7!
MF\&C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M#7[9\U;-]7YGV<YP8]'X?!]:U\W*_P#0D5^ 0P%HO"X,W@T8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M_D2PP!@&OVSYJV;ZOS/LYS@QZ/P^#ZUKYN5_Z$BOP"& M%X7!F\&C & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M[$*BLAU6ZR]75$[(U_X?B75W8A45D?(VIM6'527/K37YUD 4!!8U-KAE405
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MEBZGMP9G3T9&S.QZU&S$>QE8YRI) YCY)HW?,G )0TBLF"[5TFJ@J":R::I
M43-T%4R*%Y'*40S%TO;D8>I;\$^DM<:];E$B%#IB)!,)A*E5X-,HF$  3"4C
M$H"80* "/+GR  _L#(S.I:(T-SP!@&OVSYJV;ZOS/LYS@QZ/P^#ZUKYN5_Z$
MBOP"& M%X7!F\&C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MW1^U)_-@'BDG#?P<_P#_ !T?ZDZ_^])^P4__ #8,>C\,J:ST$"4/"\H1.?M
MG.0@##LP 3F O/\ ^=']',0YY/ZG;?T4^GWV]DS%W* (+""Z0""2@@(*DY@/
M0'ER_I?IR90JS\;K7Z3V'[ZDO><O"HK(A+J[LD;PW3TM(62P)RTU(OD4X,AT
MB2,BY<ID4[_;EZ:97*QRE/T1$.D4 -T1$.?(1SC&DEDEK^SO VWFWI^B8G?#
M?]NC]J3^;)E"HX?TC_S'_KGH/.22X8CD3N4Z)SE( UE8 $Y@* CX5B_)S$0\
MN<8]-_3.\&NWM$W^^&_[='[4G\V2*E2KO^M.?XA;_<-GH/.2#X93D)?)83F*
M0/%-\',Q@*'/PO!^3F(@'/.,>F_IG>#7;VB<_?#?]NC]J3^;)%2IV6_6LG](
M//Q*F>@\YW7AI.0FP'PG,4@>*\B',Q@*'/PC#^3F(@'/.,>F_IG>#7;VB=O?
M#?\ ;H_:D_FR14JDGQYSTV(>4!EY(0$/[?\ YQ;+K1>$0>K\OD[-PWG(38AS
M',4@>+\F',Q@*'/N[#R<Q$ SG'IOZ9U@UV]HGKWPW_;H_:D_FR14JKM0@-HL
M@@/,!GI@0$/* @,BXY" Y=:+PN"#U?E\G6.'0Y";(1,<Q2!X%E0YF,!0Y]%'
MR<Q$ S,?2]N3<'4M^"?G?#?]NC]J3^;(EBK.ZB W*VB @(#9IX0$/* @,J[Y
M" _V@.76B\+@@]7Y?)TCA[,4FS(XQS%*7P;+^4P@4/*S/_:/(,S'TO;E&X.I
M;\,L$[X;_MT?M2?S9$L5<WX0&]700$! ;98Q 0\H" S#SD(#_: Y=:+PN"#U
M?E\F]:!,4FT(,QS%*4&LSS,80* <XEX <Q'D'Z<S'TO;E'6#7;]%AG?#?]NC
M]J3^;(E2L'8X@;8%U$H@(#:)P0$!Y@(#(N.0@(>00RZT7A<$'J_+Y-KT,8I-
MJ5DQS%*4"3?,QA H!SK\H <Q'D'Z<S'TO;E&X.I;\,L3[X;_ +='[4G\V1+%
M9&SQ VP[F)1 0&PR0@(#S 0%P?D("'D$,NM%X7!'%U/^[&=T<8I=IU0QC 4H
M*RO,QA  #_R*4#RB/D#RYF/I>W*&#J6_#+&^[H#^A9+[0G__ '(EB-2?"=JI
M1M88^:+,6>(N5Q:WV\P]@\ /&5VM4-*UZ6J<U8U4J^VDEY2HK5F+;1LJQD&$
MI,,$P87%[9FC:-18#9_7<_J7"AK%&.)'I/+>F=.83LB<F$X@,J2S):D1T&G8
MRNS1I@\,%TFB76O? I"0\,=2642/;SC9,&3_ 'YY.M6&JUMCK.2J+:#C K$+
M3U8F+@E6B+F,91T)$]QB&B35R59/N<<FT:@TZ8&,B9ND<I@.0# ,Q:/PS'US
M6VNSUZ!.>@TLYSPT68QC5:#,8QC,4!,8QA8B)C&$1$1$1$1'F. M%X7!F>K3
M7'H!2>RL%[A@T=6FN/0"D]E8+W# '5IKCT I/96"]PP!U::X] *3V5@O<, =
M6FN/0"D]E8+W# '5IKCT I/96"]PP!U::X] *3V5@O<, =6FN/0"D]E8+W#
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M'H!2>RL%[ADBI67)D(E)2":9"IIIOG9$TR% A"$(NH4I"%* %*4I0 I2E
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M (8"T7A<&;P:, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M _I'_F/_ %ST'G)*<+_SSG?JPM[5B\XQZ;^F=X-=O:)QY(J5'N_ZTY_B%O\
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ML)W]23/T5(?A%LF4*G,]!YR5G"S^M;?]'Q7XEYD_J=M_13Z??;V2_DOU<_\
MX)U_L*9,[>C\/@J4ST$"4G"W^O[3]#L_QHY/ZG;?T4^GWV]DSG']77_P5?\
M0;)E"HW/0><D[PN_.FQ_0"?M%MG&/3?TSO!KM[1-O)%2H@?TC_S'_KGH/.24
MX7_GG._5A;VK%YQCTW],[P:[>T3CR14J/=_UIS_$+?[AL]!YR0O#%\_9;ZI/
MO;$%G&/3?TSO!KM[1.O)%2I>6_6LG](/?Q*F>@\YW?AF\X+_ .JTC[2A\XQZ
M;^F=X-=O:)XY(J5/6#]?3?TO)?C%LNM%X7!!ZOR^3M'#;YQ3_5Z3_P!]AG./
M3?TSK!KM[1/G)%2J:U_.FR?3\Q[1<Y=:+PN"#U?E\G6>'+SDH_0LK_I0S,?2
M]N4;@ZEOPRP#(EBJZ[?/.W?6>?\ :KO+K1>%P0>K\ODZ3P\><V.^C9?\&?,Q
M]+VY1N#J6_#+",B6*M+]\^[K];;'[8>9=:+PN"#U?E\F]\/_ )T8/^%FO9#S
M,Q]+VY1U@UV]HL0R)4J\V1YP;M]:9WVDXRZT7A<$'J_+Y-LT)YU:S_<F_P#M
M^4S,?2]N4;@ZEOPRQ?(EBL/:'G$NGUBD_P 0?+K1>%P1Q]3VX1G=&>=2I_XL
MK["E,S'TO;E#!U+?AEC^1+$7&O%WJMY28G9:+2X&UU(WAS1'UT+"LU86KR"%
MQ;:\3?VXJ$LK)U]J>\O6E9?Q+V."WU9\9\XNU8K,9!V%_$!_>_[\&82XH]6+
M5HMB25L!UCV9*GDK 0J@6A2Q+:>2X@DXPL>9<&HNATJJ789D1?@L2+ \2=,M
MJ(>  ;#_ +S')U27GH:<UU(62)DFCV!G*:YF(F525 &;^,EH4[N->(*J= #(
MO6SA!5 1 !.54GDYCRP<XM'X9ZZU+Q(5R  9./ 0A8H! 7K8! 08H<P$.ZX"
MT7A<&;\,1/[TCO\ .MOS<&CPQ$_O2._SK;\W 'AB)_>D=_G6WYN /#$3^]([
M_.MOS< >&(G]Z1W^=;?FX \,1/[TCO\ .MOS< >&(G]Z1W^=;?FX \,1/[TC
MO\ZV_-P!X8B?WI'?YUM^;@#PQ$_O2._SK;\W 'AB)_>D=_G6WYN /#$3^]([
M_.MOS< >&(G]Z1W^=;?FX \,1/[TCO\ .MOS< >&(G]Z1W^=;?FX \,1/[TC
MO\ZV_-P!X8B?WI'?YUM^;@#PQ$_O2._SK;\W 'AB)_>D=_G6WYN /#$3^]([
M_.MOS< X"RXM-!R&VK-I9I>VRMSJ*#+PZN6/DSU)E*.XFV6!:MJW4C0]72LT
M9 4N>FI.&<2B+INR9N"I@N\CY9K'!'<\5>XR^&&V:H@MW5W<-:E=:6JZ2VN*
ME/-T)D'MPOT)=)S7KVG4^KJQ:=MM=B4M]:G8F,B:]!23R<+&.)&%2D(H"/CC
M8<Q&>OLRV\N*O1'#?18C9&XKH\K-4G9N.KD4K&4J_7>==34K%R4RT8>)U"JU
MGN*"@1D/)NGAW,"BC&%:*)R2C182)F&)3_0=@@KC6;)"0UBB99 \7/14?-1I
MWR;B'>GCY1HB^9F>1,PBPEXMT9NNF+B.E&+*19*B=L^:-W*2J) ,KX8B?WI'
M?YUM^;@#PQ$_O2._SK;\W *<9/C+W!1/E1T.'G<4K*TK2^S"(Q?#79JS#UJ]
MZ;V$HIK!W*N*9LR7CCI734VY&]^B;1+PJTX]:UZX56NA 12*9GB,LH.H7QE-
M2M5WHH[1GY.01G$SQ@;<X']Y;SC.*ZOZ<N^A^)+C,IZKZL:,UO>)7:$/J+:5
MAUII35%9JMS?'AH=];Y%C&QJ4TLYEIZ1L4E#M1?*M'#LV#6L*:6J:PO-Z2I[
M)$P^+F7XFJ'P?PMLJ/%_#:VVQIC5R<UMNV06H-8[*G=Y;.8TZ+C(FEUFHV8T
M;4ZBILG8;HZ<2$;')+IR4K7HI@W0CE78",43IDW715?A$X:1)V.I:@J26R;C
M$7S95:US!EOMD9A$0C:X7B(K3;QHF&<9$MFL=$MIZ>;OGC5C'QR+5BBZ30;M
M"II%3PLVE4Y;U:TS9QO_ (JC^@I>TP_ ,I_X_O\ C_9/_P GV_/^CJVL=PM=
MA#-@[BVU<\$!'"F*\TF[[\[_ ._NET>ZLH_N?>_>9>?1[MTN[!S[GT0Z?.+#
M\8SF3K#B^4]MS>[-+19ZW8"EDH\QC0<L4I2O&XF,86#@ *4 4$1$1'D !Y1'
MR!G)T5:9Z#SDJ^%]VT:.[D+ITW; =M!@07"R:/3Z*LITNCW0Q>ET>8<^7/ES
M#G^D,G]3MOZ*?3[[>R5$Y+11H68*63CS&-%R %*#UL(B(M%@   %.8B(^0 #
MRB.3*%5F>@\Y*3AA=M6LI;1=.6[8#L(L""NLFB!A!P[$0**AB@80 0Y@'/ES
M\N3^IVW]%/I]]O9+:1EXD8]^ 2<>(BS=   ];"(B*!^0 '=<F=O1^&52YZ"!
M)WAC=-6L]9S.G*#8IXAH4IEUDT0,(/!$0**AB@(@'EY!S'ED_J=M_13Z??;V
M3$<2\3WNO_YI'?\ LJ__ +:V_P#X#?\ ZN3*%3V>@\Y);AE=-FMGL1G3A!L4
MT"0I3+K)HE,;P@V'HE%0Q0$>0<^0>7EY<XQZ;^F=X-=O:)H^&(G]Z1W^=;?F
MY(J5,C^D?^8YZ#SDC>&=RV:W&<.Y<(-R&K2Q2G7531*8WA2,'H@90Q0$W(!'
MD \^0"/Z SC'IOZ9W@UV]HFSX8B?WI'?YUM^;DBI5 ['FZ<B'E 7"P@(?V_^
M(;/0><[_ ,-+ENUO4JHY71;IC5'Q .NJ1$@F&7@Q H&4,4!,(%$0 !Y\@$>7
MD'.,>F_IG>#7;]$X/#$3^]([_.MOS<D5*IY40&4DA 0$!?O! 0'F @+A00$!
M#R" A^@<]!YSN7#:X;M;\^4<KHMTQK$@0#KJD2()AD8@0*!E#%*)A HB <^8
M@ CR\@YQCTW],[P:[>T3F\,1/[TCO\ZV_-R14JNGQ T[-&*(&*:6D1*8! 0$
M!>+" @(>00$/* AY!#+K1>$0>K\L['PYN&[;81U'*Z+=/Q?DB]T75(D3I"NQ
MY%Z2ABEZ0\AY!SYCR'_Z9SCTW],ZP:[>T3N\,1/[TCO\ZV_-R14JVM)BGL]C
M,4P&*:>ES%,40$IBC(.! Q1#F @(#S 0\@AY0RZT7A$'J_+.J</+A!ML9%5P
MLBW3\#2A>Z+*$2)TA*CR#IG,4O,>0\@Y\Q_LS,?2]N3<'4M^">OAB)_>D=_G
M6WYN1+%7MT,4]QMAR&*<A[+.F(<H@8IBFE'0E,4P<P,4P" @("(" \P\F76B
M\+@@]7Y9T;A_70;;*CE7"R2"01TL J+*$2( BS.  )SB4H"(^0 Y^7^S,Q]+
MVY1N#J6_!/SPQ$_O2._SK;\W(EBL.^'(I>+FHF8IR'M=B.0Y# 8AR&EWABF*
M8HB!BF 0$I@$0$! 0'EEUHO"X(/5^7R;QH5=%OLZ$5<+)()%:S &464(DF F
MB7@  G.)2AS$0 .8^41Y!Y<S'TO;E'6#7;VBP3PQ$_O2._SK;\W(E2LK8IR*
MWZYJ)G*HF>SS9B*$,!R'*:1<"4Q3%$2F*(>4! 1 0\H9=:+PN"&+5^6;5HI9
M%OM&M*KJIH)%)-=)190J:9>E 2A2](YQ*4.9A H<Q\HB !Y1S,?2]N4;@ZEO
MP6%^&(G]Z1W^=;?FY$L5H[-435V#<5$CD43/8)(Q%$S <ARBX/R,4Q1$IBC_
M &" B Y=:+PN"./J>W",YI)9)#:%5575312(K*=-14Y4TR\X.3*'2.<0*7F8
M0*',0YB( 'E',Q]+VY0P=2WX98J64C#!S+(L3!^CF5VW$.?_ -.8*9$L1Q0X
M4=>MWCQXE.W?_P ]M<E;;JV4DX1=KL-Y(QR$$+:[$<5U525(VK**M6)+ME6%
MI>0+QTSE[#)&%NLW&S_K7+QGN?=/A3U<C'$CTE;8F=.73L2<D6?-X4)8TM4(
MZ'3L)78M!#PP72B)=9]^"F)CP1E)-0I[8H:QB$O^\SR=9GJU7XW6TE56<-')
M5R%IZT5%0HM4EHYC'0T0*$4T0;+E43!*/2:MBM0$!%+N"1BB!B ;!SBT?AGG
MK='I1Z] F-3ZL8QH6+,8QJ_$B8QA8H")C"+01$1$>8B/E$?*.;+J[LQ)0LEH
MNQFO$6D>AU5[/1'N>)=7=FPJ*R'B+2/0ZJ]GHCW/$NKNQ"HK(>(M(]#JKV>B
M/<\2ZN[$*BLAXBTCT.JO9Z(]SQ+J[L0J*R'B+2/0ZJ]GHCW/$NKNQ"HK(>(M
M(]#JKV>B/<\2ZN[$*BLAXBTCT.JO9Z(]SQ+J[L0J*R'B+2/0ZJ]GHCW/$NKN
MQ"HK(>(M(]#JKV>B/<\2ZN[$*BLAXBTCT.JO9Z(]SQ+J[L0J*R'B+2/0ZJ]G
MHCW/$NKNQ"HK(>(M(]#JKV>B/<\2ZN[$*BLAXBTCT.JO9Z(]SQ+J[L0J*R'B
M+2/0ZJ]GHCW/$NKNQ"HK(>(M(]#JKV>B/<\2ZN[$*BLAXBTCT.JO9Z(]SQ+J
M[L0J*R'B+2/0ZJ]GHCW/$NKNQ"HK(C'6N(#AAN&W+]IJM5TD[8];$3:V67AM
M5OYJJ)V=)3803%&;3</!/RJ7"!3UI9#O(I9N@G(N41AZVZG)]A-144EU=V;\
M516_)J+KC!X(FG")*\<ZTE6TN&R+C+?*%N;K6TC&RDFC2[7/4F2:Q=-E:ZPM
MR\F\LE<DF$5%KPS9^Z J;I1!NT%19)\G5W'PS^/Q4TR.M;MVAPX</%8JEOVO
M%1$! W:^4/65;>L=:25D3=W;9ECC*I2H=Z>N5N51@B3,],,&"<I/JQ<.@HKS
M<R"0%'$NKNS/BGV7?LNV;_!7FUX [G7_ )328XK-:5&'U10I:-AE-YP58L2$
MQK;BDK@4O=D%%$E-76")2CJOOBIVD=++MK'%/ZY7F5>C[C*.Y^>D;X]AFF2]
M9=SK+XPTG$QETYKOW34Y5(:E^2.XCWO#APR591I5:WL_05C^4SD%F%7V$ZK9
MCV'C#9[DDN'C:-8V!64HV5;3&DK+=*FTFDG!(^0BHM[=7U70LAHR)AK0_P!^
M,_ML=?)3IJL">2>6%*5#U662X):[TX']S<16N];:6W;H;7UP=:O(TAZEQ5:Q
MXJ]@Z*VU#WB/TI1X]MQ%!4*7K1C&2$A*;75OB,K3YN<G$(&'914Q&PUG/*NV
M1-EU9B:PS\>^J>%:4F7?4C_2U[YJ?Y5..U=LF?BN)'7NQHFJT-M=-?V1Q2K;
MH2[06@=@24U7-VZ)4.O49[7ME4JEDV;#W.MLXU:H3\_3)V:</59EFM+I=7<?
M'!\=(=&LGGDTZQEIV9&^"LEHV_\ )M:S@Z_OK3:6V;'QH\8X- W?Q3;.T)?M
MUTC46Z=XI0VH]>;UUK-M+LQG&E<7I#N"9R,R>M$K\/"M9!BO7E>:&2ZNYT\.
M%8Y6')8<+E85BA?%9YY1_229XN>*9.'USPCZNX?8B,JHMO"7_%C$6V?E1VCK
M!757!#8.+2E\,^U-O"@O>:??-TM:Y'URR;+;R'CZN#&?6920SCV13S9=7=G*
MP+-O"GW62S_R2E+UIP[0- Z(X<-JU33O%\^X=8;6^P=G:5UQ?'M8M+,B\KK^
M4M6M8D%1ETGC9JBCLVL5:25UY*7_ +QC[8K M',.X=H,5%F88<ONNW^_WGY.
MB5;A:X/Z76'%+KFK]7LJJ[V$PVPY@W"B$JP6V1&VQA>VER.G+OWYAFPNL7'V
MQ=UTO_G+"U2EWA%WP"L.QBH[,SY)N94Q&JTB(\1E!GDN%[A:EK!=[6WTYJN1
ML.P+9K.\7V5;P,0Y<6.VZ@-#JZMFYGN)3I*O*6M6X9Q  9,B*#F*;.12472%
M06:UG/\ )J='I*4=IR?B5K4Z-;*536]5LRZ%2K*"Z%?F5D5D8&*35153CG)T
MU4E"-2G343.4#D.00,4P 8H@( .:FY6;U7<Y:4/):/L5HY8B2EX:(*$FC73P
MS#Q4MWL6O=[^$X]H_P"]^[#.=U[CWTBKW+NO<D^Z=SZ/3[F3I<^@7E/&VHAQ
MKZ*8$G,J=/9(^R4FF(UV>61J-8262A915)5*!BDU$U$V*YB*)G*T Q#D, &(
M<H@8I@ 0$!#.)=7=G<*BLBLO+D"3_#5!PLTZMY9F'BY8K=O"BW+)Q[1^" JJ
M28*"B#I%4$A4 A .).B)P(7I<^B'*>-M1#C7T4P).94Z>R3DU2*6E#RRB=0J
MZ:B<8_.FH2 BB'(<C54Q3D,5H!BF*8 ,4Q1 0$ $! 0SB75W9W"HK(K$RY D
MSPV0D--2=J),1$9+$08QAD"2;!J_*B8[AT!S)%=)*@F8X%*!A( "8"@ \P ,
MGC;40XU]%,"3F5.GLE3(4>E$8/CDI]7*<K-R8IBU^)*8IBHG$IBF!H @8! !
M 0'F ^4,XEU=V=-*'DM'V*O<N1))<-T-#S,Y9$IB)C99-&*:J(IR3%J^(D<S
MSHF.D1TDJ5,YB_T1,0 $0\@CRR>-M1#C7T4P).94Z>R6Z]&I((+"%.JP""2@
M@(5Z) 0$"#R$![T\@AG$NKN=PJ*Q5MER!(OAOAXB9LD^C,14;*HHP9%4DI)B
MU?)I*"_;D%1,CI)4I#B41+TR@!NB(ASY#RSC&X65?V=X,VYH3#\1:1Z'57L]
M$>YY.75W92%1615D/Z1_YCER!(/AQB(F9MLTWEXN.E4$JXJLFA),FSY%-8).
M-("I$W22I"* 0YR <I0,!3F+SY&$!XQN%E7]G>!2\Z?HF5XBTCT.JO9Z(]SR
M<NKNRD*BLBKAT %<N"E   %U@  #D  "A@   /(  'D  _1ER!W;ATB8J8NT
MHVEXR/E6Q*N]7(WDF;9\@1<LK"IE6*DY353*J4BBA"J 4#@10Y0'D8P#QC<+
M*O[.\"EYT_1-'Q%I'H=5>ST1[GDY=7=E(5%9%7\H0J<E(D(4I"$?.R$(0 *4
MA2N% *4I0  *4H          !RRY [5P[Q47,7EZUEHUA*-BUM^L5O(LV[U
MJQ)"*(54J+E-5,%2D44*50"],"G.4! #" \8]%Y],[P:OQ[1-;Q%I'H=5>ST
M1[GDY=7=E(5%9%8LXF1*;F$DB$333E)!---,H$(F0CM8I"$(4 *4A2@!2E*
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M*/</'D<W?LEY"/*@9^Q1=(*O&)71!4:F>-B',NV*Y(4QT!6(0%B%$R?2 !'
M/L+IL#DC,7" /%$%'2;054P<G;(J))+."(";NID$E5T$U%2E%,BBR1#& RA
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M_?,=[SDBI6'9U"*V6PJI'(HFI.2RB:B9@.10AW[@Q#D.41*8ABB!BF*(@8!
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MAY+1]BN[+$2:_#;#Q$A2I=9_%QSY8EI=I%5>,6SE0J81,,8$RG62.8" 8YS
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M82-FL*<@Q9ODTX(ATR/&R+DA#^$&Q>F0JY#E*;HB(=(  >0B'/EG&/3?TSO
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MD  \@!Y ST$#MW#DQ92%\?(/V;5ZB%9D% 1=MTG*0*%D(@I5 36(<@'*4Q@
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M7_=QAZEOP6'$KM?('(D%#D 1Y\B1C(H<_P!'/D" !SY 'E__  R):(T,Q@#
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MS7;O]RM_QA@/WY#_ 'FR_/RI(FKPSW&HM*E/$=VFN-3FL1C%(XG(Q$QB^#&
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MWC# ?OR'^\V7Y^7(DG.&2VU5I/6<SNS5]J4\0T*0SB9CD2F,#P1$"BHY*!A
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MPIR'LLZ<AR2C$Q#D-*.C%,4Q5Q Q3 ("4P"(" @(#RRRT7A<$7J_+Y.B\/\
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M39;+HV(M6EJQIR6LMC>$IY=12,+<WKA%]95+?I"U4Z]T.W3)G"0M9EZ2Z42
MG)YFZ2!I.@5\P<@1N]4$H:$2>'?1T3M*?-Q#VVQ6)MMN#XF+Q<KDO4Y.3@:!
M;K34-9APV)#$T1Y)38U*MOZ%6JB5W$*6"R3+UQ7D"SMHG2+B9(:Z?9?G/V29
MVMPXU[;,I874W)$2B+-186C2];/#-GL3*Q\7LAEL600F"&=('>Q-I4:K5VR1
M[<8]\YAY*1583<;**H/FP3',]_[,Z]KVH):^H5(H2$K*SJ%)J-<J2$W.NE'L
EW+HUR'9PZ4G+O5CJ+/)-\FS*Y?.EE%5G#E5555510YCF&'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g662434g28t07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662434g28t07.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ UP)# P$1  (1 0,1 ?_$ !\
M 0 " @(# 0$            '" 8)!0H#! L" ?_$ #T0  $$ P$   4# P(#
M!@0'  4#! 8'  $"" D1$A,5%!8A%R(Q(T$*&#(D,S="4;89)6)W)S5#4F%V
M@?_$ !@! 0$! 0$                ! @,$_\0 -1$  @$" P@" 0,$ @(#
M 0    $1(3$"05$287&!D:&Q\,'1X0,R\2)"4G)BH@03@I*RPO_:  P# 0 "
M$0,1 #\ [_& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M%W8]/SI&&AN-?Y6,VY$1,NI8<WYWKK6W"]CZ0UKG:GW/M?+O81PZ^LF^$6#
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M + 'RVXJT1D$\/BN"O[3@\8C40E$;2M&QXS&#\"C<<2"Q2:E6+<7T5&1$W&
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M.!F. , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , J9Z^]B5=XYKM.7
M3CI<_+9$H[&5G5P1RVXEEB2!JDDHNW8:<?4D(C87ARU=R^9$4_P\8'KM_N_K
MC1,"",U)MPA92[>^P=2>];VMKT]8O=J7:?2+G&W+UK#HF)Z<I0*JP3[OG:T>
M@0ESOZN%W2:;?F33(ERI*YFY;(=E734(/CT:C_7#A2WO4XXL3Q4LM-=[]A99
MS%6:,C & , 8 P".K@_\);1_^W4V_P#;1/([/@_!K!^_#_MA\H^A+G [&GKX
MEC*\&OHCX>\[XC\OF'A> SZ]"?MR,P\06E:/+(G4Z@BGI=/X-'$7\BEE>0<\
MZDTB)Z8B"P^.%6HJ1DF/3U@#=L1O#$8O\G&SUKPGUFM3QDO[W]=_"9^'KTY(
MW-.X60]1%4O1!&.3P7$O0-K^-8#+;%1AX+<QFDV@#A\"DIL1$X3-"#.9"Y<=
MKYL@^1>E1KL\N^%Q;*Q8K64*)6U"FU*5C)/@6VH7TG6E3^CW F1-+RLJ:L:E
MLJ2QROH7/Y1:T#HZAHQ81'^M5^&'-NV>&CP6M1T]&M_.],I040_FTSA%'+2Z
M Q,D#M?3'D9=5\YMQ1*[;S>C==7OZP9.D+_Q4?Q/OIT/^&K34A_GK0*;^IRH
MIU_.N?\ LQVO:=742[_CZO\ Y=8DP;;YUOZ?V&S3<[UU(&&#O^C@G^IY47'-
M\O;'2!P>DV\?"M^,5Z.^&%/T4HV\>63YSDA9)U9= G2BJ81]]W::+N4P%\MP
MZU!YZDVXYUHHQ;J"I F@V8RH652:"W H<\?Z:Q[L6OP_?H^G#Y!]A4+[FH^,
M7_YWF2$LA,AYVU?LUN4V<GA<E;H-UB\*G /2RZP"5!=N4=/&*BBS5VU79F K
MXH!)BRKT>1IX7#N6?P08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 5P]5
M>GJ]\DU 9MB?]+O^DW"(&%PP6LWXDEBSHFBY4!0N-IN>N4MO7W+1V_)$5_D.
MC<<&FY2:5; PA%TC4I:2S'&BS>B]ZV.G7;-M61?]F2*YK@,)&9Y)N4VB;5CT
MO^VH/%VJZ[@-7L&:.?DH/B@#;E;K2BG'!&1EUR,ID';@V6=J:[))(XXL6UP5
ME\\68%E,C & , 8 P!@$=V]SOJIK0YYU\^NJ[FO.M?\ KO<:)ZUK_P#W>1V?
M!FL'[\/^V'RCZ$F<#L0U=M&0WT'$UZ\LM[*GM:F$'3*:P '(G<7!V(*=?8UV
M FA$!RPEK^,J\)*MBL8'245'Y2,?$ LR&R((Z['8"<&8*P&.MZ[6J^+H=U[%
M4X<M!@#>O>6D35A0'\-T"&IPGD>UTRCBT>8;1U'?T3+3<2HT:;;MOMH<)X&_
MR5J1\'>>1]P#;ECX,U%2C6HZWHTM#HZ7X8P"5UI3I]:359')""49.'NV4+++
M;V@U"EPS&2"TT8_-VDHCZ*8OD67$93//W4CCXH_OR&?#@\?V'Z#/_CR<VZ1_
M9M+0IZKOG<XMH^T=_MH6HEPHDNH$#)MGLKEBB*J*R47 EN6BNR2S!!<7#AVL
M277AF?)*L6PIG;,]F=H6+(2$LGMA2<W,IC)BJNEB)V22(BX*F";OOGGCC2KM
M\Z65^VEPF@CSURB@DDBFFGR/:DDDE9&&X*, V6_"\^)O=7PQO0 ^T*_<.Y)6
M,F7'";MIUR_4;@+(B*"_>]J(\]_<;B)Q'4W#M["Y5PATX%O57 ][R^CA@Z()
M#&/ L:WY/0^JQYK]&U'ZUI&OO0E&RA"6UK9(-(R"(\:Y1?,EN>^VQ6/GF&E%
M5!$ECA1!V$D(A?OI8<69.FV^U.>.%5!XVFFT[HG/!!@# & , 8 P!@# & ,
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MUY[E#Z2("K ((=#$:>;=O6G0LM?;&WG\46U5ELPBC4!HJ0'9/9TRA25@\@T
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M5"I#&R\9.2($< O1LA:(<$1Y5;E(HT*BW'"+P:X3Y$)/P!@# & , 8 P!@#
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M/Z%QQ8ZT@5=G6RFNN%P]A/$]\[^?RS6!2^%?><$;C"WR7%_2EK>D=:K.QP&
M, 8 P!@&T7X:_@!KZC*<7I=@?;GSE%S+IE#H4_2ZTUOJ6 GJC0F^D"7>M<NJ
M;B)=LN*7#[^I&SI6P(BR_.H  (C+$YX\62Y_7WT.N##$-WNMVCXZ:7O;M+I)
M)())H()IHHHI\)(HI<<II)))\ZX3333XUKCA/CC6N>..=:YYYUKGG6M:UK.9
ML\F , 8 P!@# /3(#V!9@^%%6+,F+)LW(\D-(-D7K @P>H]MGC%\S<\*-W;-
MVW440<METU$5T5.TE>.N.NN=@?.Q_P"(0^"&T\8G'GL3RO&UDO+4U/)-[$@
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M0VX9B@4?!L4!@@0.:IZUPW9#V#9!HV1YU\DT4N.?Y^7SSB=3(, 8 P!@# &
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M2.W/70[Z_P#KVP@*//.M\(=[YYXU5/7X.N!TC1]G_#ZFT7.9L8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , Z/WH^7=V#Z@]13A53:ZIKT1;(?ASO?U<N1=:RI[4,87
M2[WO>^D%(E7P';;>_P##?27'.M<<\ZUVP_M1RQ_NO,)>)CJV1!FC P!@# &
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MC4HISUK^[6NA#E^BMKG^5&ZJR.];Y4ZYWG%^U^YF_P!/]W+%_P#EF[[.)U&
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M]:U_O]#GI+KY?[_+Y?[YG%^UFL'[ES\.>QO+SB=A@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MD3@YNQ]IEQ@^X7OW1D=D<B9$G?G]D_)7-'@^XV++OBDG@# 29=$P35CV^(Z
M29O'TS#R*R5L)"'X[V,\!7T,MBCYI;%0(R$:@.C9,K$"]HU=/(L*.]<PH9-
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MPQ Q'69X\!?2N,IE!GWWWP4[\I?$DKFR:"K:9WV7W7MF%?-/'HV;;U6UAQ:
M%8P*,@XS-"=7.#38XM+&<=E4KB,?T#"FI.?=D)7&F8K9Y<LW55&FJM+6/K\_
M!FOH+VCJ)1_;2JE1XZSX5Z4\.5E;-=VA#9 @>%UIZT](UU3S>2!T6QT$UW^:
MCDGE#Z&S)@\ED<;R:)'8T8%]GP,@$B 2F^F)KBDW\&>G?B ^3HO)Y'%I#:H\
M4YC$6NJ7/2BP\HX!.1?G/I3F\&XXDQ:.^71>N](N5"0?::1 P@/,.(J@?0 '
M5!HD/XZVZY%BAUFQ9S%)--"ZKR'@(6F5<2U[,FV@+4"P"AV\A)%W)%=500Z
M-P;E(K^XA9%^"59_<51(J?8<:2$CGP]_)762^^/-D)#&CDUD,PBB FO(C;C9
M@5K&PE#TBJZ=R@9"HQ.8U'QD<(F2HEQ*S8,$>9:9(GX*].@/Z@!HJB>#+/A8
M?QST]OD8T\^(72^YE"*^!QVU2LVE/H=CYO.1(G7,GA4H@$L+4Y-+W!'93')J
M.!&]Q245S!RAF*FA# DS-;VLARNV6"R+@0&RXG=/*8\Y7[&55OZR@1D&BBO-
MW-J3(]:?IB*1B.P>H)K"92N/H&T#L6G056!RDF4-;ZIGG\) IA/"#L*#G$OV
M)=QD0/?3^)Q1R$5TMG.6MJY><S&#7Q)O(P8,A)>)U*3L9ZJ:.WJ1DD;JBTS0
M&.U%(Y26AG$XE)1K#]M(ZQC\A 'Q\S%E5&TCA;@&5;28*,>-.VVPA_'/UEF;
MJNFO?/E=%[5M(F4$0H&^CPTB0#Q>3S!\F^E4A%Q0 W3"1 0<-*_D) :%C=..
M&&VC51VFL]7;-N5%N 2;<(KBZ^(AYJ8J+BWKNV&TS0M5[2?59=T+<ZEG]66C
M5!R\A$<U!F\'6.<;F-41XK,H,36;)"9:Q:.F89\Y+CR@]B$/M.41:_$R&N_5
M<'/.+$0<S-Y,##/T&_I>(0$=3<\K>>!Y.VIJ%VZI6!$%.7W;V5R -$3#Z=&K
M%TVAL,0 DDQ[AF.[CKLD3"/&LYQY,*+>\:2CJTSLH]9I,=44,\HMO2T@B;[S
MW<HZ=QV$L9;(1!RPR!EZQ2<.V:28_H"0K)K -2V)OX^4D,A*-Q3Y!JW!)NRJ
MW%U?3\S!*#+V31CWJ9,]E)4,D4(L^#4Z0ADC@<NB<S)3^T!HDQ6HD%'90(#O
MB36;"C+4B+-?2B%8,FQIS(GX1*.2'H6$->KR2=2MVU[Z"@W%BUB^.$8QN0RN
M)++2"'RZ$D6LG@DB(P^:!%P\S" 2?3J,2T,9C!9PW:KCDSH<J.0>KKL'/*8E
MB6< 8 P!@# & , 8 P!@# & , 8 P#4Y\8^F5+"\G*6B*9_?D/FV5LK86Z2X
M_P!=2NNV+Z*VPDNOSK:G D'#3CFR7R'.NM.G==B^=\_5QQO6L+C$M+,C4IK-
MJG&ZZVYR=8+.QP& , 8 P!@%[/!'N8SXOFK\)*TRTA\UV 7T2G0$8V<E#57R
MESRBV7M6$B&O"SPJ,?(HH<69!QJ*K\PW:HS*'M%YBR,Q^Q,8\,U5\]_Y]X]<
M&*FRW;]K^'\/+.D1VTXE+8O/8P!FD)D066Q"4BF1R-R:.DFA@$=#D4.'+$F*
M*,%5V;YD[0[X50<-U5$U..M;UUG(V9#@# & , 8 P#$YU.X=641.SRP)&*B4
M/C+'H@<D!IUPT'L&VE$T4_K4Z^?:SEVY609#V+;A9\2(.6H]@W<O73=NH!J2
MEDVE7I">B+1F8@G%:]AJSQ:BZM-H]-3(]=^S<BWMP6*,ZWOEC8D@"O7@B*QE
M;7;NLX84*L""B$MF$M%!>N'#%7<YX\7]JYO7=RUSX5>0YLYC & , 8!QQ@N,
MCX@H>-OFPL,$'/BY<D\4TBT'#!K95X_?.ENO[4FS1JBJX74Z_CA)/KK?\:P%
M6BNRZ7B.!E89Y^C9R4#7(J<V^2,79-QY!'I N()V.OP6CT1-\=:U\RM;U]Q#
M*P<]\\\\*<PM/KG6];^K?!N6V>C1:)+I]W+;Y , 8 P!@# & , 8 P" /4%*
M]^@J2E59-23<.;7*P*<0XH]Y5[&L+"J.Q(I;E<.C";?A1RJ#2GD&CO1Q%KQM
MVJ(T]3:_)QTGO0J</JN34/LR@DG\^S_T9ZD]R0Z8"I)6-)^C_'?DRFYXY,5X
M5,.96,%G?6*-P06!6:.DC.#!9$*B%K!Q3PVFUFW''<P9D0K73Z-ED$Q9A+58
MFU#_ -8>N6XF0!X=G<5BU\U/'[_%H4A:Y+T'(H9$7],L7TYKHUZ/>S4], 9*
MRTI\RW-JT R^PY1)X?%D(G#I:/[V% $[',186J%(!*HXJHSI2(I%Z5?:2T\;
MJ8S&O.H&C6LM&KF %0BZK;S5:+.=#ENA430B:)]:(\2G3CY*((<O%!7$MU_K
M;Z3Y):3^6]#/ II3GP[B]?<^$F<SNT?,Q/P\Z[(0RD&T8JQ> $9$7?T[U1VY
M#:9EY9<Y='QZ,,5<NMQ.))P48_D:J),LX(-!XT6T&GBEXG'[K[JITYKH1A)/
MA9SB04<&H7OU&TZA3"C[/J5T-*TDJ8#H22=V6YLL/;<5!=6^S:QZ;!%E^8@9
M<$5I,N:A7+D9&2$ ($R99V"Q5F,YOE6GO-/*T5;>4[8K$Q<(X+Z('N:DMB6V
M1:?%=/:@24+1:U+=X?%I_L?.OZB?J7=2D[!,G;#'U\H";3 84(\A?ZM.XRBL
M)>"-SE6W3=[P(X\L?#ACGFVKM>?"<V!VSYP?5S580[3,IK;;<#W:]="A8D_;
M4776G!E"+-[57CT?FD]@'XLN'5M%J:L$*3$E9=)T28K<U=]9RW\/%#,;]\1O
M;NJ&Y/-J5@PR/^;[@@(BO4*S,4TA,7E3#6<<1C#TM3YY2?@A49.HMV@^1PY<
MS$I,/A$]&LY:/&/5^R+(@(G$4JO:Z]J&2UGY5G],VO8\AKB_'+.F;2DP.QI'
M4\IKY"6RIC9(6 1"OG9&/6XXE[!VTADQ80.-%9K$S,-/FG9G\XZB\WB'!M5)
MN#<JU=53M_!5[GX43 I6-1U1++S>OP%3^/;"\H#RT:KSB-29=S+[1I6VHY:X
M]\_G$G&"S\&E%!P)PRCST,=#&>]&OR*O+5^W8L1=J]+XI:ZTMO9-%I>$RUO'
M3=ARJV0:-MR.1>*'):4"*O?-(IQ#?$7H)[Z9A$2$PQQ9SP@R>3&S3DFW+)(\
MF13OF-DAP@:);. J)-R"Q1P_J_[+9>6ECE*X\;V'60&SZX#WQ'RM/R4Q<\AK
M>(R6BPAV20YU=9J5R0O$; E[^:K#[>JN.&YJ<4CL14AT(D:HG@4!DD\D T?V
MD[$E.*:9WCW\&8UGXIKJO_/%S^7UB!![3MR_U)$=04(H6"16L8#9\,9PL[6M
M1BS)^7OH5"T$N#,A% D3+P2#D4I._ML<#CGXF."@ERGFL\YF9>_>4F]E>+Y[
MSYI,']2,[>MV5]Y_@?F:JMQ&KBK<J\B#J]*-G<YDDIC(*0R=Q*)2;XIJ#%C;
MX5W$P##B-&=B PE.0=(,Q95HHVFTWI,94N[EEY'X?(3&R8SZ"_JJ-'W2P]!U
MG>[LYNK"*,.>@*YH6U?/X2MDX$\L)"0B$M1.ZY_)?W 3FA(LSG95-T\%NHVP
M;0] )RRB.\Z:I'IU[X+,5K.(C:\>N1ANSH=:_L^;-"3NM':D0+P/V[:K2Y[&
MK8]%4;)0)NE(U/0$,)1"7L):,<-V\8Y:$@C],L_WT).7#/-*$_>I%I[X5@I>
MO+7K2)W+W'0-K>1#'EPHZ)UWJ0%FA*86S8UQ3RT_O-9U'F#A_))3:DN5:Q-N
M.'# GW1^FY!RU9=L7(NUNSF^BA+,R[W]YN!K^:[ID%0U(/(WW9)^E-G3T"KX
MH<D\J4#7S5LP.D" @&H[,OQ0]G&W<@>M5"6NN6HS[.R?ZC:2W8B=:V_#2,U(
M^(7LEN.">A7]HC-6&*]'1/T/+%$*P(C0\C8PGS79/FB&UR%"/+#5*PX:,BML
MS&6D2QHG+S;R<$>N]H#H\W:QEJ$TB,H76>>ACIKP3.4K EEQU]Z$8PFV7OK
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MFC;MG,T, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M\&'2#*+)<0V./GYM=TV_0ATR+EN,4%BBHVW\/@75)>JJ:C!03%Y7*U^).\L
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M@D2XDZ":5TWP<1V?O:NDH\#'IY'_ $%%IQ:T?+"O9"=1/O5/X2N'D;0D4@@
M*.0:=*UD+7G4BZAL=M"K(;$:W0$20O."\(8 ]R!:33@T1<[X%FT?VVKOE313
M=Z<BQ!?SZ>*^L6'I#4^8L0;+SI*J"_9#.*O$Y%SU*9S&YPK,FD\_=FV;1P/=
M1IJR:"-PA?\ L75=]%ON<)HX)E&_[^R)_-?B-*AI[6]A/I3'3$DK7S T\M.C
M<7AJ\2,7&!%'X4; 6'<SI>1'/W%.(WQ#G:$?Z2U] TA8=JEN7ZK>9-0L>!N=
MRF4M.'N2/=&>8;MAOIWTYZ/KZZ:L8=^BHG1L42B$RHN6RCB&I48,L)B&>J'
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M/S?NZ8L<OX_,YE((I*[BU8WRF-?1R93V1$ 30=#8C-'('\'$G\W_ !(=[N0
MW,:PDZW2HLM$M;28=%OA\2^,Q#S%%.;MC;S_ );_ (>]L>#^'^ZF*(?O#BS
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MY0'&&?YB//F;M;M=C+H=*V:"CX2@*+DQ":< 8 P!@# & , 8 P!@# & , 8
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MQ'3C.-F2OZ55PV0+2J5SJP#[9FDY56:1!W$$2Z0V1Z-A1@S[U+18 P!@# &
,, 8 P!@# & , __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g662434g35m74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662434g35m74.jpg
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M=9:VV",E)C4W0D-4H<'P8H&1)RAR@KB5_\0 %P$! 0$!
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M7_R=?/LLR=]7YH?7^W\0]$.F:W$JN3V'I'K_ .3KY^/_ ++,G?U_)#_T^/\
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MOXAZ(=,UN)5<GL/2/7_R=?/Q_P#99D[^OY(?^GQ_S?'I#IFMQ*KD]AZ1Z_\
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M27=H)BN159AXM=W%JL)(J#U$'ZF[VWW;9$EG]SYPO;"2;:3L62!CWJ^2E6#
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M\_P!\>A"[0#0#0$#;5_Y,.W'] V(/[OJ]H5WON_<GG0@T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
MT!K_ +G]QE%VJX7M69[^[CTHR!-%1D3&R$]%UT;':K'*-(.MUYI(2B@%!:0E
M'R!G!8]I,3"<8A(.XJ!G'K9*+=!>1#L@SO8,QT^W0UEBH-S)8_FVR9\A8_%X
MXQ7="7,)"U(Q]9>2+V0>(V2HMW2#*VQ'E"7:IL9&IV1"514M;BKU>M0[Y(G*
MN:M=_?G:ZV\TA]V2_HY?VO?X7ZAK^/KX^3U!VJ?R7MMWZ!,/?W>5W0S.JV_
M,[/9DLV4(2PPL$C8<7GICJ.=1)["TEK'&%D%:-9Y>O37BX9I,T25D';YA9:^
MI%24]$/"U6RL))I!UV3C0YS0UZM'N>C:6%^PK^2'E:KJ3')%?KD<W9.UG32N
MY5Q]F+'\@2:>FDP&8?8Y8Y>4-C'JF@2.B*NA7W2Z83B\O%BS;+M_OS;F;'[D
MJ\VFG6!'2\A/,CQ6X"B*(I0\]*P[9T+I&72.63;1SINC)D2*3DV(](L5JJ8Z
MJ $4,)M NO9^QF]LB!6V*3MBG64*WRIN"0*HX64<.%"I9_R:F!UW"QCK+K'
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M02&19F)T,S;"FGMDN<JQ%7SGGK)4U09&$PC+VP!,8QA MLGR@'([LX@4H/P
MI0%X<"E   I$6A"]"-&X)R>0N=.2Q'?G..T%J#(I@,$O;!$#%-T-;)\Q1$JC
M50 $HOQ 2B+4A3%$.)DU728@)'2Y3IY"YUY"$5>?,[ZS:4"G,@ H>6+:/$"
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M#(Q>@LFPIIY"YTY+$5>>_,W-QJBR,8QO*UJ 3&,;H6USQ2@)U':@@4H/^@%
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M0,MH!H"!MJ_\F';C^@;$']WU>T*[WW?N3SH0: : : : : : : : : : : :
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M!3B !(4T!.)2O!*4O6T@ "H+9 A!,)0 T@U%02%3>F:(JM=B^/;<J:P391,
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MEY.==KN"JP!XBJUV+X+?.*<X@/F%90$2 ;CY1I?4#"B@H*8CYU\>15%5&XB
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M'LA_2KSW_L[M>_X;M /0]D/Z5>>_]G=KW_#=H!Z'LA_2KSW_ +.[7O\ ANT
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MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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M%0[:7B\Q"P62+/1]0N'#S(J'#AVN'FU#<.V"(-NWQ\%TX>'*5OPZ<>R4$NG
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M5 >:9# EXO,L+#BN!:%1B<.%,J9.WV^WQKL.7AV?!=GAT9AQ[7DV.[?'IP\
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M]Q+Q>8A8+(!0Z,4X*!3*F!P."@'"NPX'!0JR3DIP,#/J!P<-T%P-UZ@LBDJ
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MY_#X.JG_ .)PYL)@>GPO>SSZ2(=>@#'=SITZB1[QZ=Q#M.<L[\O6TYS#WA5
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M%X)N@-EN"'@\A*Q694U[HY!$I[E5"F QB"4UBB"B!B*.4C%$!> (&*JR>)&
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M"OE8>P.,<RT?!X"QQ+HCQ7:99W)2J+O'T"]8'!0DI3*&3)V6F)TA*;&IRCW
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M;Q$G.F&Z]GQ2':[G/KY-9=[N]R1\>\+7<15Z;%1KTN)Q,%[M90$YC F#.C\
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M 12%T@8G,#@(QS/N H4\@#]-%KN(>+TV!J[,&,(A?;80!,8P%*SHPE !4<G
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MNRQ<LJZ>.Q;1T>:,Q%>K'+4U^^(9JLQ1NK.O)K'65:%7!XS<($$;=EK<]/\
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M@0?.RK.D@>NP35*#E;F$G4Y_;;MUM9;82TX#PK927U:/<WHD_BRC3);HXB'
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M-5Z:8E26:-1@;!2&C>;*G&&5GF=H1%@W23012$)7T T T T T T T T T T
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MCSV!ZYGCU)]1LDW>IY,8LD*N:'G8N[,L>&3@X^%L+L6CQ_.UV>?15NHDU /
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M?NR7]'+^U[_"_0T_'U\?)Z@[5/Y+VV[] F'O[O*[H9D]Z : : : : : : :
M: : : : : : : : : : : : : : : : Z7.8WQY9BN2V2A4NPE>3!;"[+.5:
M#EBNK 2NGJ!9QR#]BX!>8+4E5:N635Y/0KJAX0%_)IS-A QR>'\2I+%<)8NQ
MTFX(V?,B+ITFM$6(SDR3Z<DT*J6, Y6T@G:K0F^0 P).R62?*N10LQ(@X"7C
MSB61SFV,L;LD6;9GCZD-&\<<JD>W;5.!018'+)PLT4[-))@0C4Y9FMUV6*9
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8.]WO -?XQW>WVO\ DN'-3F-/Q]?'R?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g662434g76b14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662434g76b14.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[0JJ4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  8     $  0!@     0 !.$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      !M    !@              (P   +     & &< -P V
M &( ,0 T     0                         !              "P
M(P                                             X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     " X    !    <    !8
M  %0   <X   !_( &  !_]C_X  02D9)1@ ! @$ 2 !(  #_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  6 ' # 2(  A$! Q$!_]T !  '_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ #8 +@ P     0 X0DE-! 8       <
M"  !  $! /_N  Y!9&]B90!D0     '_VP"$  $! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,#
M P,! 0$! 0$! 0$! 0(" 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# __  !$( ", L ,!$0 "$0$#$0'_W0 $
M !;_Q ".   " P$  P             )"@ ("P8$!0<! 0
M       0   % P$%!0$*" @/      (#! 4& 0<("0 1%!48$A,6%PH9(3$B
M(R0T)34V-W%C528G9S@Y43(S1%1D165A@9%2LK-T1RAXN&EYJ1H1 0
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%YEL'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
